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Abstract
The existence of heterogenous subpopulations of cells in cancer has been shown to arise via natural
evolution or through movement between cellular states collectively known as “cellular plasticity.” This
heterogeneity and plasticity are critical drivers of phenotypic diversity culminating in many facets of
disease progression, such as metastasis. While the existence of heterogeneity and cellular plasticity are
well accepted, the molecular underpinnings and functional outcomes, such as metastasis, of these
populations remains limited. Here, we first investigated a form of cellular plasticity known as epithelial-tomesenchymal transition (EMT) and dissect the molecular mechanisms of a recently described partial
EMT (P-EMT) state operating in vivo in a mouse model of pancreatic ductal adenocarcinoma (PDAC),
whereby tumor cells lose their epithelial state through a post-translational mechanism. This is distinct
from complete EMT (C-EMT), which achieves the transition transcriptionally, through regulation of a
complex hierarchy of EMT transcription factors (EMT-TFs). We report that prolonged calcium signaling in
carcinoma cells induces a P-EMT phenotype characterized by the internalization of membranous Ecadherin (ECAD) and an increase in cellular migration and invasion. These effects can be recapitulated by
signaling through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through the
downstream activation of calmodulin. These results implicate calcium signaling as a potent driver of
epithelial-mesenchymal plasticity in cancer cells that may be important for the metastatic cascade. We
subsequently investigated other potential mechanisms of metastasis that may occur as tumors evolve de
novo. Specifically, we analyzed paired primary tumors and metastases using a multi-fluorescent lineagelabeled mouse model of PDAC. Genomic and transcriptomic analysis revealed, for the first time, an
association between metastatic burden and amplification of MYC. Mechanistically, we found that MYC
promotes metastasis by recruiting tumor associated macrophages (TAMs), leading to greater
bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was
associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically
in metastatic patients. These results implicate MYC activity as a major determinant of metastatic burden
in advanced PDAC. Thus, using novel mouse models of PDAC, we identified key pathways, genetic and
non-genetic, that regulate cellular plasticity and lead to increased invasion and metastatic spread. The
identification of these pathways and regulators represent an avenue for combating the most lethal
aspects of tumor progression, metastasis and therapy resistance.
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ABSTRACT

CELLULAR PLASTICITY AND HETEROGENEITY: IMPLICATIONS IN TUMOR CELL
INVASION AND METASTASIS

Robert J. Norgard
Ben Z. Stanger

The existence of heterogenous subpopulations of cells in cancer has been shown to arise
via natural evolution or through movement between cellular states collectively known as “cellular
plasticity.” This heterogeneity and plasticity are critical drivers of phenotypic diversity culminating
in many facets of disease progression, such as metastasis. While the existence of heterogeneity
and cellular plasticity are well accepted, the molecular underpinnings and functional outcomes,
such as metastasis, of these populations remains limited. Here, we first investigated a form of
cellular plasticity known as epithelial-to-mesenchymal transition (EMT) and dissect the molecular
mechanisms of a recently described partial EMT (P-EMT) state operating in vivo in a mouse model
of pancreatic ductal adenocarcinoma (PDAC), whereby tumor cells lose their epithelial state
through a post-translational mechanism. This is distinct from complete EMT (C-EMT), which
achieves the transition transcriptionally, through regulation of a complex hierarchy of EMT
transcription factors (EMT-TFs). We report that prolonged calcium signaling in carcinoma cells
induces a P-EMT phenotype characterized by the internalization of membranous E-cadherin
(ECAD) and an increase in cellular migration and invasion. These effects can be recapitulated by
signaling through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through
the downstream activation of calmodulin. These results implicate calcium signaling as a potent
driver of epithelial-mesenchymal plasticity in cancer cells that may be important for the metastatic
cascade. We subsequently investigated other potential mechanisms of metastasis that may occur
as tumors evolve de novo. Specifically, we analyzed paired primary tumors and metastases using
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a multi-fluorescent lineage-labeled mouse model of PDAC. Genomic and transcriptomic analysis
revealed, for the first time, an association between metastatic burden and amplification of MYC.
Mechanistically, we found that MYC promotes metastasis by recruiting tumor associated
macrophages (TAMs), leading to greater bloodstream intravasation. Consistent with these findings,
metastatic progression in human PDAC was associated with activation of MYC signaling pathways
and enrichment for MYC amplifications specifically in metastatic patients. These results implicate
MYC activity as a major determinant of metastatic burden in advanced PDAC. Thus, using novel
mouse models of PDAC, we identified key pathways, genetic and non-genetic, that regulate cellular
plasticity and lead to increased invasion and metastatic spread. The identification of these
pathways and regulators represent an avenue for combating the most lethal aspects of tumor
progression, metastasis and therapy resistance.

vi

TABLE OF CONTENTS

ACKNOWLEDGMENT ...................................................................................................... iv
ABSTRACT ....................................................................................................................... v
TABLE OF CONTENTS ..................................................................................................... vii
LIST OF ILLUSTRATIONS AND TABLES ............................................................................. ix
CHAPTER 1: INTRODUCTION ...........................................................................................1
Tumor cell plasticity and epithelial to mesenchymal transition (EMT) ................................... 1
Tumor cell heterogeneity and the potential for subclones to acquire metastatic capabilities 6
Pancreatic cancer, invasion, metastasis and the problem ...................................................... 9

CHAPTER 2: EMT SUBTYPE INFLUENCES EPITHELIAL PLASTICITY AND MODE OF CELL
MIGRATION ..................................................................................................................13
Brief Introduction ................................................................................................................. 13
KPCY tumors exhibit two distinct EMT programs ................................................................. 15
EMT programs are correlated with tumor differentiation and PDAC subtypes..................... 17
The P-EMT program is mediated by protein re-localization .................................................. 18
P-EMT is associated with ECAD localization in late recycling vesicles ................................... 20
Plasticity between epithelial and mesenchymal states is determined by EMT subtype ....... 21
TGFb treatment induces a C-EMT phenotype ....................................................................... 23
EMT subtypes exhibit distinct modes of tumor cell migration.............................................. 24
C- and P-EMT subtypes are conserved across multiple human cancer cell lines ................... 25
Summary and Discussion ...................................................................................................... 28
Materials and Methods ........................................................................................................ 34
Chapter 2 Figures and Figure Legends .................................................................................. 42

CHAPTER 3: CALCIUM SIGNALING INDUCES A PARTIAL EMT ........................................71
Brief Introduction ................................................................................................................. 71
Ca2+ signaling is enriched in P-EMT tumor cells ..................................................................... 72
Ca2+ influx is sufficient to drive a P-EMT phenotype and increased migration and invasion . 74
Ionomycin treatment induces mesenchymal gene transcription without repressing epithelial
gene transcription ................................................................................................................ 76
GPCR signaling through Gaq induces P-EMT ........................................................................ 78
Calcineurin (CaN) is dispensable for calcium-induced P-EMT ............................................... 78
vii

Calmodulin (CaM) acts downstream of Ca2+ mobilization to induce P-EMT .......................... 79
Summary and Discussion ...................................................................................................... 80
Materials and Methods ........................................................................................................ 82
Chapter 3 Figures and Figure Legends .................................................................................. 92

CHAPTER 4: MYC CONTROLS METASTATIC HETEROGENEITY IN PANCREATIC CANCER
.................................................................................................................................... 110
Brief Introduction ............................................................................................................... 110
Individual tumor lineages in KPCXY mice correspond to clones with distinct somatic copy
number profiles .................................................................................................................. 114
Genomic and transcriptional analyses identify Myc as a potential driver of metastatic
phenotypes......................................................................................................................... 115
A panel of cell lines that preserve the MetLow and MetHigh phenotypes .............................. 117
MYC promotes tumor cell intravasation through the recruitment of tumor associated
macrophages ...................................................................................................................... 118
Metastasis in human PDAC is associated with MYC gene amplification and elevated
expression .......................................................................................................................... 121
Summary and Discussion .................................................................................................... 123
Materials and Methods ...................................................................................................... 128
Chapter 4 Figures and Figure Legends ................................................................................ 144

CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS ..................................................... 173
Insights into the regulation of epithelial plasticity in vivo .................................................. 173
Partial EMT: The best of both worlds? ................................................................................ 176
The existence of metastatic drivers .................................................................................... 179
Concluding Remarks ........................................................................................................... 182
Chapter 5 Figures and Figure Legends ................................................................................ 184

REFERENCES ................................................................................................................ 186
MANUSCRIPTS ............................................................................................................ 212

viii

LIST OF ILLUSTRATIONS AND TABLES

Chapter 2 Figure 1: Two distinct EMT programs exist among KPCY tumors….............................42
Chapter 2 Figure 2: P-EMT is characterized by post-transcriptional regulation of the epithelial
program………………………………………...………………………...………………………………..44
Chapter

2

Figure

3:

Intracellular

ECAD

co-localizes

with

Rab11+

late

recycling

vesicles…………………………………………………………………………………...……………..…47
Chapter 2 Figure 4: Features of epithelial plasticity in C-EMT and P-EMT subtypes …………......49
Chapter 2 Figure 5: EMT subtypes exhibit distinct modes of cell migration and
dissemination………………………………………………………………………………………...…....52
Chapter 2 Figure 6: Distinct EMT subtypes occur in human pancreas, breast, and colorectal
cancer cell lines……………….……………………………………………………………………...……54
Chapter 2 Figure S1: Epithelial and mesenchymal marker expression in KPCY tumors, Related to
Figure 1……………………………………………………………………………………………..……...56
Chapter 2 Figure S2: RNAseq sample quality control, Related to Figure 1 …………….…..……...58
Chapter 2 Figure S3: GSEA confirms EMT within RNAseq samples, Related to Figure 1
..…………………………………………………………………………………………………...………..60
Chapter 2 Figure S4: KPCY tumors demonstrate distinct histological subtypes………….…….….62
Chapter 2 Figure S5: Tumor subtype correlates with EMT subtype in KPCY tumors……….……..64
Chapter 2 Figure S6: Representative flow plots for surface/intracellular ECAD staining………....66
Chapter 2 Figure S7: Tumor and EMT Subtype classification of cell lines in pancreas, breast, and
colorectal cancer cell lines, Related to Figure 6..….........................................................................68
Chapter 2 Table S1: Histology of tumors used for RNAseq…………………….......…….…............70
Chapter 2 Table S2: Gene set enrichment analysis P-values for KPCY tumors……………….......70
Chapter 3 Figure 1: Ca2+ signaling is enriched in P-EMT cells.……………………….…………....92

ix

Chapter 3 Figure 2: Ca2+ influx is sufficient to drive a P-EMT phenotype and increased migration
and invasion..........……............................................................................……………….………....94
Chapter 3 Figure 3: Ionomycin treatment induces mesenchymal gene transcription without
repressing epithelial gene transcription.….........…………………...………………….…….…..........96
Chapter 3 Figure 4: Gaq signaling acts through calmodulin to induce P-EMT...............................98
Chapter 3 Supplemental Figure S1: Enriched pathways in P-EMT and C-EMT.........................100
Chapter 3 Supplemental Figure S2: Activation of calcium signaling does not induce cell death
and promotes EMT in human carcinoma cells…………...…...….…………………………………...102
Chapter 3 Supplemental Figure S3: Epithelial proteins are conserved in exosomes.................104
Chapter 3 Supplemental Figure S4: Calcineurin activity is dispensable for calcium induced
EMT…………………………………………………………………………………….………………....106
Chapter 3 Supplemental Figure S5: GPCRs expressed in C-EMT and P-EMT pancreatic
tumors……………………………………………………………………………………….…………....108
Chapter 4 Figure 1: Advanced pancreatic tumors exhibit intertumoral differences in their
propensity for metastasis …....……..…………………………………………....………...….....…….144
Chapter 4 Figure 2: Somatic copy number alteration analysis confirms fluorescence based lineage
relationships and reveals genetic heterogeneity in in paired primary pancreatic tumors and liver
metastasis....……..…...........................................................................................................…….147
Chapter 4 Figure 3: The Methigh phenotype is associated with focal, high amplitude Myc
amplifications and elevated expression.....…………………………………………...….….....…......149
Chapter 4 Figure 4: Myc regulates metastasis by enhancing tumor cell intravasation.................152
Chapter 4 Figure 5: Myc recruits pro-metastatic macrophages to the TME....….........................155
Chapter 4 Figure 6: MYC amplification and enhanced transcriptional activity are associated with
metastasis in human PDAC.….............................................................................................…….158
Chapter 4 Supplementary Fig 1: Classifying metastatic burden in human and murine advanced
PDA. ……..……...…..…..…...........…………………………..…………………………………….…..160

x

Chapter 4 Supplementary Fig 2: Copy number alteration analysis reveals lineage relationships
and genetic heterogeneity of fluorescently labeled primary PDACs and their matching
metastasis..............………………………………………………..………………………….………...162
Chapter 4 Supplementary Fig 3: Global patterns of large scale copy number alterations do not
differ between MetHigh and MetLow clones, while Myc amplifications are maintained in metastatic
lesions.......………..……...….................................................………………………………….……164
Chapter 4 Supplementary Fig 4: Ingenuity pathway analysis of the MetHigh transcriptome
…………………………………………………………………………………………………………….166
Chapter 4 Supplementary Fig 5: Established MetHigh / MetLow cell lines maintain their overall
genomic

profile

and

do

not

select

for

Myc

amplification

during

in

vitro

culture...…..…...…...……………………………………….……………………...…...…..........….….167
Chapter 4 Supplementary Fig 6: Tumor weight and Myc expression in orthotopic primary tumors
primary and Myc overexpressing cell lines……………………………………............................….169
Chapter 4 Supplementary Fig 7: MYC amplifications are enriched in metastatic human
PDA…………………...............…..........………………………………………………...……………..171
Chapter 5 Figure 1: Graphical abstract of C-EMT versus P-EMT………...…………..……...……184
Chapter 5 Figure 2: Graphical abstract of the mechanisms behind poorly versus highly metastatic
PDAC……………………………………………………………………………………………….…….185

xi

CHAPTER 1: INTRODUCTION

Tumor cell plasticity and epithelial to mesenchymal transition (EMT)

Tumors are complex, ever changing and evolving ecosystems. Tumor cells are
exposed to diverse metabolic conditions, signaling molecules, stromal elements, and
therapeutic agents, which collectively form a volatile microenvironment that can fuel
changes in the cellular phenotype. Such changes may involve genetic alterations, but they
more commonly involve transcriptional, proteomic, or epigenetic fluctuations. The
resulting pliability in cell state, referred to as plasticity, can facilitate multiple aspects of
tumor progression, including tumor initiation and metastasis, immune evasion, and
chemoresistance (Yuan et al, 2019). Consequently, elucidating the mechanisms by which
cancer cells exploit plasticity to cope with selective pressures may lead to novel
therapeutic opportunities.
One of the most well-well-known examples of cellular plasticity that occurs in
normal development is a process known as epithelial-to-mesenchymal transition (EMT) –
or the reverse mesenchymal-to-epithelial transition (MET). In development, EMT can be
induced by any of several pleiotropic and evolutionarily conserved signaling factors (e.g.,
TGFβ, EGF, HGF, NOTCH, FGF, and WNT ligands), which initiate a signaling cascade
leading to the expression of one or more so-called EMT transcription factors (EMT-TFs).
These EMT-TFs—which include SNAIL, TWIST, ZEB, and PRRX family members—
function as transcriptional activators and repressors, whose principal function is the
repression of genes whose products are necessary for maintenance of the epithelial state
(i.e., proteins comprising junctional complexes and epithelial intermediate filaments). Loss
1

of E-cadherin, a key component of epithelial adherens junctions, is considered a hallmark
of EMT. In parallel, EMT involves the induction of genes associated with the mesenchymal
state, including the mesenchymal intermediate filament protein vimentin and components
of the extracellular matrix (ECM) (Lamouille et al, 2014).
While critical for normal embryonic development, EMT is also frequently observed
in many cancers and has been associated with invasion, metastasis, and poorer prognosis.
In carcinomas (cancers that arise from cells of epithelial origin), the manifestation of an
EMT program is reflected in a tumor's grade. High-grade disease is aggressive and
marked by an obliteration of normal tissue structure and architecture. Such tumors—often
referred to as “poorly differentiated”—bear the histopathologic and molecular hallmarks of
EMT. By contrast, low-grade disease is characterized by a “moderately-to-welldifferentiated” histology that reflects the cancer cells' retention of an epithelial phenotype.
Across human cancer, high-grade (poorly differentiated) tumors carry a worse prognosis
than low-grade (well-differentiated) tumors. Importantly, such grading schemes describe
the dominant cellular phenotype within a tumor and thus fail to capture the dynamic
plasticity that exists. Rather than being wholly comprised of cancer cells with either a
mesenchymal or an epithelial phenotype, most tumor cells exist in equilibrium between
the two states. In poorly differentiated tumors, this equilibrium is shifted to the
mesenchymal state, whereas in well-differentiated tumors it is shifted to the epithelial state.
Thus, it is the relative abundance of cells in either state that dictates tumor grade. Although
the determinants of “equilibrium constants” governing epithelial–mesenchymal plasticity
in tumors are unknown, it is likely that genetic and epigenetic factors existing before or
acquired during tumor progression are responsible. It has also been shown that the “cell
of origin” from which a tumor arises plays an important role in shaping tumor histology,
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and it likely also influences the epithelial–mesenchymal “set point” of a tumor (Latil et al,
2017).
Although most studies of EMT mechanisms have focused on transcriptional
regulatory programs, post-transcriptional programs also regulate the epithelial phenotype.
During development, the abundance or localization of E-cadherin—a critical component
of epithelial adherens junctions—can be lost through one of several post-transcriptional
mechanisms. These include p38-mediated regulation of E-cadherin protein levels during
mouse gastrulation (Zohn et al, 2006; Hirano et al, 2008; Lee et al, 2007), EGF-mediated
endocytosis of E-cadherin during zebrafish epiboly (Song et al, 2013), and transcriptionindependent

regulation

of

E-cadherin

by

the

GATA

factor

Serpent

during Drosophila endoderm development (Campbell et al, 2011). As I will show later in
my thesis, post-transcriptional programs can also mediate cancer-associated EMT, where
a significant percentage of carcinoma cells lose their epithelial phenotype through
internalization of epithelial proteins rather than transcriptional repression (Aiello et al,
2018).
EMT is rarely observed in adult tissues under homeostatic conditions, but it can
emerge upon injury or stress and is a common feature of malignancy. Many of the factors
shown to induce EMT during embryogenesis or under in vitro settings are present in
tumors, including a variety of soluble growth factors and matrix components, hypoxia,
inflammation, and increased tissue stiffness (Lamouille et al, 2014). The best studied of
these inducers is TGFβ, which can induce EMT in a wide assortment of cultured
carcinoma cells. TGFβ signaling induces the formation of an active SMAD complex, which
partners with other DNA binding proteins to induce the transcription of EMT-TFs such as
SNAIL, TWIST, and ZEB (Xu et al, 2009). But what particular (or culmination of) factors
remain important to induce EMT in vivo remains unknown.
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Importantly, EMT likely does not represent a single defined program. Rather, it
encompasses a phenotypic spectrum characterized by different degrees of epithelial and
mesenchymal features, involving a range of mechanisms. Hence, definitions of EMT have
evolved over time to accommodate a variety of phenotypic transitions that involve some
measurable changes in the epithelial or mesenchymal features of a cell (Nieto et al, 2016b;
Klymkowsky & Savagner, 2009). This conceptual flexibility has also led to the recognition
that cells having intermediate epithelial–mesenchymal phenotype—occupying a hybrid or
“partial EMT” (P-EMT) state—have properties distinguishing them from cells with a purely
epithelial or mesenchymal phenotype (Yang et al, 2020). Cells residing in such P-EMT
states may simultaneously express epithelial and mesenchymal features or may have lost
their epithelial characteristics without acquiring mesenchymal traits. Still unresolved is
whether these intermediate states are “metastable,” suggesting an incomplete or
intermediate step as cells transition, or whether P-EMT represents a stable state of its
own (Jolly et al, 2016). Such partial states may facilitate the collective cell migration of
tumor cells (Aiello et al, 2018; Lecharpentier et al, 2011; Armstrong et al, 2011), leading
to the formation of highly metastatic circulating tumor cell clusters (Aceto et al, 2014;
Maddipati & Stanger, 2015). For this reason, and the greater cellular plasticity possibly
afforded by partial EMT, P-EMT states are thought to confer carcinoma cells with a higher
degree of metastatic competence as compared with complete EMT programs (Bierie et al,
2017), making them of great interest to study.
Most molecular studies of epithelial–mesenchymal plasticity in the last decade
were conducted through in vitro manipulation of cultured carcinoma cells. Thus, the
mechanisms underlying EMT in vivo, and the functional role(s) of epithelial–mesenchymal
plasticity as tumors evolve have been hard to pin down. One challenge impeding in
vivo studies was the difficulty in distinguishing carcinoma cells that have undergone an
4

EMT (and hence exhibit a mesenchymal phenotype) from fibroblasts or other
mesenchymal cells that normally populate the tumor stroma. In addition, most metastatic
lesions were known to exhibit epithelial features, an observation that on face value
seemed at odds with a role for EMT in metastasis (discussed below). Thus, despite longstanding evidence for epithelial–mesenchymal plasticity in tumors (Brabletz et al, 2001;
Savagner, 2001), the importance of EMT in cancer biology—and even its very existence—
has long been questioned (Tarin, 2005). With more recent advances in lineage-tracing
techniques and intravital imaging, however, it has become widely accepted that cancer
cells acquire a variety of EMT-like phenotypes during tumor progression in both model
systems and patients with cancer (Lecharpentier et al, 2011; Rhim et al, 2012; Yu et al,
2013; Dongre & Weinberg, 2019).
While the existence of EMT is no longer highly disputed, the debate over EMT in
vivo has been particularly contentious regarding metastasis. When carcinomas spread,
they lose contact with neighboring epithelial cells. The acquisition of invasive behavior
thus requires (by definition) that carcinoma cells remodel the tight junctions, adherens
junctions, and other complexes that mediate their intimate intercellular connections.
Because EMT involves a loss of epithelial characteristics and/or an acquisition of
mesenchymal characteristics, it has emerged as the most straightforward mechanism to
account for cancer cell invasion. Indeed, gain-of-function approaches have clearly shown
that EMT is sufficient to enhance invasion and metastasis. For example, overexpression
of certain EMT-TFs (e.g., SNAIL1, TWIST1, ZEB1) in epithelial carcinoma cells promotes
the loss of E-cadherin, acquisition of a spindle-like mesenchymal morphology, and
enhanced migratory and invasive behavior in vitro (Cano et al, 2000; Batlle et al, 2000;
Yang et al, 2004). By contrast, loss-of-function studies have been more difficult to interpret
and suggest that tissue- and context-dependent differences dictate the molecular
5

mechanisms underlying EMT in a given tumor (Ye et al, 2015). For example, deleting
either SNAIL1 or TWIST1 in a spontaneous mouse model of PDAC had minimal effect on
metastasis (Zheng et al, 2015), whereas ZEB1 ablation in a similar model drastically
reduced colonization, invasion, and metastasis (Krebs et al, 2017). Taken together, these
results suggest that distinct and overlapping EMT inducers—including both transcriptional
and posttranscriptional mechanisms—play distinct roles in metastatic spread.

Tumor cell heterogeneity and the potential for subclones to acquire metastatic
capabilities

With advances in molecular diagnostics and sequencing techniques, the genetic
make-up of tumors has been unraveled. The process from normal to malignant is
understood to occur through sequential acquisitions of mutations or alterations that lead
to uncontrolled proliferation, circumvention of growth suppressors and death programs,
and evasion of the immune system—ultimately culminating in programs leading to
invasion and metastasis (Hanahan & Weinberg, 2011). Although portrayed to occur in a
step wise fashion, the actual events that occur are rather stochastic and can occur in a
variety of scenarios. And even after cancers arise, this process continues to flourish as
tumor cells begin to experience certain limitations and are forced to adapt to situations
such as lack of nutrients and therapy.
Tumor heterogeneity can be divided into two categories: intertumoral and
intratumoral heterogeneity. Intertumoral heterogeneity refers to differences in tumors of
the same histological type between different patients. This is typically thought to arise from
patient variations that occur due to germline mutations, somatic mutations, and
environmental factors. The idea of personalized medicine has really shaped our
6

appreciation for intertumoral heterogeneity. For example, this can be exemplified in
patients with oncogenic drivers such as BRCA mutations that are sensitive to PARP
inhibitors (Farmer et al, 2005). Intratumoral heterogeneity refers to difference within a
patient and can occur as spatial heterogeneity, where different subpopulations of tumors
exist across a tumor, or temporal heterogeneity, where tumor cells change over time
(either genetically or non-genetically). Temporal heterogeneity occurs as tumor cells
become plastic either as a result of a natural progression or a result of a selective pressure
that targets only a small subset of tumor cells. The result can be a highly aggressive
subpopulation of tumors that either is resistant to therapies or has acquired the ability to
metastasize (Dagogo-Jack & Shaw, 2018).
Metastasis is the hallmark of cancer that constitutes the primary cause of death
for >90% of cancer patients (Steeg, 2006). The metastatic process and the development
of metastases is a highly inefficient process. It requires cancer cells to leave their primary
site, survive circulation in the bloodstream, exit the bloodstream, acclimate to a foreign
environment and begin to grow. Only a select number of cells are capable of migrating out
from the primary tumor and the ones that make it into circulation are now exposed to harsh
conditions while in circulation. While this is well known, what drives these select cancer
cells to metastasize and the potential mechanisms employed by tumor cells to survive
metastasize remains poorly understood (Mehlen & Puisieux, 2006). In their seminal
perspective, Hanahan and Weinberg specify that “activating invasion and metastasis” is a
hallmark of cancer (Hanahan & Weinberg, 2011). But how this comes about in tumors is
rather unknown. One idea is that some tumor cells themselves exhibit genome
instability(Hanahan & Weinberg, 2011; Carter et al, 2006; Waddell et al, 2015). This can
range from either single base pair substitutions to entire genome amplifications and is
thought to be critical to the progression of cancers. The source of this instability is thought
7

to occur from something as simple as errors occurring under unregulated growth to
exposure to mutagens to mistakes made during DNA repair processes. Regardless of the
how the instability transpires, this genome instability results in the formation of clonally
diverse tumor cells potentially leading to the emergence of more competitive subclones(De Bruin et al, 2014; Campbell et al, 2010).
This idea of clonal evolution or the selective hypothesis was first postulated by
Peter Nowell and is based on the idea that a mutation initiates malignancy which confers
an initial growth advantage (Nowell, 1976). As expanding cells continue, genome
instability creates additional subclones that begin to become subjected to pressures
creating a survival of the fittest scenario and resulting in genetically heterogenous
subpopulations. However, the notion that clonal populations must always be in competition
has been challenged by suggesting that there is a cooperation and possible necessity for
different subclones during tumor progression and metastasis. Nonetheless, genomic
instability is thought to eventually lead to the presence of a subclone with the inherent
ability to metastasize (Cleary et al, 2014; Maddipati & Stanger, 2015).
In tumors, genome studies have comprehensively catalogued key mutations that
are

responsible

for

tumor

development.

For

example,

in

pancreatic

ductal

adenocarcinoma (PDAC), KRAS, TRP53, CDKN2A, and SMAD4 are suggested to play a
role in tumor development, paving the path for genomic investigations of metastatic
disease and the potential identification of metastasis promoting alterations (Kleeff et al,
2016). Indeed, recent sequencing studies and functional experiments in mouse models
have found genomic amplifications in KRAS to be associated with the development from
non-metastatic to metastatic disease (Chan-Seng-Yue et al, 2020; Mueller et al, 2018).
Other studies using mouse models of various cancers suggest that other genes are
metastatic drivers (e.g. MYC, GATAD2B, BLIMP1) (Chiou et al, 2017; Grzeskowiak et al,
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2018; Wolfer & Ramaswamy, 2011; Rapp et al, 2009) adding to an increasing growing
list of putative driver genes identified from massive sequencing efforts (Jamal-Hanjani et
al, 2017; Bailey et al, 2018).
Although these studies have suggested the potential for genetic drivers of
metastasis, and from a genetic point of view, it would seem plausible that sequential
additional mutations would lead to metastasis, extensive studies have not been able to
explicitly define evidence for driver mutations. In addition, heterogeneity has been
observed in metastatic lesions suggesting that many types of cells are capable of
metastasis, leaving further doubt. Recent endeavors have thus focused on studying
putative epigenetic drivers and the outcomes from active signaling pathways on
rearranging a more permissive tumor microenvironment for metastasis. In fact, several
studies have indicated that the presence of a certain cell type, (neutrophils, macrophages,
etc) can strongly influence metastatic behavior (Wculek & Malanchi, 2015; Harney et al,
2015). Thus, understanding the interplay between genetic alterations that influence
metastatic behavior and the tumor biology that promotes it – in a cell autonomous and/or
non-cell autonomous manner – is crucial for understanding metastasis and critical for the
development of more effective treatments.

Pancreatic cancer, invasion, metastasis and the problem

Pancreatic cancer is a uniformly lethal disease with a dismal overall prognosis that
has not significantly changed for many decades (five-year survival rate of less than 10%).
It is predicted to soon be the second leading cause of cancer related death in the USA
(Rahib et al, 2014). The reasons for this poor prognosis are multifactorial. It is usually
diagnosed at advanced stages, often resulting from a lack of specific symptoms and
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difficulties in non-invasive imaging for detection. Pancreatic cancer is aggressive, with
local and distant invasion and metastasis present, impeding curative surgical resection in
the majority of patients. Underlying this disease are few prevalent genetic mutations (the
most common are KRAS, TRP53, CDKN2A, and SMAD4), none of which are currently
targetable (Kleeff et al, 2016). The treatments that are available are rather ineffective since
pancreatic cancers are complex at the genome, epigenetic, and metabolic levels.
Furthermore, a complex interplay between tumor cells and the normal infiltrating tumor
cells further inhibits therapeutic intervention. Thus, pancreatic cancer is a disease needed
of further understanding.
Metastasis remains the main reason for death across cancer types and pancreatic
cancer is no exception with nearly 80% of patients presenting with metastasis (Lambert et
al, 2017). While metastasis is classically thought to be a late event in tumor progression,
brought on by increasing mutations, the use of genetically engineered mouse models has
questioned this dogma. These models have revealed that pancreatic cancer readily
undergoes EMT, dissemination and metastasis during neoplastic transformation,
surprisingly well before the transition to invasive carcinoma (Rhim et al, 2012). These
studies truly highlighted the importance and relevance of the existence of EMT tumor cells
since they are nearly impossible to distinguish from normal fibroblasts that infiltrate in
tumor development. This is known as the desmoplastic response and in some
instances >90% of PDAC tumors are composed of normal cells that have infiltrated.
As mentioned above, recent studies have investigated the molecular mechanisms
and clinical significance of EMT in vivo particularly in PDAC. While deletion of EMT-TF
SNAIL1 or TWIST1 failed to reduce metastasis in mouse models of PDAC, the lack of
these factors greatly impacted the response to chemotherapy (Zheng et al, 2015). In a
different study, deletion of ZEB1, drastically reduced colonization, invasion, and
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metastasis revealing that different transcription factors may play differing roles in EMT and
chemoresistance in PDAC (Krebs et al, 2017). Furthermore, our sequencing effort,
presented in chapter 2, to unbiasedly identify the underpinnings of EMT in PDAC revealed
that a post-translational mechanism may be the main mechanism by which PDAC cells
undergo EMT (Aiello et al, 2018), adding another level of complexity to EMT regulation in
PDAC, warranting further investigation.
Although EMT presents a major concern for the treatment of PDAC patients, the
mutational landscapes and subtype heterogeneity adds to this complexity. It is now well
accepted that histo-pathologically indistinguishable tumors often harbor substantial
molecular differences. While the molecular pathology of pancreatic cancer is dominated
by KRAS, TRP53, CDKN2A, and SMAD4, new sequencing efforts have brought to light
the prevalence of other genes that are mutated at much lower rates (KDM6A, BCORL1,
RBM10, MLL3, ARID1A, and TGFBR2 are the among the highest mutated) (refer to
Collisson et al, 2019). The identification of these mutated genes has been useful in
understanding tumor biology and guiding clinical decisions. For example, patients with
BRCA1/2 mutations, that occur frequently in ovarian cancer patients but are rare in PDAC,
have been shown to respond to PARP inhibitors, prolonging progression free survival
(Golan et al, 2019). But in addition to genomic aberrations, transcriptional subtypes have
also been identified. Three seminal papers (Bailey et al, 2016b; Collisson et al, 2011;
Moffitt et al, 2015) have identified three predominate transcriptional subtypes that exist in
PDAC: a pancreatic progenitor subtype, a squamous more aggressive subtype, and an
immunogenic, activated stroma subtype indicative of the stroma present in the tumor. The
existence of these subtypes has identified clear opportunities to advance therapeutic
development being associated with different prognoses and mutations in specific genetic
pathways. Yet, how these subtypes arise, how many exist in a given tumor and whether
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selective pressures from treatment may alter the molecular composition seen in other
tumors remains unknown. It is also likely that these subtypes exist in metastasis, and
ongoing work attempts to understand this heterogeneity in metastasis.
Based on the above introduction, this thesis aims to understand how plasticity and
heterogeneity impact tumor cell migration, invasion and metastasis by (i) understanding
the molecular changes that occur in epithelial plasticity in an unbiased fashion, (ii)
determining the molecular mechanisms of the partial EMT state, and (iii) modeling
metastatic heterogeneity found in human patients and dissect molecular and cellular
features contributing to metastasis. The ultimate goal of this project is to vastly improve
our understanding of basic biological processes in tumor cell plasticity and heterogeneity,
critical for the development of tractable therapeutics for cancer patients. While the majority
of this work is focused on pancreatic cancer, we believe that the themes and discoveries
of this thesis may be applicable to other tumor types.

Chapter 1 Acknowledgements: Excerpts within chapter one are used from: Yuan S*,
Norgard RJ*, and Stanger BZ. Cellular Plasticity in Cancer. Cancer Discovery. 2018. A
special thanks to Salina Yuan for help writing that review.
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CHAPTER

2:

EMT

SUBTYPE

INFLUENCES

EPITHELIAL

PLASTICITY AND MODE OF CELL MIGRATION

Brief Introduction

Metastasis is responsible for most cancer-related deaths, and yet the cellular and
molecular mechanisms underlying tumor cell spread remain obscure. One attractive
model for metastatic dissemination involves epithelial-to-mesenchymal transition (EMT)
(Ye et al, 2015). EMT has traditionally been viewed as a binary process involving a
complete conversion from epithelial to mesenchymal state. However, it has been
increasingly recognized that EMT also encompasses a range of hybrid states, a
phenotype that has been referred to “partial EMT” (P-EMT). Because P-EMT is not well
defined in molecular terms (Savagner, 2015), it is unknown whether this hybrid status
signifies an intermediate phase during a mesenchymal transition or represents its own
end-state. Likewise, it is unclear whether the same mechanisms of transcriptional
repression that drive a “complete EMT” also operate during P-EMT.
While EMT involving classical (transcription-dependent) mechanisms can give rise
to single cells capable of crossing basement membranes and invading blood vessels,
many tumors have been noted to exhibit “collective” migratory patterns whereby cells
retain cell-cell contacts and activate mesenchymal programs, resulting in dissemination of
multi-cellular tumor cell clusters (Cheung & Ewald, 2016; Friedl et al, 2012). While both
phenomena have been observed in mouse models and clinical specimens ((Aceto et al,
2014; Maddipati & Stanger, 2015; Jolly et al, 2017), the programs underlying these
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differences in epithelial plasticity and cell migration – and the extent to which P-EMT
contributes to either phenotype – remain unclear.
In this chapter, we explore the relationship between EMT, tumor subtype, and
invasive phenotype in vivo. We show that in a widely-used mouse model of pancreatic
ductal adenocarcinoma (PDAC), individual tumors utilize different plasticity programs – a
complete EMT program involving transcriptional repression and an alternative program in
which the epithelial phenotype is lost post-transcriptionally. Tumors utilizing these
programs are phenotypically distinguishable at a histological and transcriptional level in a
manner that correlates with the major subtypes of human PDAC. Moreover, these
divergent plasticity programs are associated with either single cell invasion or collective
migration. Finally, we provide evidence that the alternative program observed in PDAC
governs EMT in other tumor types as well. Our findings thus suggest that the mechanisms
driving EMT in vivo may differ from the classically described transcriptional programs
studied in vitro and indicate a link between the broad transcriptional programs that define
tumor subtype and the cellular mechanisms that shape epithelial plasticity and tumor
invasion.
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KPCY tumors exhibit two distinct EMT programs
To study the mechanism of EMT in vivo, we used the LSL-KrasG12D; P53loxP/+; Pdx1-cre;
LSL-Rosa26YFP/YFP (KPCY) mouse model of PDAC. In KPCY mice, pancreas-specific Cre
recombinase (Cre) activity triggers expression of a mutant KrasG12D and deletes a single
p53 allele, leading to tumor formation over a period of 14-20 weeks. In parallel, Cre
activates a yellow fluorescent protein (YFP) lineage label expressed in all mutated
pancreatic epithelial cells, enabling tracking of their contribution to all stages of tumor
progression(Rhim et al, 2012).
Loss of the adherens junction protein E-cadherin (ECAD) is considered a hallmark
of EMT. To assess the EMT state of KPCY tumors, we used the YFP lineage label to
distinguish between stromal cells (which are YFP-) and tumor cells (which are YFP+) and
looked for histological features of EMT including separation from a lumen-associated
structure and a change in cellular architecture from a cuboidal to a spindle or fibroblastlike morphology. As expected, most tumor cells (89% ± 11.9; mean ± SD) exhibiting
morphological features of EMT lacked membrane ECAD staining (Chapter 2 Figure 1A).
In addition, co-staining experiments revealed a tight correlation between the loss of
membrane ECAD staining and the loss of staining for the tight junction protein Claudin-7
(CLDN7) and the epithelial cell adhesion molecule (EPCAM) on YFP+ tumor cells
(Chapter 2 Figure S1A,B). These results indicate that loss of surface E-cadherin identifies
most tumor cells undergoing EMT in this model.
Because EMT is typically associated with both gain of mesenchymal features and
loss of epithelial features, we examined the ability of a series of mesenchymal markers to
detect EMT in KPCY tumors. Using ECAD as an “anchor” epithelial marker, we co-stained
sections for ECAD and the mesenchymal markers Zinc-finger E-box homeobox 1 (ZEB1),
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SLUG (SNAI2), Vimentin (VIM), and Fibroblast-specific protein 1 (FSP1). Staining for
these proteins was uncommon in YFP+ECAD+ cells (Chapter 2 Figure S1C-J), suggesting
that loss of membranous ECAD (M-ECAD) precedes a gain of mesenchymal markers in
most tumor cells undergoing EMT. By contrast, positive staining for these mesenchymal
markers was observed in a third to a half of YFP+ECAD- tumor cells, although this staining
showed a high degree of variability from tumor to tumor (Chapter 2 Figure S1C-J). Based
on these findings, we concluded that loss of M-ECAD, rather than the gain of any single
mesenchymal marker, would result in the identification of most cells exhibiting
morphological features of EMT in this model.
We used fluorescence-activated cell sorting (FACS) to isolate M-ECAD+
(epithelial) and M-ECAD- (mesenchymal) YFP+ cancer cells from 11 primary KPCY tumors
for RNA sequencing (Chapter 2 Figures 1B and S2A). We confirmed accurate sorting by
visual inspection and ruled out contamination of non-tumor cells by performing qPCR for
Cd45 and YFP (Chapter 2 Figure S2B-D). Unsupervised hierarchical clustering and
principal component analysis identified two subgroups organized independently of Ecadherin status (Chapter 2 Figure 1C,D). Instead, tumor pairs (matched M-ECAD+ and
M-ECAD- samples) tended to cluster together, with three tumors comprising one group
(Cluster 1) and eight comprising another (Cluster 2). To examine how EMT may be
regulated in these two clusters, we examined the transcription of epithelial and
mesenchymal genes previously implicated in EMT by comparing M-ECAD- and M-ECAD+
cells. In the smaller tumor subgroup (Cluster 1; 3/11), EMT was associated with robust
downregulation of mRNAs for Ecad, EpCAM, Claudin-7, and other epithelial genes, as
predicted from standard EMT models (Chapter 2 Figure 1E,F). Surprisingly, EMT in the
larger subgroup (Cluster 2; 8/11) was associated with stable levels of mRNA for Ecad and
other epithelial genes (Chapter 2 Figure 1E,F) when M-ECAD+ and M-ECAD- cells were
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compared. Thus, loss of the epithelial program occurs in the absence of Ecad
transcriptional repression in the majority of KPCY tumors evaluated.
To distinguish between these phenotypes, we applied the term “complete EMT”
(C-EMT) to refer to Cluster 1 tumors, in which induction of a mesenchymal phenotype was
accompanied by transcriptional repression of the epithelial program, and the term “partial
EMT” (P-EMT) to refer to Cluster 2 tumors, in which tumor cells retained epithelial
transcripts during the mesenchymal transition. Tumors in both subgroups exhibited robust
upregulation of mesenchymal-related transcripts within the M-ECAD- population (Chapter
2 Figure 1F), and gene set enrichment analysis (GSEA) of both C- and P-EMT samples
confirmed that M-ECAD- transcriptomes correlated strongly with published EMT datasets
(Chapter 2 Figure S3A). Notably, C-EMT tumors had markedly higher expression of
several EMT-associated transcription factors (Etv1, Prrx1, Zeb1, Twist1, Snai1, Snai2,
and Zeb2) compared to P-EMT tumors regardless of whether M-ECAD+ or M-ECAD- cells
were examined (Chapter 2 Figure S3B,C). Thus, tumors characterized as either C-EMT
or P-EMT exhibit overlapping mesenchymal programs during EMT despite repressing their
epithelial programs by distinct means.

EMT programs are correlated with tumor differentiation and PDAC subtypes
Histological examination of the KPCY tumors profiled in Figure 1 revealed a striking
dissimilarity between the histology of C-EMT (Chapter 2 Figure S4A) and P-EMT (Chapter
2 Figure S4B) tumors. Specifically, C-EMT tumors exhibited a poorly differentiated
histology while P-EMT tumors exhibited a moderately- to well-differentiated histology
(Table S1). We thus hypothesized that C-EMT and P-EMT programs might be associated
with distinct tumor subtypes. To test this, we compared our KPCY tumor transcriptomes
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to published signatures for human PDAC subtypes (Bailey et al, 2016b; Collisson et al,
2011; Moffitt et al, 2015) (Chapter 2 Figure S5). In all cases, C-EMT tumors were strongly
associated with poorly-differentiated transcriptional subtypes (quasi-mesenchymal
(Collisson et al, 2011)), squamous (Bailey et al, 2016b), and basal-like (Moffitt et al, 2015)
while P-EMT tumors were associated with well-differentiated transcriptional subtypes
(classical/exocrine-like (Collisson et al, 2011) pancreatic progenitor/ADEX (Bailey et al,
2016b), and classical (Moffitt et al, 2015) (Chapter 2 Table S2). Hence, the mode by which
the epithelial phenotype is lost in murine PDAC correlates with distinct histological and
transcriptional subtypes of human PDAC.

The P-EMT program is mediated by protein re-localization
To understand how the epithelial program is repressed in different tumor subtypes, we
derived a panel of non-clonal, cell lines from poorly- and well-differentiated KPCY tumors.
To determine whether the EMT phenotypes of the cells in vitro matched their behavior in
vivo, we used FACS to separate cell lines based on surface or membranous ECAD (MECAD) staining and then performed qPCR for Ecad mRNA (Chapter 2 Figure 2A). Some
cell lines (those derived from poorly-differentiated tumors) exhibited a robust downregulation of Ecad mRNA when comparing M-ECAD- cells to M-ECAD+ cells (Chapter 2
Figure 2B). By contrast, other cell lines (those derived from moderately- or welldifferentiated tumors) exhibited comparable levels of Ecad mRNA in M-ECAD- versus MECAD+ cells (Chapter 2 Figure 2B). Thus, cell lines derived from KPCY tumors retain the
distinct EMT programs observed in vivo. Henceforth, we refer to cell lines in which EMT
is associated with transcriptional repression of Ecad as “C-EMT lines” and to those cell
lines in which EMT is associated with stable levels of Ecad mRNA as “P-EMT lines.”
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The persistence of epithelial gene transcription in M-ECAD- negative cancer cells
suggested that the epithelial program is regulated post-transcriptionally in tumor cells
undergoing P-EMT. To address this possibility, we sorted KPCY cell lines into epithelial
(M-ECAD+) and mesenchymal (M-ECAD-) fractions and compared levels of several
epithelial proteins in whole cell lysates. As expected, the M-ECAD- fractions from C-EMT
lines – harboring low levels of Ecad mRNA – had no detectable ECAD protein (Chapter 2
Figure 2C). By contrast, ECAD protein was abundant in the M-ECAD- fractions from PEMT lines, at levels comparable to their E+ counterparts. Other epithelial proteins,
including CLDN7 and EPCAM also persisted in whole cell lysates in P-EMT cell lines that
had lost M-ECAD (Chapter 2 Figure 2C). Interestingly, levels of p120-catenin (p120), an
ECAD interactor (Ireton et al, 2002; Stairs et al, 2011),did not vary between M-ECAD+
and M-ECAD- in either C- or P-EMT cell lines. Nevertheless, P-EMT cell lines expressed
both the 1A (mesenchymal) and 3A (epithelial) p120 isoforms (Pieters et al, 2012) while
C-EMT cell lines expressed only the 1A isoform. These data suggest that P-EMT cells
continue to express components of the epithelial program at the protein level following
EMT, while C-EMT cells lack both RNA and protein components of the epithelial program
following EMT.
We reasoned that intracellular sequestration might account for the lack of
membranous ECAD in P-EMT tumors and cell lines. To test this, we performed dual
antibody immunofluorescence by first staining live cells for ECAD using the fluorophore
Brilliant Violet 421 (to detect membrane-associated ECAD; M-ECAD) followed by fixation,
permeabilization, and a second round of ECAD staining using the fluorophore APC (to
detect intracellular ECAD; I-ECAD) (Chapter 2 Figure 2D and Figure S6). As expected, CEMT cells lacking membranous ECAD also lacked intracellular ECAD, consistent with the
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loss of Ecad mRNA and protein (Chapter 2 Figure 2E). By contrast, most P-EMT cells
lacking membranous ECAD were positive for intracellular ECAD (Chapter 2 Figure 2E).
The relocalization of ECAD was confirmed in tissue sections from KPCY mice, where
intracellular ECAD staining was observed exclusively in P-EMT tumors (Chapter 2 Figure
2F,G; epithelial cells for comparison, Chapter 2 Figure 2H,I). Similar patterns were
observed in sections from human PDAC tissue sections (Chapter 2 Figure 2J,K; epithelial
cells for comparison, Chapter 2 Figure 2L,M). Staining for other epithelial proteins,
including b-catenin, Claudin-7, and EpCAM, revealed a punctate intracellular pattern
similar to that of ECAD (Chapter 2 Figure 2O-Q). Taken together, these results suggest
that cells undergoing a P-EMT program retain epithelial proteins intracellularly both in vitro
and in vivo.

P-EMT is associated with ECAD localization in late recycling vesicles
Turnover and endocytic regulation of surface epithelial proteins is critical to both
maintenance of epithelial cell homeostasis and cell migration during EMT (Brüser &
Bogdan, 2017; Corallino et al, 2015). This process is regulated by the Rab subfamily of
GTPases, which mark internalized proteins for recycling or degradation following
sequestration into endosomes (Delva & Kowalczyk, 2009). To further understand the
mechanism of ECAD absence from the cell surface, we stained cultured P-EMT cells and
found that ECAD protein was confined to intracellular foci in delaminated cells exhibiting
a mesenchymal morphology (Chapter 2 Figure 3A), suggestive of storage in endocytic
complexes. To examine whether Rab family members are differentially expressed in
tumors belonging to the two EMT subtypes, we measured the relative abundance of
mRNAs encoding the major endocytic proteins Rab5, Rab7, and Rab11 in our tumor panel
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from Chapter 2 Figure 1. In comparison to C-EMT tumors, P-EMT tumors had higher
mRNA levels for the late recycling endosome protein Rab11, which is associated with
storage and recycling of epithelial proteins back to the cell surface (Chapter 2 Figure 3B).
By contrast, mRNAs for Rab7, which marks endosomes targeted for lysosomal fusion and
protein degradation, were more abundant in C-EMT tumors as compared to P-EMT tumors
(Chapter 2 Figure 3B).
To further examine the localization of internalized ECAD during P-EMT, we costained P-EMT cells for ECAD and Rab5, Rab7, or Rab11 (Chapter 2 Figure 3C-E). In
cells that had undergone P-EMT (delaminated spindle shaped cells) we observed rare colocalization of ECAD with Rab5 or Rab7 (Pearson’s correlation coefficients of 0.18 and
0.19, respectively) (Chapter 2 Figure 3C ,D). By contrast, we observed prominent colocalization of ECAD with Rab11 (Pearson’s correlation coefficient of 0.70) in virtually all
cells exhibiting a mesenchymal morphology (Chapter 2 Figure 3E). These results suggest
that turnover of surface ECAD during P-EMT is associated with storage in recycling
endocytic vesicles.

Plasticity between epithelial and mesenchymal states is determined by EMT
subtype
Epithelial-mesenchymal plasticity – both EMT and the reverse process of mesenchymalepithelial transition (MET) – is thought to play a role in tumor cell invasion and metastasis
(Nieto et al. 2016). Thus, we sought to determine whether different EMT subtypes (C-EMT
vs. P-EMT) are associated with differences in cellular plasticity during EMT in vitro and in
vivo. To assess the capacity of cells from either C-EMT or P-EMT cell lines to undergo
EMT, we sorted M-ECAD- cells from several cell lines and monitored them for the re21

expression of surface ECAD by FACS. Following re-plating of cells from P-EMT lines,
most cells re-expressed M-ECAD over a period of 6-9 days (Chapter 2 Figure 4A, green
curves), consistent with their derivation from well-differentiated tumors. Likewise, a
measurable (albeit smaller) fraction of cells from C-EMT lines also became positive for MECAD (Chapter 2 Figure 4A, orange curves). As expected, mRNA levels for ECAD
changed minimally over this timeframe in P-EMT cell lines (Chapter 2 Figure 4A). By
contrast, mRNAs for mesenchymal genes including CDH11, COLA8A2, PDGFRB, and
SNAIL were downregulated as C-EMT tumor cells became positive for M-ECAD (Chapter
2 Figure 4B). These results suggest that PDAC cells are competent to undergo MET
regardless of which program they use to shed their epithelial program during EMT.
To assess the plasticity of epithelial and mesenchymal cells in vivo, we FACS
sorted M-ECAD+ and M-ECAD- populations from murine C- and P-EMT cell lines and
injected them subcutaneously into NOD.SCID mice (Chapter 2 Figure 4C). After tumors
reached 1cm in size, YFP+ tumor cells were assessed for M-ECAD expression. Sorted MECAD+ P-EMT cells (P E+) and M-ECAD- P-EMT cells (P E-) both gave rise to welldifferentiated tumors with a comparably high frequency of ECAD+ tumor cells,
recapitulating the phenotype of tumors derived from parental (unsorted) P-EMT cells
(Chapter 2 Figure 4C). Conversely, sorted M-ECAD+ C-EMT cells (C E+) and M-ECADC-EMT cells (C E-) gave rise to poorly-differentiated tumors with a comparably low
frequency of M-ECAD+ cells, recapitulating the phenotype of tumors derived from parental
(unsorted) C-EMT cells (Chapter 2 Figure 4C). These results indicate that all cell lines
tested exhibit robust plasticity between the epithelial and mesenchymal states, with an
equilibrium governed by cell line-specific “set points.” In P-EMT cell lines (which have an
epithelial phenotype at a population level), this equilibrium is skewed to the epithelial state,
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whereas in C-EMT cell lines (which have a mesenchymal phenotype at a population level)
this equilibrium is skewed towards a mesenchymal state (Chapter 2 Figure 4D).

TGFb treatment induces a C-EMT phenotype
EMT is often induced experimentally by exposing cultured cells to exogenous
growth factors – most commonly TGFβ – resulting in the downregulation of transcripts for
Ecad and other epithelial genes across a variety of tumor types (Zavadil & Böttinger,
2005). However, our data suggested that in the autochthonous setting, well-differentiated
tumor cells undergo EMT via post-transcriptional regulation of epithelial proteins without
repression of epithelial gene expression. To examine how P-EMT tumor cells respond to
TGFβ stimulation, we treated two P-EMT cell lines (PD7591 and PD798) with TGFβ for a
period of 5 days. This treatment resulted in morphological changes (Chapter 2 Figure 4E)
and robust down-regulation of Ecad mRNA (Chapter 2 Figure 4F) and protein (Chapter 2
Figure 4G). Moreover, TGFβ-treated P-EMT cells that had lost M-ECAD also lacked IECAD, contrasting with the marked cytoplasmic ECAD re-localization observed when
such cells undergo EMT in the absence of TGFβ (Chapter 2 Figure 4H). Thus, cells that
use protein relocalization to lose their epithelial phenotype under standard culture
conditions remain competent to employ classically-defined transcription dependent
mechanisms when confronted with an exogenous (and overriding) growth factor signal
such as TGFβ.
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EMT subtypes exhibit distinct modes of tumor cell migration
Metastasis is a multi-step process that begins with cellular invasion and bloodstream
entry. This process is often conceptualized as the end result of EMT leading to the
dissemination of single tumor cells (Brabletz, 2012; Lamouille et al, 2014; Nieto et al,
2016b; Savagner, 2015). However, evidence in several cancer types suggest that
metastases can also arise from the collective migration and colonization of tumor cells
(Aceto et al, 2014; Cheung & Ewald, 2016; Friedl et al, 2012; Maddipati & Stanger, 2015;
Haeger et al, 2015; Labernadie et al, 2017) and may not require E-cadherin loss (Liu et
al, 2014). To determine whether different EMT programs affect the mode of cell migration
during metastasis, we generated tumor spheres from C- and P-EMT cell lines, embedded
them in Matrigel, and performed dynamic imaging to examine invasive behavior in real
time. In the C-EMT spheres, we observed spindle-like protrusions at the edges of the
primary cell mass and the invasion of single cells (Chapter 2 Figure 5A and Movie S1 in
(Aiello et al, 2017)). In P-EMT spheres, by contrast, tumor cells retained cell-cell contacts
and invaded as a collective group, with multicellular clusters delaminating from the primary
cell mass (Chapter 2 Figure 5B and Movie S2 in (Aiello et al, 2017)). Importantly, while PEMT cell lines exhibited both modes of escape from the primary cell mass (budding
clusters and single cells), invasion in C-EMT cell lines was primarily by single cells.
To assess whether these different patterns of cell migration impacted tumor cell
entry into the bloodstream, we performed orthotopic implantation into the pancreas of
NOD.SCID mice and examined the blood for evidence of circulating tumor cells (CTCs).
When tumors were derived from a C-EMT cell line, >95% of the CTCs were present as
single-cells (Chapter 2 Figure 5C,D). By contrast, when tumors were derived from a PEMT cell line, >50% of CTCs existed as tumor cell clusters (Chapter 2 Figure 5C,D). To
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determine whether the persistence of ECAD protein in cell lines undergoing P-EMT might
contribute to the prevalence of cell clusters, we stained CTCs and CTC clusters for ECAD.
In contrast to single CTCs arising from C-EMT tumors, which lacked E-cadherin protein
altogether, tumor cell clusters arising from P-EMT tumors retained staining for ECAD at
points of cell-cell contact but not on the cluster surface (Chapter 2 Figure 5E). Overall,
these data suggest that EMT subtype influences the mode of cell migration, with the PEMT subtype exhibiting both single cell and collective migration and C-EMT subtype
exhibiting primarily a single-cell invasion phenotype.

C- and P-EMT subtypes are conserved across multiple human cancer cell lines
Our finding that a majority of murine pancreatic tumors utilize a post-transcriptional
program to shed their epithelial phenotype prompted us to ask whether human cancer
cells also employ distinct EMT programs. By cross-referencing our EMT subtype gene list
to expression data from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al, 2012),
we stratified several human pancreatic cancer cell lines as C-EMT or P-EMT. As expected
from our mouse studies, human PDAC cell lines associated with the previously-described
quasi-mesenchymal signature (Collisson et al, 2011) were predicted to have
characteristics of C-EMT whereas cell lines associated with a classical signature were
predicted to have characteristics of P-EMT (Chapter 2 Figure S7A). To determine whether
these classifications were associated with functional differences, we used M-ECAD
staining to sort two human PDAC cell lines predicted to have a C-EMT phenotype
(MIAPACA2 and PANC1) and three human PDAC cell lines predicted to have a P-EMT
phenotype (BXPC3, CAPAN2, and HPAC) and examined the sorted populations for Ecad
mRNA and/or M-ECAD vs.I-ECAD. Human PDAC cell lines carrying a C-EMT signature
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exhibited loss of Ecad mRNA and no intracellular ECAD protein upon loss of membranous
ECAD (Chapter 2 Figure 6A,B). By contrast, human PDAC cell lines exhibiting a P-EMT
signature retained Ecad mRNA despite loss of membranous ECAD (Chapter 2 Figure 6A),
and a high percentage of M-ECAD-negative cells from these lines were positive for IECAD (Chapter 2 Figure 6B). These data suggest that human tumor cells belonging to the
quasi-mesenchymal/squamous/ basal subtype of PDAC utilize transcriptionallydominated programs to lose their epithelial phenotype during EMT while those belonging
to the classical/ pancreatic progenitor/ADEX subtype rely on protein re-localization to lose
their epithelial phenotype during EMT.
We next sought to assess whether other cancer types utilize these distinct EMT
programs and applied the same strategy of gene expression analysis to stratify a panel of
human breast cancer (BC) and colorectal cancer (CRC) cell lines into those exhibiting a
C-EMT signature and those exhibiting a P-EMT signature (Chapter 2 Figure S7B, C).
Among BC cell lines, the C-EMT signature was present in the basal-like subtype, while
the P-EMT signature was associated with the luminal A/B and normal-like subtypes (Sørlie
et al, 2001) (subtype information was not available for the CRC cell lines). To determine
whether these classifications would accurately predict cell behavior during EMT, we sorted
M-ECAD+ epithelial and M-ECAD- mesenchymal populations from a subset of these BC
and CRC cancer cell lines and examined Ecad mRNA and protein localization. Consistent
with our prior results, BC and CRC cell lines categorized as P-EMT retained Ecad
transcripts in the M-ECAD- population (Chapter 2 Figure 6C,D) and exhibited
internalization in cells that were negative for M-ECAD (Chapter 2 Figure 6E,F), while cell
lines categorized as C-EMT had a complete loss of Ecad mRNA and protein (Chapter 2
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Figure 6C-F). Taken together, these results provide strong evidence that tumor subtype
defines distinct EMT programs in several types of human carcinoma.
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Summary and Discussion

KPCY tumors reflect the heterogeneity of human PDAC
We found, using a panel of murine pancreatic tumors, that the KPCY autochthonous
mouse model exhibits broad histological and molecular diversity, as originally described
(Hingorani et al, 2005). Surprisingly, we found that these heterogeneous tumors also
recapitulate the transcriptionally-defined subtypes of human PDAC (Bailey et al, 2016b;
Collisson et al, 2011; Moffitt et al, 2015). At a global transcriptional level, high-grade
poorly-differentiated murine tumors resembled human tumors belonging to the quasimesenchymal, basal, and squamous subtypes while low-grade well-differentiated murine
tumors corresponded to human tumors exhibiting a classical or pancreatic progenitor
transcriptional signature. Because the human signatures were based on analysis of bulk
tumors, while our analysis of murine tumors relied on sorted YFP+ cells, these crossspecies associations reflect similarities in the transcriptomes of the cancer cells
themselves rather than signatures derived from the tumor microenvironment.
Given that all KPCY tumors carry the same founder mutations in Kras and p53, the
phenotypic diversity exhibited by KPCY tumors is intriguing. Several possibilities could
account for this variation. First, it is possible that well-differentiated tumors (which are
associated with “partial EMT” programs) and poorly-differentiated tumors (which are
associated with “complete EMT” programs) arise from different cells in the pancreas.
Several studies have suggested that acinar cells constitute the major cellular source of
PDAC as the result of an acinar-to-ductal metaplasia (ADM) → pancreatic intraepithelial
neoplasia (PanIN) → carcinoma sequence (De La O et al, 2008; Guerra et al, 2007; Habbe
et al, 2008; Kopp et al, 2011). However, the Pdx1-Cre driver used in this model mediates
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recombination in pancreatic progenitor cells during development, meaning that multiple
pancreatic lineages are exposed to the effects of mutant Kras and p53. Indeed, non-acinar
cells, including cells within the ductal lineage, can also give rise to pancreatic tumors
(Bailey et al, 2014, 2016a; Westphalen et al, 2016). Differences in tumor subtype have
recently been linked to distinct cells-of-origin in skin cancer (Latil et al, 2017), and it is
enticing to speculate that a similar phenomenon contributes to the heterogeneity in tumorrelated EMT phenotypes observed here. Alternatively, different oncogenic “hits” may act
in combination with mutant Kras and p53 to drive tumors into one subtype or another, as
has been observed in breast cancer (Koboldt et al, 2012). Because the KPCY model
provides a ready source of tumors belonging to distinct subtypes, future studies detailing
subtype-specific genetic, genomic, and epigenetic correlates may lead to a better
understanding of the roots of intertumoral heterogeneity.

Two broadly distinct programs drive EMT in vivo
In the setting of cancer, EMT has traditionally been viewed as a transcriptionally regulated
process whereby tumor cells repress epithelial gene transcription and upregulate
mesenchymal gene transcription (Brabletz, 2012; Lamouille et al, 2014; Nieto et al, 2016b;
Savagner, 2015; Tam & Weinberg, 2013). Recent work has called attention to the fact that
EMT can also exist along a spectrum, resulting in a bi-phenotypic partial EMT state
wherein tumor cells retain both epithelial and mesenchymal programs; importantly, such
a hybrid state has been proposed to confer a greater ability to metastasize than a fully
mesenchymal state(Jolly, 2015; Nieto et al, 2016b; Li & Kang, 2016; Lambert et al, 2017).
Our finding that the majority of murine PDAC tumors and cell lines examined use
protein re-localization rather than transcriptional repression to subdue the epithelial
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program provides molecular insight into epithelial-mesenchymal plasticity. These tumors
exhibit low expression of EMT TFs and co-express epithelial and mesenchymal genes,
consistent with a partial EMT state. Evidence for partial EMT in human cancer has been
reported, as single cell analysis of head and neck tumors indicates the existence of an in
vivo partial EMT program that correlates with increased metastatic potential and differs
fundamentally from the EMT programs defined in vitro (Puram et al, 2017). Considering
our observation that loss of the epithelial program is achieved post-transcriptionally in
several human cancer cell lines, it is enticing to speculate that protein re-localization,
rather than transcriptional repression, is responsible for the hybrid epithelial-mesenchymal
phenotypes observed in human carcinoma.
It remains unclear whether cells that undergo P-EMT are paused in a transitional
state (i.e. an intermediate stage in a mesenchymal differentiation continuum) or whether
it represents a final state in its own right. While different tumors appeared to use either
transcriptional or post-transcriptional programs to lose their phenotype, we found no
evidence that these two programs co-exist within the same tumor, suggesting that the
tendency to use either a C- or P-EMT program to undergo a mesenchymal transition is a
specific and stable feature of an individual tumor. Thus, the P-EMT program described
here appears to represent the end-manifestation of EMT in many KPCY tumors.
Nevertheless, we cannot rule out the possibility that tumors exhibiting a P-EMT
phenotype at the time of analysis might exhibit a C-EMT phenotype at some later time
point (or vice versa). Consistent with this notion, we found that P-EMT cells execute a CEMT program when exposed to TGFb, suggesting that signals within the tumor
microenvironment may also influence the EMT phenotype. In either event, the equilibrium
between the epithelial vs. mesenchymal phenotype appears to be subject to tumor cell30

intrinsic “set-points,” as evidenced by the tendency of pure populations of sorted tumor
cells to give rise to tumors with the same ratios of M-ECAD+ and M-ECAD- cells as the
parental population, both in vivo and in vitro.
P-EMT is associated with the re-localization of ECAD and other epithelial proteins to the
interior of the cancer cell, clearing its plasma membrane of molecules that facilitate cellular
adhesion while preserving the capacity to redeploy such proteins to the surface. The
finding that intracellular ECAD is localized to Rab11+ recycling endosomes is consistent
with this notion and suggests that P-EMT involves an interruption of the last step in ECAD
trafficking: the return of the protein to the plasma membrane. These findings regarding
protein re-localization and epithelial-mesenchymal plasticity are consistent with prior
studies relating ECAD trafficking to cell motility. ECAD is subject to substantial recycling
in normal epithelial cells (Brüser & Bogdan, 2017), providing cancer cells with an alternate
means to efficiently lose and re-establish their epithelial properties (Corallino et al, 2015).
Indeed, post-transcriptional mechanisms have been shown to mediate EMT-like
processes during normal embryonic development. During zebrafish epiboly, for example,
protein endocytosis, rather than transcriptional repression, accounts for the loss of MECAD protein and subsequent increases in cell motility (Song et al, 2013). Similarly,
mesoderm formation during sea urchin embryogenesis and mesoderm formation during
mouse gastrulation rely on post-transcriptional mechanisms to downregulate ECAD
protein (Wu & McClay, 2007; Zohn et al, 2006). Thus, carcinoma cells appear capable of
repurposing either of two distinct developmental EMT mechanisms – transcriptional
regulation or protein trafficking – to enhance their motility.

EMT subtype impacts invasion and dissemination
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Our study also has implications for the mechanism of cellular invasion. Two distinct
patterns of invasive growth leading to metastases have been described: single cell
migration leading to dissemination of individual tumor cells, and collective (group)
migration resulting in multi-cellular circulating tumor cell (CTC) clusters (Cheung & Ewald,
2016; Friedl et al, 2012; Lambert et al, 2017). We find that both modes of cell migration
occur in KPCY tumors in a manner that correlates with EMT subtype. In C-EMT tumors,
where cells that have undergone EMT lack ECAD protein entirely, tumor cells tend to
invade and disseminate as single cells. In P-EMT tumors, by contrast, dysregulated
trafficking of ECAD and other epithelial proteins allows tumor cells to retain some
associative properties, resulting in cell clusters that lack epithelial features on the outer
surface. The P-EMT program may thus confer tumor cells with invasive properties while
simultaneously allowing them to retain intercellular cohesions that facilitate collective
behavior (Cheung et al, 2013; Lambert et al, 2017; Liu et al, 2014; Revenu & Gilmour,
2009; Westcott et al, 2015).
In addition, we found that these divergent EMT programs were correlated with
tumor subtype in several human carcinoma lines. In breast cancer cell lines harboring a
luminal-A, luminal-B, or normal-like signature, for example, EMT was associated with a
persistence of ECAD mRNA and a re-localization of ECAD protein inside the cell, features
of the P-EMT program. Cell lines harboring a basal signature, by contrast, had complete
loss of ECAD mRNA and protein. These results suggest that the mechanisms by which
tumors undergo EMT and invasive spread are dictated at least in part by the same broad
molecular programs that determine their subtypes across a variety of carcinomas.
These differences in EMT programs are likely to translate into different invasive
mechanisms. Specifically, tumors associated with a P-EMT program may be predisposed
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to form CTC clusters, a notion that is consistent with the finding that P-EMT cell lines gave
rise to CTC clusters more readily than C-EMT cell lines. Our results are also in line with
the findings of Gampieri et al., who showed that TGFβ signaling in breast cancer cells
prompted a switch from collective to single cell migration (Giampieri et al, 2009)– a
phenomenon that we hypothesize is attributable to a switch from a P-EMT to a C-EMT
program. Considering the observation that tumor cell clusters display enhanced metastatic
potential compared to single cells (Aceto et al, 2014; Cheung & Ewald, 2016; Maddipati &
Stanger, 2015), it is tempting to speculate that tumors exhibiting a P-EMT phenotype
might exhibit an increased metastatic rate compared to tumors exhibiting a C-EMT
phenotype. However, the factors governing metastasis and patient survival are complex
and multifaceted, reflecting the ability of tumor cells to overcome many challenges besides
invasion. Thus, while these EMT programs are likely to be relevant for the invasive
mechanisms utilized by a given tumor, the relationships between C-EMT, P-EMT, and
clinical outcome remain to be defined. Likewise, considering the finding that tumor cells
with different degrees of epithelial-mesenchymal plasticity are prone to metastasize to
different sites (Reichert et al, 2018), the extent to which the divergent EMT programs
described here contribute to metastatic organotropism also remains to be explored.
Chapter 2 Acknowledgements: A special thanks to Nicole Aiello and Ravikanth
Maddipati for collection of data and writing this chapter. Thanks to David Balli for
bioinformatics and statistical analysis. This chapter was published: Aiello NM*, Maddipati
R*, Norgard RJ*, et al. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration.
Dev Cell. 2018
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Materials and Methods

Mouse Strains
KrasLSL-G12D; p53L/+; Pdx1-cre; Rosa26YFP/YFP (KPCY) mice have been described previously
(Rhim et al, 2012). Mice were palpated and examined for evidence of morbidity twice per
week. Tumor-bearing animals were sacrificed when moribund. NOD.SCID mice were used
for tumor cell injection experiments as KPCY cell lines are of mixed background and would
be rejected by an immuno-competent animal. Both male and female KPCY and
NOD/SCID animals were used in this study. Tumors were examined by a GI Pathologist
(E.E.F.) and categorized as moderately-to-well- or poorly-differentiated based on the
predominant histology following examination of multiple regions. Mice were housed in
standard microisolator cages and chow with a 12 hour light cycle. All vertebrate animals
were maintained and experiments were conducted in compliance with the National
Institutes of Health guidelines for animal research and approved by the University of
Pennsylvania Institutional Animal Care and Use Committee.

Cell lines
Murine PDAC cell lines PD7591 (female), PD798 (male), PD454 (male), PD7242
(unknown), PD883 (male), PD6910 (female), PD483 (female) and PD3077 (male) were
derived from primary KPCY tumors. The PD832 (male) cell line was obtained from the
ascites fluid of KPCX mice (Maddipati & Stanger, 2015). The C- and P-EMT status of all
cells was confirmed by RT-PCR for Ecad mRNA after sorting as well as and intracellular
staining for ECAD. Human PDAC cell lines Capan2, HPAC, Bxpc3, and Panc1 were
provided by Dr. Anil Rustgi, University of Pennsylvania. Human breast cancer cell lines
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MCF7, BT474 and MDA-MB-453 were provided by Dr. Erica Carpenter, University of
Pennsylvania. Human breast cancer cell lines MDA-MB-157, MDA-MB-231, MDA-MB436, MDA-MB-468 and HCC1937 were provided by Dr. Andy Minn, University of
Pennsylvania. Human colorectal cancer cell lines DLD1, HCT116 and SW480 were
provided by Dr. Anil Rustgi, University of Pennsylvania. Human colorectal cancer cell lines
Hs255T (CRL-7213), Hs675T (CRL-7400) and Hs698T (CRL-7435) were purchased
directly from ATCC. All human lines provided by previously mentioned investigators were
originally obtained from ATCC. Human cell lines were authenticated by the University of
Arizona Genetics Core. Cell lines were regularly tested for mycoplasma using MycoAlert
Mycoplasma Detection Kit (Lonza).
Murine cell lines were cultured in Dulbeccos’ Modified Eagle Medium/F12 medium
supplemented with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL soybean trypsin inhibitor
type I (Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS Premix; BD Biosciences), 25
μg/mL bovine pituitary extract (Gemini Bio-Products), 5 nmol/L 3,3′,5-triiodo-L-thyronine
(Sigma), 1 μmol/L dexamethasone (Sigma), 100 ng/mL cholera toxin (Sigma), 10 mmol/L
nicotinamide (Sigma), 5% Nu-serum IV culture supplement (ThermoFisher Scientific), and
antibiotics (gentamicin 150 μg/mL, Gibco; amphotericin B 0.25 μg/mL, Invitrogen). Human
cell lines were cultured in 10% Dulbecco’s Modified Eagle Medium supplemented to 10%
decomplemented fetal bovine serum at 37°C, 5% CO2, 21% O2 and 100% humidity. Cell
lines were maintained and passaged according to ATCC recommended procedures.
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Immunofluorescence
Tissues were fixed in Zn-formalin and embedded in paraffin prior to staining. Sections
were deparaffinized, rehydrated and subjected to antigen retrieval. For staining cell lines,
cells were fixed in 4% paraformaldehyde for 15 mins. For staining, sections and fixed cells
were blocked in 5% donkey serum for 1 hour at room temperature (RT), incubated with
primary antibodies for 1 hour at RT, washed, incubated with secondary antibodies for 1
hour at RT, washed and mounted. Primary antibodies used include goat anti-GFP
(Abcam), rat anti-Ecadherin (Takara Bio), rabbit anti-Zeb1 (Santa Cruz), rabbit anti-Slug
(gift of Dr. Joel Habener), rabbit anti-Vimentin (Cell Signaling Technologies), rabbit antiFsp1 (DAKO), rabbit anti-Rab5 (Cell Signaling Technologies), rabbit anti-Rab7 (Cell
Signaling Technologies), rabbit anti-Rab11 (Cell Signaling Technologies), rabbit antiEpCAM (Abcam), rabbit anti-Claudin-7 (Abcam), and rabbit anti-B-catenin (Cell Signaling
Technologies). Zeb1 required additional tyramide signaling amplification (PerkinElmer).
Slides were visualized using an Olympus IX71 inverted multicolor fluorescent microscope
equipped with a DP71 camera. Select slides were also visualized using a Zeiss LSM 710
confocal microscope with Zen 2011 software.

Flow cytometry
For surface/intracellular E-cadherin staining of KPCY tumor cell lines, cells were stained
with rat anti-E-cadherin (Takara Bio, clone M108) at 1:250 and Brilliant Violet 421 goat
anti-rat (Biolegend) at 1:100 for 15 min. at 4oC in the dark for each step with three washes
between. Cells were then fixed and permeabilized using Foxp3/Transcription Factor
Staining Buffer Set (eBioscience) according to the manufacturer’s instructions. Cells were
then stained with rat anti-E-cadherin again at 1:250 and APC donkey anti-rat (Jackson
36

Immunoresearch) at 1:100 for 15 min. at 4oC in the dark for each step with three washes
between. Finally, the cells were resuspended in 5% FCS in PBS and analyzed on a BD
LSR II flow cytometer.

Fluorescence-Activated Cell Sorting (FACS)
To create a single cell suspension, pancreatic tumor tissue was rinsed in cold, sterile 1X
PBS before mincing with scissors (approximately 100 chops). The minced pieces were
then incubated in preheated collagenase with protease inhibitors (2 mg/ml; Sigma) for 20
min at 37°C. Vigorous vortexing was performed every 5 min during this incubation. The
dissolved pieces were then poured over a 70 μM cell strainer and large pieces were
mechanically broken down. The flow through was resuspended in cold DMEM/F12,
centrifuged, washed once, and kept on ice in the dark. The cells were then stained with
rat anti-E-cadherin (1:250; Takara Bio, clone M108) for 15 minutes at 4oC in the dark,
followed by three 5 minute washes in 5% FCS in PBS and incubation with APC donkey
anti-rat (1:100; Jackson Immunoresearch) prior to FACS (FACSVantage with FACSDiva
option, BD).

RNA isolation, library construction, and next-generation sequencing
RNAseq libraries were prepared using the Clontech Ultra low RNA kit – HV, with 12 cycles
of PCR for cDNA amplification, and the Clontech Low Input Kit for library prep, with 9
cycles of PCR amplification, following the manufacturer’s protocol. The amplified library
was purified using AMPure beads, quantified by Qubit and QPCR, and visualized in an
Agilent Bioanalyzer. The libraries were pooled equimolarly, and loaded on either one rapid
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run HiSeq 2500 flow cell, onboard clustering protocol, or on HiSeq 2500 high output flow
cell lanes, as paired 50 nucleotide reads.

Sequencing alignment, differential gene expression and clustering analysis
The quality of raw reads was assessed using Fastqc (v0.11; Babraham Bioinformatics).
Reads passing quality control were aligned to the mouse genome version UCSC
GRCm38/mm10 with STAR (v2.3.1) (Dobin et al, 2013) using default parameters. Total
reads, with alignment quality of at least 10, mapping to each gene were counted using
HTseq-count (Anders et al, 2015) and GRCm38/mm10 gene annotation files. Differential
gene expression analysis was performed using the R/Bioconductor package DESeq2
(Love et al, 2014). Genes with Benjamini-Hochberg adjusted P values ≤ 0.1 and absolute
log2 fold change ≥ 1.0 were considered differentially expressed. As an alternate approach
to obtain gene and transcript level abundances, transcripts per million (TPM) were
calculated using RSEM (v1.2.18) (Li & Dewey, 2011) with default parameters. Microarray
expression data for human pancreatic cancer cell lines were obtained from the Cancer
Cell Line Encyclopedia (Barretina et al, 2012).

Gene expression Heat Maps and Box Plot Generation
For unsupervised hierarchical clustering and heat map generation, variance-stabilized
expression values were clustered using average linkage with distance metric equal to 1
minus the Pearson correlation coefficient using the 2000 genes with the most variable
expression levels. To visualize expression of specific genes involved in EMT, the log2
ratio of normalized TPM values between paired mesenchymal (YFP+/M-Ecad-) and
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epithelial (YFP+/M-Ecad+) fractions from each individual tumor sample were plotted with
ggplot2 in R. Markers specific for epithelial cells, mesenchymal cells and EMT
transcription factors were selected from published literature (Lamouille et al, 2014; Nieto
et al, 2016b).

Gene Set Enrichment Analysis
Gene expression signatures from published EMT profiles (Anastassiou et al, 2011;
Gotzmann et al, 2006; Jechlinger et al, 2003) were obtained from GSEA/MSigDB. Gene
set lists corresponding to established PDAC subtypes were obtained from original
publications (Bailey et al, 2016b; Collisson et al, 2011; Moffitt et al, 2015). Statistical tests
and enrichment association was calculated using Gene Set Enrichment Analysis (GSEA
v.2.2.0).

RNA isolation and qPCR
Total RNA was extracted from samples consisting of less than 5 x 105 cells using the
RNeasy Micro Kit (Qiagen), while samples consisting of greater than 5 x 105 cells were
subjected to the RNeasy Mini Kit (Qiagen). High Capacity cDNA Reverse Transcription
Kit (Life Technologies) was used to generate cDNA. qPCR was performed with
SsoAdvanced SYBR (BioRad) using a CFX384 Real-Time System (BioRad). Transcript
quantities were determined using the difference of Ct method and values were normalized
to Gapdh. Primary sequences are listed in Table S3.

Tumor sphere invasion assay
39

Murine PDAC cell lines PD798, PD7591, PD3077, and PD832 were plate at 5000cells/well
in 96-well ultra-low attachment plate (Corning) media for 2 days to enable sphere
formation. Equal amounts of matrigel was then added to each well and cells were
incubated for 3 days at 37°C, 5% CO2, 21% O2 and 100% humidity. Live imaging was
then performed for 72hrs in a humidified chamber at 37°C, 5% CO2. Imaging was
performed using the Olympus IX81 microscope with Brightfield/DIC and automated stage
for imaging multiple stage positions.

Analysis of circulating tumor cells
Blood was isolated from orthotopic tumor bearing mice via cardiac puncture with a 1-ml
insulin syringe containing 100ul of 1mg/ml heparin sulfate (Sigma-Aldrich, H3149) to
prevent coagulation. Fluid was immediately placed in a 100cm gridded plate (BD Falcon)
containing RBC lysis buffer (BD biosciences). Following 10 minutes of lysis, PBS was
added to the plate and CTCs were directly visualized on a fluorescent microscope and
imaged. CTC immunofluorescence was performed by manual isolation of CTCs under
microscope visualization followed by embedding in matrigel. Cells were then fixed and
stained for E-cadherin and YFP and visualized by confocal microscopy.

Human Specimens
De-identified primary PDAC tissue samples were obtained from patients who consented
to a research autopsy in association with the IRB approved Johns Hopkins Rapid Medical
Donation Program (PMID: 19273710).
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QUANTIFICATION AND STATISTICAL ANALYSIS
Differences between two groups were analyzed by two-tailed Student’s t-test unless
otherwise noted. All statistical analyses were performed using GraphPad Prism 6
(GraphPad, La Jolla, CA).

DATA AND SOFTWARE AVAILABILITY STATEMENT
RNAseq data reported in Chapter 2 Figure 1 and Chapter 2 Supplementary Figure S3 has
been deposited into the NCBI SRA database with the SRA accession: SRP144501.
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Chapter 2 Figure 1: Two distinct EMT programs exist among KPCY tumors

(A) Representative image of a KPCY tumor (n=9 mice, 115 fields examined) stained for
YFP (red) and ECAD (green) (DAPI nuclear counterstain, blue). Arrow: YFP+ tumor
cells within epithelial structures that are positive for membranous ECAD (M-ECAD).
Arrowhead: YFP+ tumor cells that have delaminated from epithelial structures and are
negative for M-ECAD. Scale bar, 25µm
(B) Strategy for isolating epithelial and mesenchymal tumor cells by fluorescence
activated cell sorting.
(C) Heatmap of unsupervised hierarchical clustering of expression of the 2000 most
variable genes between epithelial and mesenchymal tumor cells from KPCY tumors.
Tumor IDs are color-coded and listed below the heatmap, with M-ECAD+ (plus) and
M- ECAD- (minus) fractions indicated.
(D) Principal components of 2000 most variable genes across all samples. Shape
represents M-ECAD sorting status (Triangles = M-ECAD+, Circles = M-ECAD-) and
color represents clustering identity (Orange = Cluster 1, Green = Cluster 2).
(E) Fold-difference in mRNA levels for Ecad, EpCAM, and Claudin-7 comparing
mesenchymal (M-ECAD-) and epithelial (M-ECAD+) populations (TPM, transcripts per
million) in tumors belonging to Cluster 1 (orange) or Cluster 2 (green).
(F) Heatmap of expression fold change for selected epithelial, mesenchymal, and
extracellular matrix collagen genes comparing mesenchymal (M-ECAD-) and epithelial
(M-ECAD+) populations in tumors belonging to Cluster 1 (“C-EMT”) or Cluster 2 (“PEMT”).
See also Figures S1-S3.
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Chapter 2 Figure 2: P-EMT is characterized by post-transcriptional regulation of the
epithelial program.

(A) Strategy for assessing E-cad mRNA and protein expression from a panel of KPCY
tumor cell lines. In total, 3 C-EMT and 5 P-EMT cell lines were used.
(B) Aggregate data showing differences in E-cad mRNA abundance (by qPCR) comparing
mesenchymal (M-ECAD-) and epithelial (M-ECAD+) cells from 8 murine PDAC cell
lines classified as either C-EMT (N=3: PD6910, PD483, PD3077) or P-EMT (N=5:
PD7591, PD798, PD7242, PD454, PD422). A marked decrease in E-cad mRNA in
association with EMT is observed in C-EMT cell lines, while no decrease is observed
in P-EMT cell lines.
(C) Western blot comparing epithelial protein levels in sorted M-ECAD- (E-) and MECAD+ (E+) cells from 2 C-EMT and 2 P-EMT PDAC cell lines.
(D) Strategy for detecting internalized E-cadherin by flow cytometry.
(E) E-cadherin internalization in murine cell lines was quantified by measuring the
percentage of cells negative for membranous E-cadherin (M-ECAD-) that were
positive for intracellular E-cadherin (I-ECAD+). P-EMT cell lines: PD7591, PD798
(69.8% ± 9.0; mean ± SD). C-EMT cell lines: PD483, PD3077 (0.13% ± 0.1). Each cell
line was assessed in triplicate. Data are representative of at least two independent
experiments for each cell line.
(F-I) Representative confocal 3-D projections of mesenchymal (F,G) and epithelial (H, I)
tumor cells from P-EMT (F, H) and C-EMT (G, I) KPCY tumors. Sections were stained
for YFP (red) and ECAD (green) (DAPI nuclear counterstain, blue).
(J-M) Representative confocal 3-D projections of mesenchymal (J, K) and epithelial (L, M)
tumor cells from two human primary PDAC tumors. Sections were stained for ECAD
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(green) (DAPI nuclear counterstain, blue). Mesenchymal tumor cells are outlined for
clarity.
(O-Q) Representative confocal 3-D projections of mesenchymal tumor cells from P-EMT
KPCY tumors stained for ECAD (green), YFP (red), and additional epithelial proteins
(grey) b-catenin (O), Claudin-7 (P), and EpCAM (Q).
Bar graph data are presented as mean ± standard deviation (SD) in this and subsequent
figures. Scale bars, 10µm. Statistical differences were identified by Student’s t-test in this
and all subsequent figures unless otherwise noted (*, p<0.05; **, p<0.0001).
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Chapter 2 Figure 3: Intracellular ECAD co-localizes with Rab11+ late recycling vesicles

(A) Representative confocal images of cultured cells from a P-EMT cell line showing a
colony of cells with epithelial features (left) and a delaminated spindle shaped
mesenchymal cell (right) stained with ECAD and DAPI. Arrows show membranous
ECAD staining pattern in epithelial cells while arrowheads show punctate cytoplasmic
staining pattern in mesenchymal cells
(B) Relative mRNA expression of Rab11 (marker of late recycling vesicles), Rab5 (marker
of early endosomes), and Rab7 (marker of late endosomes targeted for lysosomal
degradation) in P-EMT tumors from Figure 1. (*,p<0.05)
(C-E) Co-immunofluorescent staining of mesenchymal P-EMT cells (as depicted in (A))
with ECAD and Rab5, Rab7, or Rab11. Images representative of data from 20 different
cells for each experiment. Mean Pearson’s correlation coefficients of colocalization are
0.18, 0.19, and 0.70 for Rab5, Rab7, and Rab11, respectively.
See also Figures S4-S6.
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Chapter 2 Figure 4: Features of epithelial plasticity in C-EMT and P-EMT subtypes
(A) Kinetics of mesenchymal-to-epithelial transition (MET) in vitro. ECAD negative cells
(>99% purity) were sorted from P-EMT (7591 and 798) and C-EMT (3077, 483, 832)
cell lines and cultured for 9 days in standard conditions. At day 6, P-EMT and C-EMT
cells were 98.07% ± 1.98 (mean ± SD) and 28.49% ± 26.40 M-ECAD+ respectively.
At day 9, P-EMT and C-EMT cells were 86.75% ± 0.73 and 14.61% ± 11.38 M-ECAD+
respectively. Baseline percentage of M-ECAD+ cells prior to sorting for 7591, 798,
3077, 483, and 832 are 97%, 90%, 47%, 12%, and 6% respectively. Insert in A
demonstrates stable Ecad mRNA expression in the sorted P-EMT cells from day 0 to
6. Data representative of two independent experiments with cell lines assessed in
triplicate.
(B) Mesenchymal gene expression changes during recovery of the epithelial phenotype
in P-EMT cells. qPCR for mesenchymal markers Cdh11, Col8a2, Pdgfrb, and Snail
was measured in sorted M-ECAD- P-EMT cells during 6 days of culture in standard
conditions.
(C) Quantification of M-ECAD-expressing YFP+ cells in tumors generated from unsorted
and M-ECAD-sorted KPCY tumor cell lines. C- and P-EMT cell lines were sorted
based on membrane ECAD (>99% purity of M-ECAD+ or M-ECAD-) and 1 x 104 cells
were injected subcutaneously into NOD.SCID mice. The resulting tumors (harvested
when tumors reached 1 cm diameter) were assessed for ECAD expression in YFP+
tumor cells by immunofluorescence staining and manual quantification. Data are
pooled (mean ± SD) from 5 P-EMT cell lines (PD7591, PD454, PD798, PD7242,
PD883) and 3 C-EMT lines (PD6910, PD483, PD3077). Unsorted P, 95.0% ± 5.3; P
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E+, 80.5% ± 25.3; P E-, 76.0% ± 24.5; unsorted C, 22.7% ± 32.0; C E+, 26.7% ± 33.7;
C E-, 15.4% ± 13.8.
(D) Schematic summarizing the experimental design and results from (B)
(E) Representative phase-contrast images of P-EMT KPCY tumor cell lines ± TGFβ
treatment (10 ng/mL, 5 days).
(F) qPCR for E-cad mRNA with TGFβ treatment or vehicle-only control (10 ng/mL, 5 days)
in P-EMT KPCY tumor cell lines.
(G) Western blot for ECAD protein ± TGFβ treatment in P-EMT KPCY tumor cell lines.
(H) Quantification of M-ECAD-, I-ECAD+ cells ± TGFβ treatment by flow cytometry.
PD7591, 67.1% ± 3.3; PD7591 + TGFβ, 16.5% ± 2.1; PD798, 85.6% ± 2.3; PD798 +
TGFβ, 33.8% ± 2.8.
All data are representative of two or more independent experiments. *, p<0.05; **, p<0.01;
***, p<0.005; ****, p<0.001
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CTC-Cluster

Chapter 2 Figure 5: EMT subtypes exhibit distinct modes of cell migration and
dissemination

(A) Time-lapse DIC microscopy of P-EMT 798 cells embedded in matrigel. Collectively
migrating cells emerge from primary tumor sphere. Representative of n=15 tumor
spheres from 2 independent experiments
(B) Time-lapse DIC microscopy of C-EMT 3077 cells embedded in matrigel. Collectively
migrating cells emerge from primary tumor sphere. Representative of n=18 tumor
spheres from 2 independent experiments
(C) Representative bright field and fluorescent images of CTCs detected in the blood
stream of NOD.SCID mice following orthotopic injection of P-EMT 798 or C-EMT 3077
cells. Data representative of n=3 NOD.SCID mice per condition
(D) Comparing percentage of single and cluster CTCs/ml between P-EMT 798 or C- EMT
3077 orthotopic injections in (C). N=5 NOD.SCID mice from two independent
experiments.
(E) Single CTC and cluster CTCs from blood of 3077 and 798 orthotopic mice respectively.
CTCs are stained for YFP (red), ECAD (green) and DAPI (blue).
Scale bars 100μm for A and B, 25μm for (C), and 10μm for (E). *, p<0.005.

53

i ur

Aiello_Figure 6

A

B

Ecad mRNA
sorted human PDAC lines
Predicted C-EMT

% I-ECAD+
of M-ECAD- cells

Relative expression
Normalized to GAPDH

Predicted P-EMT

Intracellular ECAD
sorted human PDAC lines

4

2

0

EE+ E
E+ EE+ E2
1 c1
3
a
C
3
C
c
c
C
A
A P
n an
P
PC
Pa
HP H
Pa P
ia
Bx Bx
M

C

Predicted C-EMT
Predicted P-EMT

Predicted P-EMT

D

Intracellular ECAD
sorted human BC lines

Predicted
C-EMT

100

% I-ECAD+
of M-ECAD- cells

2.0
1.5
1.0
0.5

80
60
40
20
0

Predicted C-EMT
Predicted P-EMT

F

Ecad mRNA
sorted human colorectal cancer lines
1.5

Intracellular ECAD
sorted human CRC lines

Predicted
C-EMT

80

% I-ECAD+
of M-ECAD- cells

Predicted P-EMT

1.0
0.5

60
40
20

16
SW
48
0

T1

LD
D

C
H

S6
75
T
H
S6
98
T

H

1

0

0.0

D
LD
1
D E+
H LD1
C
T1 E
H 16
C
T1 E+
SW 16
48 ESW 0 E
4 +
H 80
s2 E
5 H 5T
s6 E
7 H 5T
s6 E
98 T
E-

Relative expression
Normalized to GAPDH

M
D

B

B

E

A
M MB
D
A -15
M MB 7
D
A -23
-M
1
B
-4
36
B
T4
74
M
C
H
F
M CC 7
19
D
A
-M 37
B
-4
68

74
E
T4 +
7
M 4E
C
F7 M E+
H CF
C
C 7E
1
H 937
C
M
D C1 E+
A
- 93
M MB 7 E
D
A -46 M MB 8 E
+
D
A -46
M MD 8 E
D
A -15 M MD 7 E
D
A -23 -M
1
E
B
-4 36
E-

0.0

T4

Relative expression
Normalized to GAPDH

Ecad mRNA
sorted human breast cancer lines

Predicted C-EMT
Predicted P-EMT

Chapter 2 Figure 6

54

Chapter 2 Figure 6: Distinct EMT subtypes occur in human pancreas, breast, and
colorectal cancer cell lines

(A, C, E) Relative Ecad mRNA expression in human PDAC (A), breast cancer (C), and
colorectal cancer (E) cell lines sorted on membranous E-cadherin.
(B, D, F) Quantification of M-ECAD-, I-ECAD+ cells within human PDAC (B), breast (D)
and colorectal (F) cancer cell lines. BXPC3, 39.37 ± 3.1% 3 (mean ± SD), CAPAN2,
40.33 ± 13.1%, HPAC, 53.93 ± 1.629%, PANC1, 7.47 ± 1.9%, MIAPACA2, 1.567 ±
0.24%. MDA-MB-157, 0.12% ± 0.03; MDA-MB-231, 2.3% ± 0.30; MDA-MB-436, 0.93%
± 0.09%; BT747, 83.0 ± 1.3%; MCF7, 83.8 ± 4.7%; HCC1937, 80.6% ± 1.6; MDA-MB468, 61.1% ± 11.3; HS675T, 0.6% ± 0.5; HS698T, 0.7% ± 0.1; DLD1, 31.6% ± 2.9;
HCT116, 69.0% ± 3.7; SW480, 64.0% ± 3.4.
Each cell line was assessed in triplicate. Lines represent mean ± SD. Data are
representative of at least two independent experiments for each cell line.
See also Figure S7.
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Chapter 2 Figure S1: Epithelial and mesenchymal marker expression in KPCY tumors,
Related to Chapter 2 Figure 1

(A and B). Representative immunofluorescence images from KPCY tumors demonstrating
that all YFP+ Claudin7 (top panel) and Epcam (bottom panel) negative cells are also
ECAD negative.
(C-F) KPCY tumors stained for YFP (red) and ECAD (green) (DAPI nuclear counterstain,
blue). (C’-F’) KPCY tumors stained for YFP (red) and ZEB1 (C’), SLUG (D’), VIM (E’),
FSP1 (F’) in green (DAPI nuclear counterstain, blue). Arrows denote M- ECAD- tumor
cells expressing mesenchymal markers. Arrowheads denote M-ECAD- tumor cells that
lack expression of mesenchymal markers.
(G-J) Quantification of ZEB1 (G), SLUG (H), VIM (I) and FSP1 (J) expression in M- ECAD(white bars) and M-ECAD+ (black bars) tumor cells (n=6 tumors; 3 well- differentiated
and 3 poorly-differentiated). Bars represent mean ± SD.
Scale bars denote 50 μm.
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Chapter 2 Figure S2: RNAseq sample quality control, Related to Figure 1

(A) Representative FACS plots of a KPCY tumor and its corresponding unstained control.
(B) Representative images of sorted KPCY tumor cells illustrating cell purity.
(C-D) qPCR for a subset of RNAseq samples for CD45 (C) and YFP (D) to check for nontumor cell contamination. Bars represent means ± SEM.
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Zeb2

Chapter 2 Figure S3: GSEA confirms EMT within RNAseq samples, Related to Chapter 2
Figure 1

(A) Sorted epithelial (M-ECAD+) and mesenchymal (M-ECAD-) populations from KPCY
tumors were separated into C-EMT and P-EMT groups as described in Figures 1-3.
Gene set enrichment analysis (GSEA) was performed between epithelial and
mesenchymal fractions within each group versus gene sets of established EMT gene
signatures.
(B and C) Boxplot distribution of mRNA abundance of several EMT transcription factors
comparing C-EMT (n=3) and P-EMT (n=8) tumors. Separate comparisons were made
using M-ECAD+ cells from each tumor type (B) or M-ECAD- cells from each tumor
type (C).
p<0.05 for all comparisons between C- and P-EMT cells by Mann-Whitney test.
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Chapter 2 Figure S4: KPCY tumors demonstrate distinct histological subtypes

H&E images of 11 KPCY tumors used in the RNAseq analysis. Tumor categorized as CEMT exhibited poorly-differentiated histology (A) whereas P-EMT tumors exhibited a
moderately- to well-differentiated histology (B). Scale bars denote 50 µm.

63

Aiello_Fig S5

Collisson
Classical
Exocr − ke
M− ke

PD2523E_minus
PD2523E_plus
PD3003E_minus
PD2904E_plus
PD2904E_minus
PD798E_minus
PD798E_plus
PD9210E_minus
PD9210E_plus
PD3090E_minus
PD3003E_plus
PD2329E_plus
PD2329E_minus
PD3090E_plus
PD2342E_plus
PD2342E_minus
PD2204E_plus
PD2204E_minus
PD345E_plus
PD345E_minus
PD2412E_minus
PD2412E_plus

PD9210E_minus
PD2904E_plus
PD2342E_plus
PD2342E_minus
PD2904E_minus
PD3090E_plus
PD3090E_minus
PD9210E_plus
PD2329E_minus
PD2329E_plus
PD798E_minus
PD798E_plus
PD2412E_plus
PD2523E_minus
PD2523E_plus
PD3003E_plus
PD3003E_minus
PD345E_plus
PD345E_minus
PD2412E_minus
PD2204E_plus
PD2204E_minus

KPCY

Bailey
GP1 Pancreatic Progenitor
GP2 Squamous
GP3 Squamous

4

2

0

−2

−

PD2904E_minus
PD2904E_plus
PD2342E_plus
PD2523E_plus
PD9210E_plus
PD3090E_minus
PD3003E_minus
PD3003E_plus
PD3090E_plus
PD2329E_minus
PD2329E_plus
PD798E_plus
PD2342E_minus
PD9210E_minus
PD798E_minus
PD2523E_minus
PD2412E_plus
PD2204E_plus
PD345E_plus
PD345E_minus
PD2412E_minus
PD2204E_minus

Chapter 2 Figure S5

64

Moffitt
Classical
a al−l ke

Collison subtypes

C-EMT
P-EMT

Bailey subtypes

Moffitt subtypes

KPCY
C-EMT
P-EMT
KPCY
C-EMT
P-EMT

2
3

3

1
2

0
1

0

−
−

−2

−2
−

−

Chapter 2 Figure S5: Tumor subtype correlates with EMT subtype in KPCY tumors

(A) Unsupervised hierarchical clustering of PDA subtype genes from Collisson et al., 2011.
(B) Unsupervised hierarchical clustering of PDA subtype genes from Moffitt et al., 2015
(C) Unsupervised hierarchical clustering of PDA subtype genes from Bailey et al., 2016.
See Tables S1-S2.
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Chapter 2 Figure S6: Representative flow plots for surface/intracellular ECAD staining,

(A) Gating strategy and representative flow plots for P-EMT KPCY cell line PD483. First,
cellular debris was excluded by FSC-A and SSC-A, then a “single cell” gate was
established using FSC-A and FSC-H. M-ECAD- (440/40 Violet-negative) events were
selected for analysis of I-ECAD (660/20 Red) positivity. A negative control (secondary
antibody alone) was used for each cell line to determine the placement of gates.
(B) Representative flow plots for P-EMT KPCY cell line PD798.
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Chapter 2 Figure S7: Tumor and EMT Subtype classification of cell lines in pancreas,
breast, and colorectal cancer cell lines, Related to Figure 6

(A) Principal components of human PDAC cell lines present in CCLE stratified based on
PDAC subtype (Classical or Quasi-mesenchymal-like) and EMT subtype (C- or PEMT).
(B) Principal components of breast cancer cell lines present in CCLE stratified based on
breast cancer subtype (Basal, Luminal A, Luminal B, or Normal-like) and EMT subtype
(C- or P-EMT).
(C) Principal components of colorectal cancer cell lines present in CCLE stratified based
on EMT subtype (C- or P-EMT).
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upp

nta

Case
PD345
PD2412
PD2204
PD798
PD2329
PD2342
PD2523
PD2904
a
PD3003
PD3090
PD9210

Differentiation
Sarcomatoid
Sarcomatoid
Poor
Moderate
Moderate
Well
Moderate
Moderate
Well
Well
Moderate

EMT subtype
Complete
Complete
Complete
Partial
Partial
Partial
Partial
Partial
Partial
Partial
Partial

Table S2. Gene set enrichment analysis P-values for KPCY tumors, Related to Figure 3
Publication
Collisson, Nat. Med. 2011
Collisson, Nat. Med. 2011
Collisson, Nat. Med. 2011
Moffitt, Nat. Gen. 2015
Moffitt, Nat. Gen. 2015
Bailey, Nature 2016
Bailey, Nature 2016
Bailey, Nature 2016

Gene set
Quasi-mesenchymal PDA
Classical
Exocrine-like
Basal-like
Classical
Squamous (GP2)
Squamous (GP3)
Pancreatic Progenitor (GP1)
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Complete EMT
P = 0.001
NA
NA
P = 0.02
NA
P = 0.001
P = 0.003
NA

Partial EMT
NA
P = 0.002
P = 0.244
NA
P = 0.001
NA
NA
P = 0.001

CHAPTER 3: CALCIUM SIGNALING INDUCES A PARTIAL EMT

Brief Introduction
It is increasingly accepted that carcinoma cells exist along a continuum of hybrid E-M
states (Jolly et al, 2019; Grigore et al, 2016; Yang et al, 2020; Dongre & Weinberg, 2019).
As reversible transitions between E and M phenotypes appear to be important at different
stages of metastatic spread (Ocaña et al, 2012; Tsai et al, 2012; Kröger et al, 2019; Tran
et al, 2014), carcinoma cells exhibiting such hybrid or partial EMT (P-EMT) states can
more easily navigate barriers to metastatic spread and may thus possess greater
metastatic competence (Nieto et al, 2016a; Zhang & Weinberg, 2018). Yet the
mechanisms by which cells adopt such intermediate states are unknown.
In the previous chapter, we used an autochthonous model of pancreatic ductal
adenocarcinoma (PDA), we reported and characterized a P-EMT subtype that is a
common feature of stochastically-arising pancreatic tumors (Aiello et al, 2018). P-EMT in
vivo is not associated with transcriptional repression of epithelial genes but rather occurs
through a non-canonical program characterized by the relocalization of epithelial proteins
(Aiello et al, 2018). Importantly, this phenomenon is not limited to PDA but also describes
the molecular events underlying P-EMT in a variety of human carcinomas.
In this chapter, we investigated the molecular signals underlying this newly
described P-EMT program. We find that prolonged calcium signaling induces a P-EMT
phenotype characterized by the internalization of membranous E-cadherin (ECAD) and
an increase in cellular migration and invasion. These effects are recapitulated by signaling
through Gaq-associated G-protein coupled receptors (GPCRs) and are mediated through
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downstream activation of calmodulin. These results implicate calcium signaling as a driver
of a hybrid/partial epithelial-mesenchymal state in carcinoma cells.
Ca2+ signaling is enriched in P-EMT tumor cells
For clues regarding the molecular pathways responsible for P-EMT, we examined
transcriptomic data from our prior in vivo analysis (Aiello et al, 2018). In that study, we
used flow cytometry for the epithelial protein E-cadherin (ECAD) to isolate tumor cells
exhibiting an epithelial phenotype (surface ECAD+) or a mesenchymal phenotype (surface
ECAD-) and performed RNA-seq. This analysis stratified tumors into two “EMT subtypes”
– those that employed a classical or complete EMT program (C-EMT), involving
transcriptional repression of epithelial genes, and those that employed an alternative
partial EMT program (P-EMT) characterized by post-translational internalization of
epithelial proteins including ECAD (Aiello et al. 2018 and Chapter 3 Fig. S1A, B).
At a global transcriptional level, both subtypes carried robust EMT signatures
(Aiello et al, 2018). Hence, our re-analysis focused on pathways that were exclusively
enriched in P-EMT tumors relative to C-EMT tumors. To this end, we performed gene set
enrichment analysis (GSEA) of the entire dataset – comparing the ECAD+ and ECAD- cell
populations of each EMT subtype – and ranked those pathways that were uniquely
associated with the P-EMT program (Chapter 3 Fig. S1C). Strikingly, 15 of the top 25 PEMT-associated gene sets were related to ion transport, especially calcium (Chapter 3
Fig. 1A, S1C). Likewise, HOMER motif analysis of differentially expressed genes in ECADvs. ECAD+ cells revealed strong enrichment for Nuclear Factor of Activated T cells
(NFAT), a calcium regulated transcription factor, only in P-EMT tumors (Chapter 3 Fig.
1B). As expected, a complementary analysis of C-EMT tumors revealed enrichment for
pathways related to mRNA binding, DNA/chromatin binding, and SMAD signaling
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(Chapter 3 Fig. S1D), and enrichment for binding sites for the EMT-TF Slug-Snai2
(Chapter 3 Fig. S1E). Based upon these results, we hypothesized that calcium signaling
may contribute to P-EMT.
To test this hypothesis, we first asked whether the E-M state of a cell is correlated
with intracellular calcium concentration ([Ca2+]). We previously demonstrated that in the
absence of any EMT inducer, carcinoma cells exist in an equilibrium between epithelial
and mesenchymal states, whereby EMT and its reverse process mesenchymal-toepithelial transition (MET) occur spontaneously (Aiello et al, 2018; Yuan et al, 2020). We
therefore introduced a genetically encoded Ca2+ indicator protein, GCaMP6, into three
murine PDA cell lines, designated cells as either E or M based upon morphology (see
Methods), and measured relative levels of fluorescence as a function of cellular state. As
shown in Chapter 3 Fig. 1C, cells with an E morphology (typically part of a colony; red
arrows) exhibited low fluorescence levels, while cells with an M morphology (typically
spindle-like and separated from colonies; yellow arrows) exhibited high fluorescence
levels. To quantitate this effect, we performed flow cytometry on GCaMP6 expressing
tumor cells pre-incubated with either 0 mM or 2 mM Ca2+ and then determined E-M status
by staining cells for surface ECAD expression. Cells grown in 0 mM Ca2+ exhibited
low/background GCaMP6 fluorescence that was equivalent in ECADLow (mesenchymal)
and ECADHigh (epithelial) cells. In 2 mM Ca2+, both populations exhibited an increase in
GCaMP6 fluorescence; however, ECADLow (mesenchymal) cells exhibited significantly
greater fluorescence (Chapter 3 Fig. 1C). Similar results were obtained with the ratiometric
Ca2+ indicator Indo-1 (Chapter 3 Fig. 1D). Taken together, these results suggest that
carcinoma cells with a mesenchymal phenotype have a higher intracellular [Ca2+]
compared to cells with an epithelial phenotype.
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Ca2+ influx is sufficient to drive a P-EMT phenotype and increased migration and
invasion
Altered calcium homeostasis has been described in association with several hallmarks of
cancer, including proliferation, survival, migration, metastasis, and C-EMT under certain
contexts, (Stewart et al, 2015; Monteith et al, 2017; Davis et al, 2014). We therefore sought
to determine whether the observed association between intracellular Ca2+ and EMT was
correlative or whether Ca2+ influx could directly influence a P-EMT state. To this end, we
treated a panel of murine PDA carcinoma cell lines with either vehicle (DMSO), TGFb (a
potent EMT inducer), or ionomycin, a calcium ionophore that promotes Ca2+ influx
(Chapter 3 Fig. S2A). Because sustained elevations in intracellular [Ca2+] are toxic to
normal cells (Roderick & Cook, 2008), we first confirmed that the treatment did not reduce
the viability of our carcinoma cells (Chapter 3 Fig. S2B).
Next, we examined the effects on cell morphology following treatment with these agents.
As expected, TGFb-treated cells adopted a spindle-like morphology and complete loss of
ECAD staining, consistent with an EMT (Chapter 3 Fig. 2A, bottom row). Ionomycin
treatment also led to significant changes in cell morphology; however, cells retained
expression of ECAD (Chapter 3 Fig. 2A, middle panel). Notably, ECAD was found in the
cytoplasm of ionomycin-treated cells, as compared to the predominant membrane staining
observed in vehicle-treated cells (Chapter 3 Fig. 2A, compare middle and top rows). This
loss of membrane staining was confirmed by flow cytometry, which revealed a significant
reduction of surface ECAD (Chapter 3 Fig. 2B). Next, we performed a time course
experiment, collecting protein and mRNA samples at 24h intervals following treatment with
ionomycin or TGFb. As expected, TGFb treatment resulted in a rapid decrease of ECAD
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at both the protein and mRNA level (Chapter 3 Fig. 2C (Top)). By contrast, cells treated
with ionomycin exhibited no change in ECAD mRNA or protein (whole cell lysate), while
vimentin, a mesenchymal marker, was upregulated at the protein level following both
treatments (Chapter 3 Fig. 2C (Bottom)).
To examine whether Ca2+-induced P-EMT is generalizable to human cancer cells, we
treated human lung (HCC827), breast (MCF7), and PDA (Capan2) carcinoma lines with
either ionomycin or TGFb. While both agents prompted striking morphological changes
and a decrease in surface ECAD levels (Chapter 3 Fig. S2C, S2D), ionomycin-treated
cells exhibited no change in ECAD mRNA and an increase in VIM mRNA (Chapter 3 Fig.
S2E), consistent with our results using murine lines. Of note, P-EMT in human cells
occurred more rapidly with ionomycin than TGFb. Specifically, robust changes in cellular
phenotype and surface ECAD were observed after only 48h of ionomycin treatment, while
comparable changes following TGFb treatment were not observed before day 10 (Chapter
3 Fig. S2C).
Increases in migration and invasion are hallmarks of EMT. To determine whether
increased intracellular [Ca2+] prompts cells to move, we performed live cell imaging
following treatment with TGFb, ionomycin, or vehicle. Cells treated with ionomycin
exhibited a 1.7-fold increase in movement, as compared to a 2.4-fold increase following
TGFb treatment (Chapter 3 Fig. 2D). To study invasion, we performed a Boyden chamber
transwell migration assay and measured cellular mobility through Matrigel. Ionomycin
treatment led to a significant increase in cellular invasion (Chapter 3 Fig. 2D). Taken
together, these results indicate that carcinoma cells treated with ionomycin exhibit multiple
phenotypic characteristics of P-EMT: (i) adoption of a mesenchymal morphology, (ii)
internalization of ECAD protein without change in corresponding mRNA levels, (iii)
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acquisition of mesenchymal protein expression, and (iv) an increase in migratory and
invasive properties.

Ionomycin treatment induces mesenchymal gene transcription without repressing
epithelial gene transcription
Classically, EMT has been associated with the simultaneous repression of epithelial genes
and induction of mesenchymal genes. We reported previously that while loss of the
epithelial program occurs post-transcriptionally in P-EMT, the induction of mesenchymal
genes at the mRNA level is comparable in P-EMT and C-EMT (Aiello et al, 2018). To
obtain a global picture of changes in gene expression associated with increased
intracellular [Ca2+], we treated murine PDA cell lines with vehicle, ionomycin, or TGFb for
48 hours and performed RNA-sequencing (Chapter 3 Fig. 3A). By principal component
analysis (PCA), TGFb-treated samples were widely separated from vehicle- and
ionomycin-treated samples, suggesting that ionomycin treatment brought about
comparatively fewer transcriptional differences (Chapter 3 Fig. S3A). Next, we examined
the abundance of specific epithelial and mesenchymal transcripts previously implicated in
EMT. As expected, TGFb treatment led to a robust downregulation of mRNAs for epithelial
genes such as ECAD, EpCAM, and epithelial cytokeratins, while ionomycin treatment had
little effect on the abundance of these epithelial transcripts (Chapter 3 Fig. 3A, Chapter 3
Fig. S3B). Consistent with our previous in vivo findings regarding P-EMT and C-EMT, both
ionomycin and TGFb treatment resulted in an upregulation of mesenchymal-related
transcripts (Chapter 3 Fig. 3A), and GSEA confirmed that the transcriptomes of ionomycintreated cells were highly enriched for EMT signatures (Chapter 3 Fig. 3B). As expected,
calcium-related signatures were strongly enriched following ionomycin treatment, whereas
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these signatures were not enriched following TGFb treatment (Chapter 3 Fig. 3C). We
then compiled lists of genes that were differentially expressed between ECAD+ and
ECAD- cells from our in vivo analysis and compared them to the genes whose mRNAs
changed following TGFb or ionomycin treatment in vitro. TGFb treated samples were
strongly enriched for the C-EMT signature, whereas ionomycin treated samples were
strongly enriched for the P-EMT signature (Chapter 3 Fig. 3D). Finally, a multinomial
logistic regression (MLR)-based quantitative EMT metric (Chakraborty et al, 2020)
revealed that TGFb-treated cells exhibited a more mesenchymal state relative to those
treated with DMSO or ionomycin (Chapter 3 Fig. S3C). Thus, TGFb treatment
recapitulates the transcriptional changes associated with C-EMT programs in vivo, while
ionomycin treatment recapitulates the transcriptional changes associated with P-EMT
programs in vivo.
To investigate changes in protein abundance accompanying these divergent EMT
programs, we examined tumor-derived exosomes as a window into the proteome. We
collected exosomes from three cell lines after 72h of treatment with vehicle, ionomycin or
TGFb and performed mass spectrometry, capturing approximately 2700 proteins (Chapter
3 Fig. S3D). The three treatments resulted in highly distinctive proteomes as visualized by
PCA (Chapter 3 Fig. 3SE). Consistent with our mRNA results, TGFb treatment depleted
epithelial proteins from tumor-derived exosomes, whereas ionomycin had little effect on
the abundance of these proteins (Chapter 3 Fig. S3F, G). These results confirm that the
epithelial program is preserved at the protein level following ionomycin-induced P-EMT.
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GPCR signaling through Gaq induces P-EMT
Many signals could potentially drive a P-EMT by mobilizing intracellular Ca2+. We
hypothesized that G protein coupled receptors (GPCRs) – particularly those that utilize a
Gaq subunit, which mobilizes Ca2+ following receptor engagement – might play such a
role, as GPCRs are frequently overexpressed in cancer (Dorsam & Gutkind, 2007; BarShavit et al, 2016). To test this hypothesis, we employed a synthetic ligand system in
which GPCR-Gaq signaling can be induced with the experimentally derived drug
clozapine-N-oxide (CNO) (Armbruster et al, 2007; Vaqué et al, 2013; Conklin et al, 2008).
We generated two murine PDA lines overexpressing Gaq-GPCR Designer Receptors
Exclusively Activated by Designer Drugs (DREADD), an engineered receptor that
mobilizes Ca2+ following addition of CNO (Chapter 3 Fig. 4A, top). Treatment with CNO
resulted in a change in cell morphology and loss of surface ECAD, recapitulating the
phenotypes observed with ionomycin (Chapter 3 Fig. 4B). Of note, a transient calcium
spike, as elicited by ATP, was not sufficient to cause this phenotype (Chapter 3 Fig. 4A,
bottom), suggesting that sustained but not transient Ca2+ mobilization is required for
induction of P-EMT.

Calcineurin (CaN) is dispensable for calcium-induced P-EMT
An increase in intracellular [Ca2+] results in the activation of several downstream
mediators, including the transcription factor NFAT, the adaptor protein calmodulin, and
calcium-activated protein kinases. Based on our HOMER motif analysis (Chapter 3 Fig.
1B), we initially hypothesized that the calcium responsive transcription factor NFAT might
be responsible for the P-EMT phenotype. In support of such a hypothesis, several in vitro
and in vivo studies have reported a role for NFAT in tumor development, migration, and
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EMT (Baumgart et al, 2014; Singh et al, 2015; Mancini & Toker, 2009; Subbalakshmi et
al, 2020). To test this hypothesis, we inactivated the NFAT regulator calcineurin (CaN),
which is required for the activity of nearly all NFAT family members (NFAT1-4) (Crabtree
& Olson, 2002; Heit et al, 2006). To this end, we deleted the calcineurin B (CnB) regulatory
subunit in two PDA cell lines (Chapter 3 Fig. S4A) and used the pGL3-NFAT Luciferase
reporter, which contains 3x NFAT binding sequences upstream of a luciferase reporter, to
confirm that CnB KO cells lacked detectable NFAT activity following ionomycin treatment
(Chapter 3 Fig. S4B). Nevertheless, CnB KO cells treated with ionomycin continued to
exhibit a P-EMT phenotype (Chapter 3 Fig. 4C and data not shown), indicating that CaN
and NFAT activity are dispensable for Ca2+-induced P-EMT.

Calmodulin (CaM) acts downstream of Ca2+ mobilization to induce P-EMT
We next considered calmodulin (CaM), which acts as a multifunctional calcium binding
protein upstream of calcineurin and NFAT. When calcium binds to the EF hands of
calmodulin, a conformational shift allows calmodulin to interact with and regulate a variety
of kinases, phosphatases, and other signaling proteins (Villalobo & Berchtold, 2020).
Because the mammalian genome contains three dispersed CaM genes, whose functions
are essential for cell viability, genetic targeting of CaM is challenging. Consequently, we
tested the ability of the CaM antagonist W7 to inhibit P-EMT (see Methods). Pretreatment
of cells with W7 for 24h blocked ionomycin-induced P-EMT, as measured by loss of
surface ECAD (Chapter 3 Fig. 4D). Moreover, W7 treatment alone resulted in increased
surface ECAD expression (Chapter 3 Fig. 4D). These results indicate that CaM is
necessary for Ca2+-mediated P-EMT.
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Summary and Discussion
While EMT has long been associated with tumor cell migration and chemoresistance,
recent studies have pointed to the importance of a hybrid E-M state – P-EMT – as this
state exhibits greater plasticity and metastatic potential (Nieto et al, 2016a; Zhang &
Weinberg, 2018). Ca2+ signaling is known to play a role in cellular migration and cancer
progression (Davis et al, 2014; Monteith et al, 2017; Azimi & Monteith, 2016) and a
requirement for Ca2+ mobilization has previously been reported in hypoxia- or EGFinduced EMT in breast cancer (Davis et al, 2014; Monteith et al, 2017; Azimi & Monteith,
2016).Here, using an unbiased approach based on in vivo observations, we show that
Ca2+ mobilization induces a stable P-EMT characterized by the re-localization of epithelial
proteins and increased invasion and migration. Given that our in vitro findings recapitulate
the cellular phenotypes observed in authochthonous tumors (Aiello et al, 2018), we
conclude extracellular signals resulting in increased Ca2+ flux are at least one mechanism
by which tumor cells achieve a partial EMT state.
These findings raise several questions. First, which GPCR(s) are responsible for
EMT in native tumors, and what are their cognate ligands? The mammalian genome
contains hundreds of GPCRs, many of which are orphan receptors. We identified 90
GPCRs that are differentially expressed between P-EMT and C-EMT tumors in vivo
(Chapter 3 Fig. S5A), a number that is impractical to study sequentially. This issue
highlights a broader problem in the EMT field, which is that the physiologic inducers of
EMT in vivo remain ill-defined. Consequently, it is possible (or even likely) that multiple
signals act in combination within the tumor microenvironment to achieve critical thresholds
of intracellular calcium, TGFb pathway activation, and/or other EMT mediators. A second
question concerns the mechanism by which elevated intracellular [Ca2+] alters the
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epithelial program. Our data indicate that Ca2+- induced EMT requires calmodulin, a
calcium binding protein that interacts with hundreds of cellular proteins. This complexity
poses a challenge for the elucidation of a simple molecular pathway, as multiple
calmodulin binding partners may be involved in the cellular processes underlying epithelial
plasticity. Finally, our findings raise the possibility that Ca2+ mobilization plays a role in
EMT in other contexts, such as embryonic development, as is the case for the canonical
EMT programs driven by epithelial gene repression.
In summary, our data suggest a model wherein activation of a Gaq associated
GPCR mobilizes calcium, which in turn acts through calmodulin to prompt changes in gene
expression, the cytoskeleton, and protein trafficking, resulting in a stable, hybrid E-M state
(Chapter 3 Fig. S4C). As the Ca2+-mediated effects described here are not limited to
murine PDA but are also observed in human cancer cells, this P-EMT program is likely to
operate widely, with therapeutic implications.

Chapter 3 Acknowledgements: Thanks to Jason Pitarresi for his assistance in
elucidating the mechanism downstream of calcium.
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Materials and Methods
Cell lines
Murine PDA cell lines PD7591 (female), PD798 (male), PD483 (female), PD3077 (male),
PD454 (male), PD883 (male) were derived from primary KPCY tumors of mixed genetic
background. All human cell lines (Capan2, MCF7, HCC827) were obtained originally from
ATCC. Cell lines were regularly tested for mycoplasma using MycoAlert Mycoplasma
Detection Kit (Lonza). Murine cell lines were cultured in Dulbecco’s Modified Eagle
Medium/F12 medium supplemented with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL
soybean trypsin inhibitor type I (Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS
Premix; BD Biosciences), 25 µg/mL bovine pituitary extract (Gemini Bio-Products), 5
nmol/L 3,3′,5-triiodo-L-thyronine (Sigma), 1 µmol/L dexamethasone (Sigma), 100 ng/mL
cholera toxin (Sigma), 10 mmol/L nicotinamide (Sigma), 5% Nu-serum IV culture
supplement (ThermoFisher Scientific), and antibiotics (gentamicin 150 µg/mL, Gibco;
amphotericin B 0.25 µg/mL, Invitrogen). Human PDA and breast cell lines were cultured
in Dulbecco’s Modified Eagle Medium supplemented to 10% decomplemented fetal
bovine serum and 1% penicillin/streptomycin. Human lung cell lines were cultured in RPMI
1640

supplemented

to

10%

decomplemented

fetal

bovine

serum

with

1%

penicillin/streptomycin. All lines were cultured at 37°C, 5% CO2, 21% O2 and 100%
humidity. Cell lines were maintained and passaged according to ATCC recommended
procedures.

Drugs and ligands
Mouse (Cell Signaling Technology (CST) 5231LC) or human (CST 8915LC) TGFb was
resuspended in 20mM Citrate pH 3.0 per instructions. Ionomycin calcium salt (CST
9995S) was resuspended in DMSO per instructions. W7-HCl (Santa Cruz sc-201501) was
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resuspended in DMSO per instructions. All solutions were used as indicated in text or
figure legends.

Flow cytometry and Fluorescence-Activated Cell Sorting (FACS)
For detailed protocol see references(Aiello et al, 2018; Norgard & Stanger, 2021). Briefly,
for ECAD flow cytometry, cells were dissociated to single cells with Hanks Enzyme Free
Cell Dissociation Solution (EMD Millipore). Cells were washed in staining solution (HBSS
with 5% FBS and DNase I (Sigma) and stained with anti-ECAD (BioLegend 147308 or
147319) or isotype control (BioLegend 400418 or 400430) at 1:100 in staining solution on
ice for 30 min. Cells were washed 3X in staining solution, filtered through a 70 µM strainer,
and counterstained with DAPI prior to flow cytometry on a LSR II or FACSJazz, BD. Flowjo
software was used for analysis. For more information see

Lentivirus production and transduction
Transfection of 293Ts for lentivirus production was performed using Opti-MEM I (GIBCO),
DNA (expression plasmid, psPAX2, and pVSVg mixed in a 4:2:1 ratio), and
polyethylenimine (PEI, Polysciences) at a 3:1 ratio with total DNA. Recipient cells were
transduced with filtered, unconcentrated viral supernatant in the presence of 8 μg/mL
polybrene. Puromycin antibiotic selection at 5-10 μg/mL was applied for at least 72 hours.

RNA Isolation, real-time quantitative PCR (RT-qPCR)
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RNA was prepared from cultured tumor cells using RNeasy Mini Kit (Qiagen) or
NucleoSpin RNA (Takara). For RT-qPCR, cDNA was generated using High- capacity
cDNA Reverse Transcription Kit (Life Technologies). RT-qPCR analysis was performed
with SsoAdvanced SYBR (Bio-Rad) using a CFX384 Real-Time System (Bio- Rad).
Transcript quantities were determined using the difference of Ct method and values were
normalized to the expression of GAPDH or TBP. Primer sequences are listed in
Supplementary Table S1.

Plasmid construction and cloning
GCaMP6 (a gift from Bruce Freedman) was cloned into pCDH-FHC-EF1 using BamH1
and Swa1. GCaMP6 was transduced in YFP- tumor cells that were generated by inserting
sgRNA towards YFP into lentiCRISPR v2, a gift from Feng Zhang (Addgene plasmid #
52961) using BsmBI. Primers used are listed in Supplementary Table S2. Gaq-DREADD
lentiviral vector DNA was a kind gift from Dr. Silvio Gutkind.

Measurement of cytosolic Ca2+ flow cytometry by GCaMP6
Tumor cells expressing GCaMP6 were dissociated with Hanks Enzyme Free Cell
Dissociation Solution (EMD Millipore). Cells were then stained with anti-ECAD (BioLegend
147308 or 147319) or isotype control (BioLegend 400418 or 400430) at 1:100 in staining
solution on ice for 30 minutes. Cells were washed three times in staining solution and then
placed in either 0mM or 2mM Tyrodes solution on ice. After equilibrium for 1 hour, cells
were stained with DAPI prior to flow cytometric analysis on BD LSR II flow cytometer.
Flowjo software was used for analysis.
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Measurement of cytosolic Ca2+ flow cytometry by Indo-1 calcium indicator
Cells were loaded with Indo-1 at a final concentration of 1.5μM for 45 mins at 37°C in an
incubator. Cells were washed twice with PBS and dissociated with Hanks Enzyme Free
Cell Dissociation Solution (EMD Millipore). Cells were then stained with anti-ECAD
(BioLegend 147308 or 147319) or isotype control (BioLegend 400418 or 400430) at 1:100
in staining solution on ice for 30 minutes. Cells were washed three times in staining
solution and then placed in either 0mM or 2mM Tyrodes solution on ice. After equilibrium
for 1 hour, cells were stained with DAPI prior to flow cytometric analysis on BD LSR II flow
cytometer. Single cell ratios of bound to unbound was performed using flowjo software.

Measurement of cytosolic Ca2+ changes
Cytosolic Ca2+ was assessed by plating cells on glass coverslips. Cells were loaded with
Fura-2 AM (Invitrogen F1221) at 1μM for 30 minutes at 37°C. Time-lapse images were
recorded (2s interval) using a NikonTi system using a 20x/0.75 NA objective for
fluorescence at 340 nm excitation/515 nm emission (Ca2+-bound Fura2) and 380nm
excitation/515 nm emission (Ca2+-free Fura2). ATP, TGFb, CNO, or ionomycin were
spiked in after equilibration. Data were analyzed with ImageJ and presented as traces of
mean (bold line) and SEM (error bars) for all data points (time vs fluorescent ratio).

Matrigel invasion assay
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Transwell inserts (Corning 3464) were coated with matrigel and placed above complete
DMEM. Cells were serum starved in 0.2% serum DMEM for 24 hours. Cells were seeded
in serum-free DMEM on top of the matrigel layer and incubated for 24 hours. Transwell
inserts were removed, washed three times, and fixed in 4% PFA for 15 minutes. Fixed
matrigel inserts were washed three times, stained with DAPI, and imaged.

Live cell migration
Cells were seeded on glass coverslips and treated for 24 hours prior to imaging with
DMSO, Ionomycin (2.5 μM) or TGFb (5ng/ml). Images were recorded every 8 minutes
using an ImageXpress Micro 4 High Content Imaging Device. IMARIS (Bitplane, Oxford
Instruments) was used to quantify migration and create movies.
Cell viability assay
Cells were plated in a six well dish and treated with DMSO, Ionomycin (2.5 μM), or TGFb
(5ng/ml) for 48 hours. Etoposide (50μM) was added for 24 hours as a positive control.
Cells were stained with eBioscience Annexin V Apoptosis Detection Kit APC (88-8007-72)
according to manufacture instructions. DAPI (1mg/ml) was added prior to analysis by flow
cytometry.

RNA-seq, GSEA, and HOMER
RNA samples were extracted using the Qiagen RNeasy or Takara NucleoSpin RNA kit
following manufacturer’s instructions. RNA was sent out to Novogene for library
preparation and high-throughput sequencing using Illumina sequencers to generated
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paired-end results. Raw counts of gene transcripts were obtained using an alignmentindependent tool, Salmon (https://combine-lab.github.io/salmon/), using standard settings.
The raw count matrix was subsequently imported into R-studio (R version 3.5) and used
as

input

file

for

DESeq2

analysis

(https://bioconductor.org/packages/release/bioc/html/DESeq2.html) with default settings
from online software instruction for normalization and differential gene expression analysis.
Salmon was used to normalize and quantitate gene expression in transcripts-per-million
(tpm) through quasi-alignment. Differentially expressed genes were used as input for
principal

component

analysis

(PCA),

gene

(https://www.gsea-msigdb.org/gsea/index.jsp)

set

and

enrichment
motif

analysis

analysis

(GSEA)

using

HOMER

(http://homer.ucsd.edu/homer/ngs/index.html). Detailed Scripts and parameters used for
each steps of analysis could be provided by reasonable request to the authors.

Western blot analysis
Cells were washed with ice cold PBS and lysed in an appropriate amount of RIPA buffer.
Equal amounts of protein were run in reducing conditions on SDS-PAGE gels and
transferred to PVDF membrane, blocked in 5% non-fat milk in PBS plus 0.1% Tween-20
for 1 hour at room temperature. After blocking, membranes were incubated in primary
antibody diluted in 5% non-fat milk in PBS plus 0.1% Tween-20 overnight at 4°C. After
PBS-T washes, membranes were incubated with horseradish peroxidase-conjugated
secondary antibodies (Jackson Immunoresearch) diluted in 5% non-fat milk in PBS plus
0.1% Tween-20 for 1 hour at room temperature. Primary antibodies used are located in
Supplementary Table S3.
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Immunofluorescent staining (IF)
Cells were seeded into 8-well Nunc Lab-Tek II chamber slides (Thermo Scientific) and
fixed in 4% paraformaldehyde for 15 mins. Fixed cells were blocked and permeabilized in
PBS with 0.3% Triton-X and 5% donkey serum for 1 hour. After blocking, cells were
incubated in primary antibody diluted in 5% donkey serum overnight at 4°C. After PBS-T
washes, cells were incubated in fluorescently-conjugated secondary antibodies, and
mounted with Aqua Polymount (Polysciences, Inc). Slides were visualized using an
Olympus IX71 inverted multicolor fluorescent microscope equipped with a DP71 camera.
Primary antibodies used are located in Supplementary Table S3.

NFAT Reporter Assay
pGL3-NFAT luciferase (addgene #17870) and pRL-SV40 (Promega E2231) were
transfected into tumor cells using Lipofectamine 2000 at a ratio of 3:1 for PDAC cells.
Media was changed after 6 hours. Cells were treated with DMSO, Ionomycin (2.5 μM), or
TGFb (5ng/ml) for 24 hours. Luciferase activity was analyzed using dual-luciferase
reporter assay system (Promega E1910) and read on a luminometer.

Exosomes purification, characterization and analyses
Exosomes were purified by sequential ultracentrifugation, as described previously
(Hoshino et al, 2015). In brief, cell contamination was removed from 3-4 day cell culture
supernatant by centrifugation at 500 xg for 10 min. To remove apoptotic bodies and large
cell debris, the supernatants were then spun at 3,000 xg for 20 min, followed by
centrifugation at 12,000 xg for 20 min to remove large microvesicles. Finally, exosomes
were collected by spinning at 100,000 xg for 70min. Exosomes were washed in PBS and
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pelleted again at 100,000 xg for 70min by ultracentrifugation in a Beckman Coulter Optima
XE or XPE ultracentrifuge. The final exosomes pellet was resuspended in PBS, and
protein concentration was measured by BCA (Pierce, Thermo Fisher Scientific).
Exosomes size and particle number were analyzed using the LM10 or DS500 nanoparticle
characterization system (NanoSight, Malvern Instruments) equipped with a violet laser
(405 nm).

Data-dependent analysis of exosomes samples
Exosomes samples (5ug - adjusted based on BCA measurements) were dried by vacuum
centrifugation and re-dissolved in 30-50uL 8M Urea/50mM ammonium bicarbonate/10mm
DTT. Following lysis and reduction, proteins were alkylated using 20 or 30mM
iodoacetamide (Sigma). Proteins were digested with Endopeptidase Lys C (Wako) in <4M
urea followed by trypsination (Promega) in <2M Urea. Peptides were desalted and
concentrated using Empore C18-based solid phase extraction prior to analysis by high
resolution/high mass accuracy reversed phase (C18) nano-LC-MS/MS. Typically, 30% of
samples were injected. Peptides were separated on a C18 column (12 cm / 75 µm, 3 µm
beads, Nikkyo Technologies) at 200 or 300 nl/min with a gradient increasing from 1%
Buffer B/95% buffer A to 40% buffer B/60% Buffer A in typically 90 or 120 min (buffer A:
0.1% formic acid, buffer B: 0.1% formic acid in 80% acetonitrile). Mass spectrometers (QExactive, Q-Exactive Plus, Q-Exactive-HF or Fusion Lumos, Thermo Scientific) were
operated in data dependent (DDA) positive ion mode.

Proteomic database search
High resolution/high mass accuracy nano-LC-MS/MS data was processed using
Proteome Discoverer 1.4.1.14/Mascot 2.5. Mouse data was queried against UniProt’s
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Complete MOUSE proteome (March, 2020; 55,412 sequences) using the following
parameters: Enzyme: Trypsin/P, maximum allowed missed cleavage sites: 2,
monoisotopic precursor mass tolerance: 10 ppm, monoisotopic fragment mass tolerance:
0.02 Da, dynamic modifications: Oxidation (M), Acetyl (Protein N-term), static modification:
Carbamidomethyl (C). Percolator was used to calculate peptide False Discovery Rates
(FDR), which was calculated per file. 1% FDR was applied to each separate LC-MS/MS
file. For exosomes samples that had been in contact with Fetal Bovine Serum (FBS,
exemplified by samples that originated from cell culture) an FBS specific database was
concatenated to the mouse databases when querying the data.

EMT score analysis
EMT scores for RNA-seq data were calculated using MLR and 76GS EMT scoring
methods (Chakraborty et al, 2020). The higher the MLR score, the more mesenchymal
the sample is. The higher the 76GS score, the more epithelial the sample is.

Software
PRISM software was used for the statistical analysis and data visualization
(http://www.graphpad.com). ImageJ software (U.S. National Institutes of Health) was used
for data analysis. The R language and environment for statistical computing and graphics
(https://www.r-project.org) was utilized in this study for the statistical and bioinformatics
analysis of RNA-seq. The R packages used for the analysis described in the method
section were obtained from the Bioconductor (https://www.bioconductor.org) and CRAN
(https://cran.r- project.org/web/packages/). Biorender (https://biorender.com) was used to
create illustrations.
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Data Resources
All sequencing data has been deposited in the Gene Expression Omnibus (GEO):
GSE157892.

Quantification and Statistical Analysis
Statistical analysis of multiple comparisons was performed using ANOVA with Tukey’s
multiple comparison test, and comparisons between two groups were performed using
Students’ unpaired t-test. All statistical analyses were performed with Graphpad Prism 8.
Error bars show standard deviation (SD) or standard error of the mean (SEM) as indicated.
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Chapter 3 Figures and Figure Legends
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Chapter 3 Figure 1: Ca2+ signaling is enriched in P-EMT cells

(A) Representative calcium signature enriched in P-EMT tumors (comparing ECAD- vs.
ECAD+ tumor cells). NES, nominal P-value, and FDR are shown.
(B) HOMER motif analysis comparing P-EMT ECAD- versus ECAD+ tumor cells. The five
most enriched motifs are shown.
(C) Representative image of tumor cells transduced with GCaMP6 (LEFT). Yellow arrows
(mesenchymal cells), red arrows (epithelial cells), scale bar = 50µm. GCaMP6 mean
fluorescent intensity (MFI) in ECADHIGH or ECADLOW cells cultured in indicated
medium (0 Ca2+ or 2 Ca2+) for 1h (RIGHT). Representative of 3 independent cell
lines run in triplicate. Statistical analysis by Student’s unpaired t-test (*, p<0.05; nonsignificant (NS); ±SD).
(D) Flow cytometry analysis of ECADHIGH or ECADLOW cells loaded with Indo-1 and
cultured in indicated medium (0 Ca2+ or 2 Ca2+) for 1h. Representative of 2
independent cell lines with n indicating the number of cells analyzed in each group.
Each experiment was performed in triplicate. Statistical analysis by Student’s unpaired
t-test (****, p<0.0001; non-significant (NS); ±SD).
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Chapter 3 Figure 2: Ca2+ influx is sufficient to drive a P-EMT phenotype and increased
migration and invasion

(A) Representative 20X brightfield and fluorescent images of YFP+ tumor cells treated for
72h with vehicle control (DMSO), 2.5µM Ionomycin, or 10ng/ml TGFb and co-stained
for E- cadherin (Red) and DAPI (Blue).
(B) Representative flow cytometry analysis of surface ECAD (Left), MFI of surface ECAD
(Middle), and percentage of surface ECAD negative cells (Right), after treatment with
DMSO, 2.5µM Ionomycin (IONO), and 10ng/ml TGFb for 72h. Statistical analysis by
ANOVA (****, p<0.0001; non-significant (NS); ±SD).
(C) Top: Relative mRNA expression of Ecad after treatment with 2.5µM ionomycin or
10ng/ml TGFb for denoted time. Bottom: Western blot analysis of total E-cadherin and
Vimentin protein for denoted time. Experiment was run in duplicate with three different
cell lines. Statistical analysis by ANOVA (***, p<0.001; non-significant (NS); ±SEM).
(D) Quantification of live cellular migration over 4h (TOP). N=16 cells per condition.
Experiment was run in triplicate in two different cell lines. Quantification of transwell
migration after treatment with DMSO, 2.5µM Ionomycin (IONO), or 10ng/ml TGFb for
72h (n= 2 cell lines, 3 replicates per cell line with 3 20X images taken per transwell)
(BOTTOM). Statistical analysis by ANOVA (*, p<0.05; ****, p<0.0001; non-significant
(NS); ±SD).
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Chapter 3 Figure 3: Ionomycin treatment induces mesenchymal gene transcription without
repressing epithelial gene transcription

(A) Schematic for RNA sequencing after EMT induction for 48h. Heatmap illustration of
EMT related genes in three independent cell lines, sequenced in duplicate, treated
with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb.
(B) GSEA of ionomycin versus DMSO (left) or TGFb versus DMSO (right) for EMT
signatures. NES, nominal P-value, and FDR are shown.
(C) GSEA of ionomycin versus DMSO (left) or TGFb versus DMSO (right) for calcium
signatures. NES, nominal P-value, and FDR are shown.
(D) Leading edge plots showing enrichment of C-EMT gene signatures in TGFb treated
cells (left) or P-EMT gene signatures in ionomycin (IONO) treated cells (right), based
on GSEA. Enrichment scores (ES), NES, nominal P-value, and FDR are shown.
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Chapter 3 Figure 4: Gaq signaling acts through calmodulin to induce P-EMT

(A) Fura-2 Ca2+ measurements after addition of 5µM CNO (top) or 10µM ATP (bottom)
in cells expressing a Gaq-DREADD. Blue line indicates average of n=22 cells. ±SD.
Tracings are representative of experiments performed twice in 2 independent cell lines.
(B) Representative 20X brightfield images of Gaq-DREADD-expressing cells 48h after
addition of CNO (LEFT). Scale bar = 100µm. MFI of surface E-cadherin in cells
expressing a Gaq- DREADD after treatment with DMSO, 5µM CNO, or 2.5µM
ionomycin (RIGHT). Statistical analysis by ANOVA (**, p<0.01; ±SD).
(C) MFI of surface E-cadherin in CnB knockout lines after 48h treatment with DMSO,
2.5µM ionomycin, or 10ng/ml TGFb. Statistical analysis by ANOVA (***, p<0.001; ****,
p<0.00001; ±SD).
(D) MFI of surface E-cadherin of cells pretreated with 20µM W7 for 24h and then DMSO,
2.5µM ionomycin, or 10ng/ml TGFb for 24h. Statistical analysis by ANOVA (**, p<0.01;
***, p<0.001; non-significant (NS); ±SD).
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Chapter 3 Supplemental Figure S1: Enriched pathways in P-EMT and C-EMT

(A) Western blot comparing ECAD in sorted ECAD+ vs. ECAD- cells from two C-EMT and
three P-EMT murine PDA cell lines.
(B) qPCR comparing Ecad mRNA in sorted ECAD+ vs. ECAD- cells from a P-EMT (454)
and C-EMT (483) cell line. Statistical analysis by Student’s unpaired t-test (****,
p<0.0001; non-significant (NS); ±SEM).
(C) Left: Bioinformatic schematic for GSEA comparing ECAD- versus ECAD+ tumor cells
in either P-EMT tumors (n=8) or C-EMT (n=3). Right: GO and KEGG pathways
upregulated in P-EMT tumors. Normalized enrichment score (NES) for the top 25
pathways with a false discovery rate (FDR) <0.15 are shown, ordered by FDR. Red
text indicates pathways of interest.
(D) Gene ontology (GO) and KEGG pathways upregulated in C-EMT tumors. NES score
for the top 25 pathways with an FDR<0.15 are shown ordered by FDR value. Red text
indicates pathways of interest.
(E) HOMER Motif analysis comparing C-EMT ECAD- tumor cells versus C-EMT ECAD+
tumor cells. The five most enriched pathways shown.
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Chapter 3 Supplemental Figure S2: Activation of calcium signaling does not induce cell
death and promotes EMT in human carcinoma cells

2+
(A) Representative average Fura-2 Ca
measurements after addition of 2.5µM
Ionomycin (purple) or 10ng/ml TGFb (green). Colored line indicates average of n=12
cells. Black error bars represent SD. 2 cell lines were analyzed.
(B) Flow cytometry analysis of cellular viability. Viable cells were defined as Annexin/DAPI-. Cell lines were treated with DMSO, 2.5µM ionomycin, or 10 ng/ml TGFb for 72
hours or 50µM etoposide for 24 hours. Statistical analysis by ANOVA with significance
indicated (****, p<0.0001; error bars indicate SD).
(C) Representative 20X images of the human lung cancer cell line HCC827 after treatment
with 7 µM ionomycin for 2 days or 10ng/ml TGFb for 10 days. Scale bars = 100µm
(D) Mean fluorescent intensity of surface E-cadherin of human pancreatic (Capan2), lung
(HCC827), or breast (MCF7) carcinoma cell lines following treatment with DMSO, 7
µM ionomycin for 3 days or 10ng/ml TGFb for 10 days. Statistical analysis by ANOVA
with significance indicated (****, p<0.0001; error bars indicate SD).
(E) Representative relative mRNA expression of ECAD and VIM after treatment with
DMSO, 7 µM ionomycin for 3 days, or 10ng/ml TGFb for 10 days. Statistical analysis
by ANOVA with significance indicated (*, p<0.05; ***, p<0.001; NS, non-significant;
error bars indicate SD).
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Chapter 3 Supplemental Figure S3: Epithelial proteins are conserved in exosomes

(A) Principal component analysis of differentially expressed genes of cell lines treated for
48 hours with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb. Each cell line per condition
was sequenced in duplicate.
(B) Counts per million reads (CPM) of three cell lines pooled together after treatment with
DMSO, ionomycin (IONO) or TGFb as described in (A). Statistical analysis by ANOVA
with significance indicated (****, p<0.0001; NS, non-significant; error bars indicate SD).
(C) EMT scores calculated via MLR and KS methods. Error bars represent SD. *, p < 0.05
for Students’ two-tailed t-test. N=3.
(D) Schematic for exosome collection and mass spectrometry after EMT induction for 72
hours.
(E) Principal component analysis of proteins contained within exosomes in cell lines
treated for 72 hours with DMSO, 2.5µM Ionomycin, or 10ng/ml TGFb. 3 different cells
line analyzed per condition.
(F) Heatmap illustrating representation of EMT-related proteins found within exosomes.
(G) Relative abundance of E-cadherin protein within exosomes of three cell lines pooled
together in duplicate treated with DMSO, ionomycin (IONO) or TGFb. Statistical
analysis by ANOVA with significance indicated (**, p<0.01; NS, non-significant; error
bars indicate SD).
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Chapter 3 Supplemental Figure S4: Calcineurin activity is dispensable for calcium induced
EMT

(A) Top: Relative mRNA expression of CnB in two cell lines (PD798 and PD7591)
comparing Cas9 control cells to CnB knockout (KO). Bottom: Western blot analysis
showing loss of CnB in KO cells.
(B) NFAT luciferase activity in Cas9 control and CnB knockout cells after treatment with
DMSO, 2.5µM ionomycin (IONO), or 10ng/ml TGFb for 24 hours. Statistical analysis
by ANOVA with significance indicated (**, p<0.01; All other comparisons to DMSO are
non- significant; error bars indicate SD).
(C) Model for a GPCR-calcium-calmodulin signaling axis resulting in EMT.
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Chapter 3 Supplemental Figure S5: GPCRs expressed in C-EMT and P-EMT pancreatic
tumors
(A) Heat map illustrating GPCRs differentially expressed between P-EMT and C-EMT
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CHAPTER 4: MYC CONTROLS METASTATIC HETEROGENEITY IN
PANCREATIC CANCER

Brief Introduction
Tumor heterogeneity, most commonly studied in a primary disease setting, is a critical
driver of phenotypic diversity, culminating in metastatic, lethal cancers (Gundem et al,
2015a; Hunter et al, 2018; McGranahan & Swanton, 2017; Turajlic et al, 2018; Zhao et al,
2016). In most cancers, prognosis and therapeutic decisions are defined by the presence
or absence of metastasis. However, tumor heterogeneity is increasingly being questioned
at the level of metastatic disease, with recent studies in several cancer types suggesting
that metastasis is not a binary phenotype but rather a disease spectrum ranging from
oligo- (limited) to polymetastatic (widespread) disease (Foster et al, 2020; Pitroda &
Weichselbaum, 2019; Weichselbaum & Hellman, 2011). Heterogeneity in the
manifestation of metastatic disease can guide decisions on use of local regional vs.
systemic therapies with emerging evidence of its importance in clinical outcome (Deek &
Tran, 2020; Phillips et al, 2020; Weickhardt et al, 2012). Despite its clinical significance,
the mechanisms that underlie this spectrum of metastatic states remains unclear and
largely understudied.
Pancreatic ductal adenocarcinoma (PDAC) represents a disease entity well suited
for the study of metastasis, as most PDACs present with metastatic disease that is
associated with dismal prognosis (Ryan et al, 2014). One barrier to understanding
metastatic heterogeneity has been a paucity of model systems that capture this natural
variation and allow for direct assessments of paired primary tumors and metastases in
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vivo. This has limited our ability to define the factors intrinsic to primary tumors that
influence the extent of metastatic spread. We previously developed an autochthonous
model of PDAC – the KPCX model – that employs multiplexed fluorescence-based
labeling to track the simultaneous development of multiple primary tumor cell lineages and
follow them as they metastasize (Maddipati & Stanger, 2015). Importantly, this technique
facilitates confirmation of lineage relationships in vivo, such that primary tumor clones with
substantial metastatic potential can be distinguished from those having poor metastatic
potential.
Here, we show that this system recapitulates the variation in metastatic burden
found in human PDAC and use it to dissect molecular and cellular features contributing to
metastatic heterogeneity. We analyzed primary tumors and paired metastases using a
multi-fluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma
(PDAC) – a tumor type where most patients present with metastases. Genomic and
transcriptomic analysis revealed an association between metastatic burden and gene
amplification or transcriptional upregulation of MYC and its downstream targets.
Functional experiments showed that MYC promotes metastasis by recruiting tumor
associated macrophages (TAMs), leading to greater bloodstream intravasation.
Consistent with these findings, metastatic progression in human PDAC was associated
with activation of MYC signaling pathways and enrichment for MYC amplifications
specifically in metastatic patients. Collectively, these results implicate MYC activity as a
major determinant of metastatic burden in advanced PDAC.
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Metastatic burden is variable in human and murine PDAC
While the vast majority of PDAC patients have metastases (principally liver and lung), the
number of metastases is highly variable from patient to patient (Iacobuzio-Donahue et al,
2009; Yachida & Iacobuzio-Donahue, 2009). Importantly, data regarding metastases have
largely been obtained at autopsy and thus confounded by varying treatment histories and
reseeding due to end-stage disease (Gundem et al, 2015b). Thus, we first sought to
characterize the burden of metastases in treatment-naïve patients. To this end, we
performed a retrospective analysis of initial CT scans from 55 patients newly diagnosed
with metastatic (stage IV) PDAC at the University of Pennsylvania (Chapter 4 Fig. 1a).
The total number of lesions in the lung and liver were counted by examining both coronal
and sagittal planes for both organs and binned into groups of ten, revealing a wide
distribution of metastatic burden (Chapter 4 Fig. 1b). K-means clustering identified two
metastatic subgroups: a Metlow subgroup (< or = to 10 metastases, 25/55) and a Methigh
subgroup (>10 metastases, 30/55) (Chapter 4 Fig. 1b, Chapter 4 Fig. S1a). Primary tumor
size, age, sex, and race were not correlated with differences in metastatic burden (Chapter
4 Fig. 1c, Chapter 4 Fig. S1b). However, having a greater number of metastases was
associated with worse overall survival (Chapter 4 Fig. 1d). Thus, even among patients
with stage IV PDAC, metastatic burden is variable and correlates with clinical outcome.
We hypothesized that the differences in metastatic burden seen in human PDAC
may also be present in autochthonous murine models. To test this, we used the KPCXY
model – in which Cre-mediated recombination triggers expression of mutant KrasG12D and
p53R172H in the pancreatic epithelium along with YFP and confetti (X) lineage tracers
(Chapter 4 Fig. 1e, Chapter 4 Methods) – to measure metastatic heterogeneity in a cohort
of tumor bearing mice. By exploiting the multi-color features of the KPCX model, we
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previously showed that these mice harbor (on average) 2-5 independent primary tumor
clones; importantly, the clonal marking of tumors with different fluorophores makes it
possible to infer the lineages of primary tumors with different metastatic potential
(Maddipati & Stanger, 2015). In our earlier work with this model, we noted that in most
tumor-bearing animals – even those with multiple primary tumors – metastasis to the liver
and lung were driven by a single tumor clone (Chapter 4 Fig. 1e, Chapter 4 Fig. S1c). This
suggested that tumor cell-intrinsic factors strongly influence the metastatic behavior of a
tumor, even within a single animal.
To quantify differences in metastatic burden, we examined a panel of mice with at
least 2 uniquely labeled fluorescent tumors where most metastases could be attributed to
a specific tumor on the basis of color (Chapter 4 Fig. 1e, Chapter 4 Fig. S1c). A total of 85
primary tumors from 30 mice were examined, and gross metastases to the liver and lung
arising from each tumor were then quantified by stereomicroscopy (Methods). Murine
PDACs exhibited a wide distribution of metastatic burden, with a pattern resembling that
of the human disease (Chapter 4 Fig. 1f). Similarly, k-means clustering grouped murine
samples into a low metastasis subgroup (£10 metastases, 58/85) and a high metastasis
subgroup (>10 metastases, 27/85), which we similarly refer to as the Metlow and MetHigh
subgroups, respectively (Chapter 4 Fig. 1f, Chapter 4 Fig. S1d). As with the human
disease, neither primary tumor size nor tumor cell proliferation correlated with metastatic
burden (Chapter 4 Fig. 1g, Chapter 4 Fig. S1e). Thus, the KPCXY model recapitulates the
intertumoral metastatic heterogeneity seen in human PDAC and provides a unique
experimental model for comparing highly metastatic and poorly metastatic tumor clones.
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Individual tumor lineages in KPCXY mice correspond to clones with distinct
somatic copy number profiles
Although primary KPCXY tumors were easily distinguishable based on the expression of
a distinct fluorophore, each tumor could have arisen via the clonal expansion of a single
cell or through fusion of multiple tumors which happened to share the same color. Somatic
copy number alterations (SCNAs) have been shown to provide an unambiguous picture
of genomic heterogeneity and lineage relationships between primary tumors and matching
metastases in human disease (Navin et al, 2010). Consequently, we performed copy
number analysis via genome sequencing on a set of 20 primary tumors, including multiregional sampling on a subset of the tumors where sufficient tissue was available (9
tumors with 2-4 regions sampled per tumor) (Chapter 4 Fig. 2a). Tumors bearing different
colors exhibited unique DNA copy number profiles, indicating that they arose
independently (Chapter 4 Fig. 2b, Chapter 4 Fig. S2a) (Baslan et al, 2012). By contrast,
multi-regional sampling of monochromatic tumors revealed shared copy number
alterations, indicating that all subregions within a given tumor (defined by color) shared a
common ancestral lineage (Chapter 4 Fig. 2c, Chapter 4 Fig. S2b). In addition, subregionspecific alterations were also observed, suggesting that subclonal heterogeneity is also
present in each tumor (Chapter 4 Fig. 2c, Chapter 4 Fig. S2b). These results suggest that
the monochromatic tumors observed in KPCXY mice are clonal in origin and continue to
undergo subclonal evolution during tumor progression.
To ascertain the lineage relationships between primary tumors and metastases,
we compared DNA copy number profiles between liver metastases and primary tumors
within a given mouse. This revealed that primary tumors and metastases of the same color
shared common DNA copy number profiles across the dataset, confirming on a genetic
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basis the fluorescence based lineage relationships (Chapter 4 Fig. 2d-f, Chapter 4 Fig.
S2c). As most lung metastasis were microscopic and difficult to isolate by dissection, they
were not included in the molecular analysis. Together, these results indicate that the
lineage history of metastases can be inferred by color and genomic analysis, allowing
primary tumors with high vs. low metastatic potential to be unambiguously classified.

Genomic and transcriptional analyses identify Myc as a potential driver of
metastatic phenotypes
We next sought to examine the molecular differences that distinguish primary tumors with
high vs. low metastatic potential. We began by examining large scale (mega-base level
as well as chromosome wide) SCNAs in 20 MetHigh and MetLow primary tumor samples.
This analysis revealed largely similar genome-wide copy number patterns between Methigh
and Metlow primary tumors with key PDAC associated genes, such as loss-ofheterozygosity (LOH) at Cdkn2a/b and Trp53 as well as chromosomal gain of Kras
occurring at similar frequencies (Chapter 4 Fig. S3a). Thus, KPCXY tumors exhibit
frequent copy number alterations in canonical PDAC genes, but these alterations do not
account for the variation in metastatic behavior between Methigh and Metlow tumors.
We next asked whether other factors (genomic and/or transcriptional) may be
acting to enhance metastasis in the MetHigh group. Focal amplifications in driver
oncogenes – Cdk6 and Yap in breast cancer and mutant Kras in PDAC – have been linked
to the acquisition of metastatic competence (Chan-Seng-Yue et al, 2020; Klotz et al, 2020;
Mueller et al, 2018; Shih et al, 2020). Consistent with prior studies, we observed focal
amplicons at genomic regions encoding Cdk6, Yap, and Kras in our tumors (Chapter 4
Fig. 3a) (Chan-Seng-Yue et al, 2020; Dhanasekaran et al, 2020; Klotz et al, 2020; Mueller
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et al, 2018; Shih et al, 2020). However, in contrast to these amplifications, which occurred
at equal frequencies in MetHigh and MetLow tumors, focal high amplitude amplifications in
Myc were found in 42.8% (3/7) of MetHigh tumors compared to 7.6% (1/13) of MetLow tumors
(Chapter 4 Fig. 3b). Thus, Myc amplifications are enriched in Methigh tumors. In all cases,
these amplifications were maintained in paired metastases (Chapter 4 Fig. S3b). In
addition, RNA-seq analysis demonstrated significantly higher levels of Myc transcripts in
MetHigh tumors and metastases compared to MetLow tumors (Chapter 4 Fig. 3c); overall,
Myc was the third-most significantly upregulated gene in MetHigh tumors compared to
MetLow tumors (Chapter 4 Fig. 3d). Gene set enrichment analysis (GSEA) of the
differentially expressed genes between MetHigh and MetLow tumors identified MYC and E2F
signatures as highly enriched, along with other signatures that have been implicated in
PDAC metastasis including unfolded protein response, oxidative phosphorylation, and
hypoxia (Chapter 4 Fig. 3e) (Chiou et al, 2017; McDonald et al, 2017; Pommier et al,
2018). Moreover, MetaCore transcription factor enrichment analysis identified MYC as the
TF most significantly associated with genes overexpressed in MetHigh tumors (Chapter 4
Fig. 3f), and Ingenuity Pathway Analysis placed Myc at the center of the interactome
generated by these differentially expressed genes (Chapter 4 Fig. S4). Collectively, these
results demonstrate a strong association between a tumor’s metastatic behavior and the
abundance and/or activity of Myc at the genomic and transcriptional levels.
Human PDAC can be grouped into two main transcriptomic subtypes – a welldifferentiated

classical/exocrine-like/progenitor (classical)

subtype

and

a

poorly

differentiated squamous/quasi-mesenchymal/basal (basal-like) subtype (Bailey et al,
2016b; Collisson et al, 2011; Moffitt et al, 2015; Cancer Genome Atlas Research Network.
Electronic address & Cancer Genome Atlas Research, 2017). We found that MetHigh
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tumors were strongly associated with basal-like PDACs, in line with their more aggressive
behavior (Chapter 4 Fig. 3g). Likewise, applying murine MetLow and MetHigh signatures (see
Methods) to human TCGA data predicted a worse survival – indicative of disease
recurrence – for patients with a MetHigh signature (Chapter 4 Fig. 3h). These data indicate
that murine MetHigh tumors correspond to the more aggressive subtypes of human PDAC.

A panel of cell lines that preserve the MetLow and MetHigh phenotypes
To understand the mechanisms underlying these different metastatic properties, we
generated a panel of cell lines from six MetHigh tumors and five MetLow tumors. Consistent
with the parent in vivo tumors, Myc gene expression and Myc protein levels were higher
in the MetHigh lines compared to the MetLow lines (Chapter 4 Fig. 4a-b). SCNA analysis in
these cells lines found that they retained the majority of the genomic alterations found in
the matched primary samples, including Myc amplifications (Chapter 4 Fig. S5a-b).
Furthermore, Myc amplifications were not found in any of the cell lines whose tumors were
originally characterized as non-Myc amplified, indicating that in vitro culture does not
select for this specific copy number alteration. Importantly, elevations in Myc mRNA and
protein were observed in both the Myc amplified and non-amplified MetHigh lines,
suggesting that elevated Myc expression is a stable phenotype of these cells in culture.
To investigate the metastatic properties of the MetHigh and MetLow lines in vivo, we
performed orthotopic implantation of 5 MetHigh and 5 MetLow lines into the pancreas of
NOD.SCID mice and examined distant organs for evidence of metastasis. Although the
weights of MetHigh and MetLow tumors were not significantly different (Chapter 4 Fig. S6a),
MetHigh tumors gave rise to 28-fold more liver and lung metastases compared to MetLow
tumors (Chapter 4 Fig. 4c). Consistent with the cell line expression differences, the
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orthotopic MetHigh tumors expressed higher levels of Myc compared to MetLow tumors
(Chapter 4 Fig. S6b). To further confirm that differences in Myc expression were sufficient
to drive the metastatic phenotype, we introduced a Myc overexpression construct into 4
MetLow lines and generated orthotopic tumors (Chapter 4 Fig. S6c). Myc overexpression
led to a dramatic (22-fold) increase in liver and lung metastases (Chapter 4 Fig. 4d) which
could not be accounted for by the modest increase in tumor weight (Chapter 4 Fig. S6d).
Thus, cell lines derived from spontaneously-generated MetHigh and MetLow tumors retain
their metastatic phenotypes upon implantation.

MYC promotes tumor cell intravasation through the recruitment of tumor
associated macrophages
To form distant metastases, cancer cells must navigate a series of events collectively
referred to as the “metastatic cascade.” These events include (i) intravasation into the
bloodstream or lymphatics, (ii) survival in the circulation, (iii) extravasation from the vessel,
and (iv) growth and survival at the distant site (Welch & Hurst, 2019). To determine the
step(s) at which Myc was exerting its prometastatic effects, we began by measuring the
number of circulating tumor cells (CTCs) in orthotopically-implanted MetHigh and MetLow
tumors and in MetLow tumors engineered to overexpress Myc (Myc-OE). Remarkably,
CTCs arising from MetHigh and Myc-OE tumors were 38-fold and 17-fold more abundant
than those arising from MetLow tumors (Chapter 4 Fig. 4e), far greater than the
approximately 2-fold increase in tumor weight resulting from Myc overexpression (Chapter
4 Fig. S6d). Next, we performed a tail vein metastasis assay, which bypasses the invasion
step by introducing tumor cells directly into the bloodstream and measuring lung
metastases. Surprisingly, in contrast to the orthotopic tumor experiment, there was no
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difference in the number of metastases between MetHigh and MetLow lines (Chapter 4 Fig.
4f). Taken together, these data suggest that MetHigh tumors achieve a higher metastatic
rate principally by promoting cancer cell invasion into the circulation which can be driven
by increased Myc expression.
Beyond activation of tumor intrinsic programs, Myc can also affect tumor
phenotypes by altering the tumor immune microenvironment (TiME) (Kortlever et al, 2017;
Muthalagu et al, 2020; Sodir et al, 2020). Thus, we sought to determine if differences in
Myc levels between MetHigh and MetLow tumors were associated with distinct TiMEs. To
this end, we examined the immune composition of parental primary tumors by staining for
markers of immune cells previously implicated in metastasis of PDAC and other cancers.
While MetHigh and MetLow tumors had a similar degree of neutrophil infiltration, MetHigh
tumors had lower numbers of CD3+ T-Cells and were highly enriched for F4/80+
macrophages (Chapter 4 Fig. 5a). In particular, there was an increased abundance of
macrophages positive for Arg1 (Chapter 4 Fig. 5b), a marker of alternatively activated
tumor associated macrophages (TAMs) (Jablonski et al, 2015). Thus, compared to MetLow
tumors, the TiME of MetHigh tumors contains an increased number of TAMs.
To examine the ability of MetHigh and MetLow tumors to recruit macrophages in our
system, we co-cultured these cell lines with primary bone marrow derived murine
macrophages in a transwell migration assay (Dhanasekaran et al, 2020). Compared to
MetLow lines, MetHigh co-cultures resulted in higher levels of macrophage migration towards
the tumor cells (Chapter 4 Fig. 5c). Consistent with these in vitro results, orthotopic tumors
generated from MetHigh cell lines exhibited greater TAM infiltration than those generated
from MetLow cell lines (Chapter 4 Fig. 5d). Furthermore, MetLow lines overexpressing Myc
(Myc_OE) gave rise to tumors with greater TAM infiltration compared to controls (Chapter
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4 Fig 5e). These results demonstrate that MetHigh tumors exhibit enhanced macrophage
recruitment and implicate Myc expression as a driver of macrophage infiltration.
The recruitment of macrophages to tumors can occur in response to factors
secreted by tumor cells. To identify potential mediators of macrophage recruitment by
MetHigh tumors, we mined our RNAseq data to identify secreted factors that are
differentially expressed between MetHigh and MetLow tumors (p value <0.01 and logFC >1).
This resulted in identification of six cytokines/chemokines upregulated in MetHigh tumors
(Chapter 4 Fig 5f). Importantly, MYC overexpression in the MetLow cell lines resulted in
upregulation of these factors as well (Chapter 4 Fig 5g). Interestingly, each of these
factors has been previously implicated in regulating macrophage recruitment in pancreatic
and other cancer types (Hoshino et al, 2015; Steele et al, 2016; Jia et al, 2016; Kodama
et al, 2020; Miao et al, 2020). These data suggest that multiple Myc-regulated factors likely
act in concert to induce macrophage recruitment and metastsis.
To directly test the role of TAMs in metastasis, we generated orthotopic tumors
from MetLow+Myc_OE lines. After 10 days, we treated mice with a combination of colony
stimulating factor receptor inhibitor (CSFRi) to inhibit macrophage migration and liposomal
clodronate (CLD) to ablate tissue resident macrophages (Chapter 4 Fig. 5h). This regimen
was highly effective at depleting macrophages (Chapter 4 Fig. 5i), consistent with prior
studies (DeNardo et al, 2009; Zhu et al, 2017, 2014). Macrophage depletion resulted in a
4-6-fold reduction in metastases (Chapter 4 Fig. 5j), suggesting that MYC enhances
metastatic spread in part by creating a TAM-rich environment in the primary tumor. While
previous studies have implicated macrophages in tumor cell infiltration, our work directly
links this process to the genomic and transcriptional activation of Myc, which occurs
naturally in our model and is subsequently selected for as a driver of metastasis (Cassetta
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et al, 2019; Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al,
2015; Lee et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele
et al, 2016; Zhu et al, 2014).

Metastasis in human PDAC is associated with MYC gene amplification and elevated
expression
Given the finding that genomic and transcriptional variation in Myc was associated with
metastatic heterogeneity in murine PDAC, we sought to determine whether MYC is
associated with similar metastatic phenotypes in human PDAC. Since the majority of
PDAC samples in the ICGC and TCGA are derived from resected stage I/II tumors (Cancer
Genome Atlas Research Network. Electronic address & Cancer Genome Atlas Research,
2017), these datasets provide limited insight into the determinants of metastatic burden.
Consequently, we analyzed data from the COMPASS trial cohort (NCT02750657) which
is focused on metastatic PDAC patients and utilizes laser capture microdissection (LCM)
to enrich for tumor cells prior to whole genome sequencing or RNA-seq (Aung et al, 2018;
Chan-Seng-Yue et al, 2020). By comparing primary tumors and metastases, we found
that 11.3% (n=17/133) of metastatic tumors were enriched for MYC amplifications
compared to 1.61% (n=4/244) of resectable disease (Chapter 4 Fig. 6a-b; p=7.6e-5,
Fishers test). Likewise, advanced tumors (defined as either locally advanced or
metastatic) were significantly enriched for MYC amplifications (9.22%; n=19/206)
compared to resectable tumors having no evidence of metastasis at diagnosis (1.04%;
n=2/192) (Chapter 4 Fig. S7a; p=1.33e-4). As predicted, amplification was associated with
higher levels of MYC mRNA (Chapter 4 Fig. S7b). MYC amplified tumors did not exhibit
greater genomic instability compared to non-amplified tumors (Chapter 4 Fig. S7c).
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Moreover, metastases expressed higher levels of MYC than primary tumors at the mRNA
level (Chapter 4 Fig. 6c; p=0.00312). These results indicate that MYC amplification and
transcriptional upregulation are strongly associated with PDAC metastases.
Next, we examined a separate patient cohort (N=20) in which matched primary
PDAC tumors and metastases were available for comparison. MYC amplifications were
common in patients with metastatic disease (35.0%; N=7/20), and these amplifications
were retained in the matching metastasis (Chapter 4 Fig. S7c), similar to our mouse
model. The enrichment of MYC amplifications in metastatic samples and the observed
retention of the amplification when analyzing matched primary/metastasis samples
suggests that amplification and/or transcriptional upregulation of MYC in primary PDACs
are selected for and retained during tumor metastatic progression. Consistent with this
notion, we identified a PDAC patient in whom single cell analysis of a paired primary tumor
and metastasis revealed enrichment of a MYC amplified subclone in the metastatic lesion
compared to the primary (Chapter 4 Fig. 6d-e, Chapter 4 Fig. S7d). Collectively, these
data suggest that enhanced expression and/or genomic amplification of MYC is
associated with metastatic spread in human PDAC, complementing our findings from the
mouse model.
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Summary and Discussion
Phenotypic variation, the result of inter- and intra-tumoral heterogeneity arising
during tumor progression,

has made it challenging to understand the molecular

mechanisms underlying tumor spread (McGranahan & Swanton, 2017; Turajlic et al,
2019). Consequently, the demonstration that certain genes function as “metastasis
drivers” – promoting metastasis through mechanisms distinct from their roles in primary
tumor growth – has proven elusive (Lambert et al, 2017). In this study, we exploited an
autochthonous PDAC model with varying degrees of metastatic spread to explore the
molecular basis of naturally-arising variation in metastatic burden. This system revealed
a strong association between the level of Myc – at either the genomic or transcriptional
level – and tumor metastasis, a relationship that was also observed in human PDAC
samples. Myc exerts its pro-metastatic effect at least in part by recruiting pro-invasive
TAMs, leading to greater tumor cell intravasation into the bloodstream. These activities
are not directly related to Myc’s well-described role in primary tumor growth (Farrell et al,
2017; Hessmann et al, 2016; Sodir et al, 2020), as tumors with different levels of Myc
expression grow at comparable rates despite dramatic differences in metastatic ability.
Prior work by us and others has examined the genetic events associated with PDAC
metastasis. In one study, a comparison of matched primary tumors and metastases from
four patients failed to reveal nonsynonymous mutations in driver oncogenes that
distinguished primary tumors from metastases (Makohon-Moore et al, 2017). By contrast,
examination of DNA copy number changes in mouse and human PDAC revealed a
significant association between increased mutant KRAS gene dosage and metastatic
progression (Chan-Seng-Yue et al, 2020; Mueller et al, 2018). While our mouse studies
did not detect an association between Kras focal amplification and metastatic potential,
123

Kras gains (via entire gain of chromosome 6) were detected with comparable frequency
in both MetHigh and MetLow tumors, consistent with the ability of both tumor populations to
metastasize. Interestingly, the MYC_TARGETS geneset represented the most highly
enriched signature in PDAC patients with KRAS amplifications or major allelic imbalances
(Chapter 4 Fig. 6f) mirroring the enrichment of this signature in MYC amplified PDAC
tumors (Chapter 4 Fig. S7f). Signaling through KRAS has long been known to impact MYC
expression (Dang, 2012; Kortlever et al, 2017; Sodir et al, 2020; Vaseva et al, 2018), and
thus our results are consistent with a model in which elevated MYC activity – as a result
of MYC and/or KRAS amplification, or some other mechanism – enhances metastatic
activity. This interpretation is consistent with recent studies of lung, breast, and prostate
cancers identifying a link between MYC amplification and brain or bone metastasis
(Arriaga et al, 2020; Klotz et al, 2020; Shih et al, 2020).
Although tumor formation in the KPCXY model results from shared founder
mutations (KrasG12D activation and Trp53 loss) our genomic analysis revealed ongoing
somatic events during tumor progression, resulting in heterogeneous patterns of genomic
alterations within a given tumor. Such alterations were largely present at the level of copy
number gains and losses rather than point mutations or small insertion/deletions. Although
the complexity of genomic rearrangements varied between tumors, the degree of genome
instability did not correlate with metastatic burden. Thus, the increase in metastasis
observed in MetHigh tumors is not a function of overall SCNA burden but is instead specific
to Myc.
While subregions within a tumor shared many genomic alterations, consistent with
a clonal origin, distinct copy number alterations were also present, suggesting ongoing
subclonal evolution. Clonally related metastases exhibited unique (“private”) alterations;
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however most copy number gains and losses were shared with the parent primary tumor
clone, suggesting that they were present prior to dissemination. In this respect, it is
noteworthy that MYC amplifications in human PDAC were far more common in
metastases than primary tumors, including one case in which we were able to trace a
metastatic lesion directly to a MYC-amplified subclone in the primary tumor. Collectively,
these results suggest that subclonal MYC amplifications, which have been observed in
human primary tumors, provide a selective advantage during metastatic progression
(Baslan et al, 2020; Hayashi et al, 2020). Given that our analysis identified a Myc signature
in tumor MetHigh clones without Myc amplifications, and MYC amplifications are present in
only 11% of human PDAC metastases, other mechanisms for the increased expression
of MYC mRNA in PDAC metastases are likely to exist.
As one of the best-studied oncogenes, MYC has been associated with multiple tumorpromoting activities (Dang, 2012). Given MYC’s role in tumor cell growth and proliferation,
one possible explanation for our results is that MetHigh tumors had an earlier onset and/or
grew more rapidly, leading to increased metastasis by mass effect. Against this possibility,
we found that tumor size and proliferation rates showed no correlation with metastatic
burden. Likewise, our MetHigh and MetLow cell lines exhibited dramatic differences in
metastatic ability despite giving rise to primary tumors of comparable size, suggesting that
Myc can have a context dependent role wherein it drives tumor growth in early progression
and enhances metastatic spread later. Indeed, prior studies have shown that Myc
overexpression in the pancreas in the context of tumor initiation does not result in PDAC
but rather insulinomas (Lewis et al, 2003). By contrast, our work provides strong evidence
that Myc overexpression following the establishment of a primary PDAC confers
metastatic properties.
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Our studies implicate non-cell autonomous mechanisms involving the recruitment
of tumor associated macrophages (TAMs) as contributors to metastatic heterogeneity.
The ability of TAMs to promote tumor cell invasion is well-documented (Cassetta et al,
2019; Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al, 2015;
Lee et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele et al,
2016; Zhu et al, 2014), a property that is in agreement with our finding that MetHigh and
Myc_OE tumors exhibit enhanced vascular intravasation. Furthermore, MYC expression
in tumor cells is known to shape the makeup of the surrounding immune
microenvironment, making it more immunosuppressive (Dhanasekaran et al, 2020;
Kortlever et al, 2017). In line with these observations, we find that MetHigh tumors are
enriched for alternatively activated TAMs and have decreased T-cell infiltration – features
that favor metastasis (Cassetta et al, 2019; Cassetta & Pollard, 2020; Chen et al, 2011;
Ginter et al, 2019; Kitamura et al, 2015; Lee et al, 2018; Linde et al, 2018; Qian et al, 2011;
Roh-Johnson et al, 2014; Steele et al, 2016; Zhu et al, 2014; Pommier et al, 2018; Li et
al, 2018). Our data thus support a model wherein stochastically-arising tumor subclones
with elevated levels of MYC alter the tumor immune microenvironment to facilitate
intravasation and metastasis.
While the specific molecular mediator of TAM recruitment is unknown, we
speculate that MYC acts indirectly. Consistent with this, we identified several
chemokines/cytokines that were upregulated in MetHigh tumors and could also be induced
by Myc overexpression. Thus, we hypothesize that multiple secreted factors, as opposed
to a single factor, act in concert to drive the MYC-associated increase in pro-invasive
macrophages.
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Most patients with PDAC develop metastases. Our data show that even within this
population, the extent of metastatic disease varies widely between patients and impacts
survival. While many steps are required for tumor cells to metastasize, our data indicate
that bloodstream invasion may be a rate limiting event for metastasis in PDAC. Our work
further suggests that in addition to its well-documented cell autonomous role in tumor
growth, MYC acts non-cell autonomously to promote metastasis. Given that MYC family
members are focally amplified in 28% of human cancer (Schaub et al, 2018) these results
have broad implications for metastasis in tumor types other than PDAC.

Chapter 2 Acknowledgements: Thanks to Ravikanth Maddipati for starting this project
and helping to collect data. Thanks to Timour Baslan for copy number analysis and other
bioinformatic analysis.
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Materials and Methods
Data and Code Availability
The datasets generated during this study are available in public databases under the
accession numbers PRJNA647834, PRJNA646123, and PRJNA646156. Additional
primary data needed for review or to replicate the findings will be made available on
request.

Code

generated

during

this

study

is

available

at

https://github.com/rmaddipati79/Maddipati_PDAC_metastasis.git

Mouse models
All experiments were performed in accordance with the National Institutes of Health
policies on the use of laboratory animals and approved by the Institutional Animal Care
and Use Committee of the University of Pennsylvania.

KPCX mice were generated

through a series of backcrosses as previously described (Maddipati & Stanger, 2015). The
RosaConfetti (“X”) reporter allele was introduced into mutant strains bearing Pdx1CreER
(“C”), KrasG12D (“K”), and p53fl/+ (“P”) alleles to obtain Pdx1CreER; KrasG12D; p53fl/+;
RosaConfetti (“KPCX”) mice (Maddipati & Stanger, 2015). For most experiments, animals
were heterozygous for the confetti reporter and also contained the RosaYFP in lieu of the
second confetti allele to generate “KPCXY” mice. The Yfp reporter was introduced to
enable fluorescent lineage labeling of tumors that undergo a “no-color” recombination
event in the confetti reporter as previously described (Snippert et al, 2010). To induce
recombination, a suspension of TAM (MP Biomedicals) in corn oil (Sigma Aldrich) was
administered to pups via lactation following oral gavage of the mother with 6 mg of the

128

drug on post-natal day 0, 1, 2. On average, tumor bearing KPCXY mice were 14-16 weeks
of age at time of sacrifice.

Cell Lines
Pancreatic tumors were dissociated into single-cell suspensions through mechanical
separation and enzymatic digestion as previously described (Rhim et al, 2012). Murine
PDAC

cell

lines

852_MetHigh_1,

471_MetHigh_1,

853

MetHigh_1,

832_MetHigh_1,
471_MetLow_2,

836_MetHigh_1,

850_MetHigh_4,

832_MetLow_2,

842_MetLow_2,

850_MetLow_1, 852_MetLow_2 were derived from KPCXY mice primary tumors that were
also evaluated by SCNA and RNAseq (Chapter 4 Fig. 3c and Chapter 4 Fig. S2). Murine
cell lines were cultured in Dulbeccos’ Modified Eagle Medium/F12 medium supplemented
with 5 mg/mL D-glucose (Invitrogen), 0.1 mg/mL soybean trypsin inhibitor type I
(Invitrogen), 5 mL/L insulin-transferrin-selenium (ITS Premix; BD Biosciences), 25 μg/mL
bovine pituitary extract (Gemini Bio-Products), 5 nmol/L 3,3′,5-triiodo-L-thyronine (Sigma),
1 μmol/L dexamethasone (Sigma), 100 ng/mL cholera toxin (Sigma), 10 mmol/L
nicotinamide (Sigma), 5% Nu-serum IV culture supplement (ThermoFisher Scientific), and
antibiotics (gentamicin 150 μg/mL, Gibco; amphotericin B 0.25 μg/mL, Invitrogen) at 37°C,
5% CO2, 21% O2 and 100% humidity. Cell lines were maintained and passaged according
to ATCC recommended procedures and regularly tested for mycoplasma using MycoAlert
Mycoplasma Detection Kit (Lonza).
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Multicolor image analysis
Pancreatic tumors and organs form tumor bearing KCPXY mice were isolated and
analyzed by fluorescent stereomicroscopy using the Lecia M216FA fluorescent
microscope with CFP, YFP, and dsRED filters (Chroma). As previously described
(Maddipati & Stanger, 2015), distinct colorimetric tumor clones in the primary tumor mass
are defined as an anatomically contiguous region of monochromatic cells that share
distinct borders with adjacent clones of a different color (Chapter 4 Fig. 1d, Chapter 4 Fig.
S1c). In order to accurately quantify the contribution of a different colorimetric tumors to
metastasis we used the following criteria to identify KPCXY mice suitable for analysis: (1)
presence of at least one metastatic lesion to the liver and/or lung, (2) two or more tumors
present, (3) each metastatic primary tumor carries a unique fluorescent color, and (4)
metastatic lesions can be linked to specific tumor based on a shared unique fluorescent
lineage label. Using these criteria, we identified a panel of 30 mice with a total of 85
tumors. Metastasis were quantified by fluorescent stereomicroscopy. Tumor size was
determined using ImageJ to measure the largest circumference of each fluorescent tumor.

Murine tumor and metastasis sample acquisition
Pancreatic tumors and associated liver and lung tissues were isolated from tumor bearing
KPCXY mice. Under fluorescent stereomicroscopy, individual colored tumors were
identified and biopsied using a 6mm punch biopsy. Initial biopsy was placed in 750ml of
RNAlater (Sigma Aldrich) for downstream DNA/RNA isolation. Subsequent biopsies were
submitted for cell line generation and histology. In tumor where sufficient tissue was
available, additional biopsies were taken from anatomically distinct regions of the tumor
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to obtain subclonal biopsies for genomic analysis (Fig 2a). From 7 KPCXY mice, we
obtained biopsies from 20 tumors, 8 of which were amenable to additional sub-regional
biopsies. Paired primary tumor and metastasis in each mouse were identified by shared
fluorescent lineage labels. Metastasis were harvested by microdissection under
fluorescent stereomicroscopy and placed in 500ml of RNAlater for DNA/RNA isolation or
cell line generation. Remainder of tissue was embedded for histology. In total, 56
metastases were isolated for genomic analysis. While individual liver metastases were of
sufficient size for microdissection, lung lesions were microscopic and could not be readily
isolated for molecular analysis.

Immunofluorescence and histological analysis
Tissue samples were fixed in 4% paraformaldehyde (EMS) at room temperature for 45
minutes followed by an overnight incubation in 30% weight/volume sucrose solution
(Sigma Aldrich). Samples were then embedded in O.C.T. (Tissue-Tek) and frozen on dry
ice. Staining was performed on 10

m sections by first blocking with 5% donkey serum

and 0.1% Tween-20 for 1 h followed by overnight incubation with primary antibody diluted
in blocking buffer in a humidified chamber. Sections were washed three times in PBS
containing 0.1% Tween-20. For Immunofluorescence (IF) staining slides were then
incubated with DAPI (Life Technologies, 1:1000), and Alexa flour conjugated antibodies
(Jackson ImmunoResearch). For immunohistochemistry (IHC), slides were first incubated
with biotinylated secondary antibodies (Jackson ImmunoResearch) followed by
development using the ABC HRP and DAB kits per manufactures protocol (Vectorlabs).
Primary antibodies used were as follows: rat anti-Ki67 (eBioscience, 14-5698-82), rabbit
anti-c-Myc [Y69] (Abcam, Ab32072), rabbit anti-CD3 (Invitrogen, PA1-29547), rabbit anti131

F4/80 (Novus, NBP2-12506), rat anti-neutrophil (ABCAM, NIMP_R14), and Rabbit AntiArg1 (Cell Signaling, 93668).

Orthotopic, subcutaneous, and Circulating Tumor cell analysis
Mice were anaesthetized using isoflurane. For orthotopic injections, NOD.SCID mice were
shaved and their abdomen was sterilized using iodine followed by ethanol. An incision
was made over the left upper quadrant of the abdomen, and the pancreas was
exteriorized. 1.0x104 tumor cells in 50 μl sterile PBS were injected into the pancreas via a
27-gauge 5/8’’ insulin needle. The pancreas was returned to the peritoneal cavity, and the
peritoneum and overlying skin were closed with 4-0 coated Vicryl violet FS-2 sutures
(Ethicon). Tumors, lungs, and livers were harvested, weighed, measured, and imaged 46 weeks following implantation. Blood was drawn from tumor-bearing animals via cardiac
puncture with a 1 mL insulin syringe coated with 0.5M EDTA pH 8.0 (Gibco) to prevent
coagulation and was immediately placed in a 150mm plate containing 5-10ml RBC lysis
buffer (BD Biosciences). After 10 min of lysis at room temperature, PBS was added to the
plate and CTCs were directly visualized on a fluorescent microscope and counted.
Subcutaneous injections were performed under anesthesia with 1x105 tumor cells in
NOD.SCID mice. Tumors were harvested 3-4 weeks after injection.

Lung metastasis colonization assay
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1.0x105 tumor cells were injected via tail vein into NOD.SCID mice. After 21 days, lungs
were fluorescently imaged. The tail vein injection experiment was performed in one
experiment, 3 mice per group (MetHigh and MetLow) for analysis. Total metastasis counts
were quantified using fluorescent stereomicroscopy.

Immune flow cytometry analysis
Subcutaneous tumors following 20-30 days of implantation were chopped into small
pieces and digested in collagenase (1 mg/mL in DMEM; Sigma-Aldrich) at 37°C for 30
minutes and filtered through a 70-μM cell strainer. Single-cell suspensions were stained
with LIVE/DEAD Fixable Aqua (Thermo Scientific L-34966) for 10 minutes on ice, followed
by antibodies on ice for 30 minutes and washed twice with PBS with 5% FBS for flow
cytometric analysis. No intracellular staining is needed for this analysis. Cells were then
analyzed by flow cytometry using BD FACS (BD Biosciences) and FlowJo software
(Treestar). Antibodies used for the analysis: anti-CD11b PerCP-Cy5.5 (M1/70; BD
550993), anti-F4/80 APC/Cy7 (BM8; Biolegend 123118), anti-I-A/I-E (MHCII) PE/Cy7
(M5/114.15.2; Biolegend 107630), anti-Ly-6C BV570 (HK1.4; Biolegend 128030), anti-Ly6G V450 (1A8; BD 560603) anti-CD45 AF700 (30-F11; Biolegend 103128), anti-CD206
APC (C068C2; Biolegend 141708), anti-CD115 (CSF-1R) AF488 (AFS98; Biolegend
135512). Gating Strategies for immune cells are as follows: Macrophages –
CD45+CD11b+F4/80+, CSF-1R+ Myeloid cells – CD45+CD11b+CSF1R+, Neutrophils –
CD45+CD11b+F4/80-Ly6G+. The flow analysis of immune infiltration of MetLow and MetHigh
tumors were performed in two experiments with 4-5 mice per tumor cell clone.
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Bone marrow derived Macrophage isolation
Bone marrow immune cells were isolated as shown previously (Liu & Quan, 2015). 2x106
isolated immune cells were plated in a six well dish in IMDM (Gibco, 12440053)
supplemented with 10% fetal bovine serum (Gibco), 1% L-glutamine (Corning,
MT25005CI), 1% Non-essential Amino Acids (Corning, 11140076), 1% Sodium pyruvate
(Gibco, 11360-070), 0.001% 2-mercaptoethanol (Gibco, 21985023), 1% PenicillinStreptomycin (Gibco, 15140163), 20ng/ml recombinant murine M-CSF (PeproTech, 31502) at 37°C, 5% CO2, 21% O2 and 100% humidity. Bone marrow derived macrophages
(BMDMs) were differentiated for 7 days and used by gentle scraping before 10 days

Macrophage Transwell migration assay
Macrophage invasion was assessed using a 12 well transwell chamber with 8 mm filter
inserts (Corning). Growth factor reduced Matrigel (Corning 356231) was diluted 1:1 in PBS
and plated onto the transwell. Tumor cells were plated to the lower chamber 24 hours
before addition of bone marrow derived macrophages (BMDMs). 100,000 BMDMs were
plated in the transwell. After 24 hours, the non-migrated BMDMs and Matrigel were gently
removed with a swab. Cells in the lower surface (migrated BMDMs) of the membrane were
fixed in 4% paraformaldehyde (PFA) for 15 mins. DAPI (Invitrogen D21490) was added in
PBS to the transwells. The membranes were imaged and number of macrophages
counted in 4 random fields. The experiment was performed in triplicates and was repeated
twice.
Macrophage Depletion in vivo
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10,000 tumor cells were orthotopically injected into the pancreas of NOD.SCID mice.
Treatments started 10 days after implantation. GW2580, CSF-1R inhibitor (AdooQ
Bioscience, A11959-200) was dissolved in 0.5% hydroxypropyl methyl cellulose and 0.1%
Tween and dosed 3 times a week at 160mg/kg by oral gavage. 200ul of Clodronate or
control liposomes (Liposoma, CP-025-025) was given one time a week by intraperitoneal
injection. Blood from tail snips was used to analyze depletion. Experimental and control
mice were euthanized 14 days after treatment start and analyzed for metastasis and
immune cells by flow cytometry. Control and experimental groups were run in triplicate.

Molecular cloning, Lentivirus generation and transduction
Murine Myc was cloned into pCDH-EF1-FHC (Addgene plasmid # 64874). The vectors
were transfected into 293T cells using PEI reagent and packaged into lentivirus for
transduction. Lentivirus was collected 48 hours after transfection and 0.45um filtered for
usage. Tumor cells were transduced with packaged virus with 4ug/ml polybrene for 48
hours. Cells were selected with puromycin for 10 days. Overexpression efficiencies were
assessed by gene-specific quantitative PCR analysis.

Immunoblotting
Cells were washed with cold PBS and lysed in RIPA buffer on ice. Lysis was spun down
at max speed and supernatant was collected. Protein was separated by SDS-PAGE,
transferred to PVDF membrane, blocked in 5% non-fat milk in PBS plus 0.1% Tween- 20,
probed with primary antibodies, and detected with horseradish peroxidase- conjugated
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secondary antibodies (Jackson ImmunoResearch). Primary antibodies used include: antiMyc [Y69] (Abcam, ab32072); anti-GAPDH (CST, 2118S)

Real-time PCR
RNA was prepared from cultured tumor cells using RNeasy Mini Kit (Qiagen). cDNA was
generated using High-capacity cDNA Reverse Transcription Kit in a 20 ul reaction volume
and diluted 1:10 for qPCR analysis (Life Technologies). qPCR analysis was performed
using 1 ul diluted cDNA with biological (2-3) and technical replicates (2- 3) using
SsoAdvanced SYBR reagent (Bio-Rad) and Bio-Rad qPCR platform, and results were
normalized to the expression of Gapdh using the Bio-Rad software. Primer sequences
utilized

for

qPCR

were:

mGapdh

F-

atgttccagtatgactccactcacg,

mGapdh

R-

gaagacaccagtagactccacaca,
mMyc F-

gcatgaggagacaccgccca, mMyc R- ggtttgcctcttctccacaga, mCxcl3 F-

cagccacactccagccta, mCxcl3 R- cacaacagcccctgtagc, mCxcl2 F- ccaaccaccaggctacagg,
mCxcl2

R-

gcgtcacactcaagctctg,

tgtgttgaagaaagggccagt,

mCcl3

mIl24
F-

F-

gagcctgcccaactttttgtg,

ccaagtcttctcagcgccata,

mIl24

mCcl3

RR-

gatgaattggccgtggaatctt, mCcl4 F- tgctcgtggctgccttct, mCcl4 R- ctgccgggaggtgtaagaga,
mMif F- gccagaggggtttctgtcg, mMif R- gttcgtgccgctaaaagtca

DNA and RNA isolation and purification
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Tumor and metastasis biopsy samples were stored in RNAlater (Sigma Aldrich) prior to
processing. Bulk tissues were homogenized in triazol (ThermoFisher) and followed by
phase separation with 0.2ml chloroform per 1ml of Triazol. Aqueous phase was isolated
and RNA extracted with RNAeasy Mini Kit (Quiagen) per manufactures protocol. To
extract DNA, the remainder of the solution following removal of aqueous phase was mixed
with 300ul of Back extraction buffer (4M Guanidine Thiocyanate, 50mM Sodium Citrate
dihydrate, 1M Tris free base, and molecular grade water. All reagents from Sigma Aldrich)
per 1ml of triazol. Solution was incubated on a shaker for 10 min followed by centrifugation
for 30 minutes at 12000xg at room temperature. Aqueous solution was isolated and 0.4ml
of Isopropanol was added followed by centrifugation for 15 minutes at 12000xg at 4C. The
DNA pellet was then washed with 70% Ethanol.

Analysis of RNA-seq, Differential gene expression, GSEA, and molecular subtype.
RNA sequencing was performed on bulk tumor and metastasis samples from 7 KPCX
mice resulting in 66 samples for analysis (Primary tumor with subregional biopsies and
metastasis). RNA purity and integrity were verified on the Agilent Tapestation prior to
library construction followed by paired-end 75bp sequencing on an Illumina HiSeq 4000
high-throughput sequencer. Alignment of fastq files was performed with STAR aligner
v2.5.2b using mm10 as the reference genome (Dobin et al, 2013). Gene level expression
data in terms of expected counts and FPKM was obtained using RSEM v1.2.28 (Li &
Dewey, 2011). Low expressing genes were removed using cutoff of 100 for count and 10
for FKPM. For primary tumor clones where subregional biopsies were taken, count data
for the tumor was obtained by merging expression data of the subclone count data using
the mean value. This resulted in a total of 54 samples for downstream analysis (MetLow =
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13, MetHigh = 7, and Metastasis = 34). For differential expression analysis, count data was
normalized using the voom function in the limma R-package followed by batch correction
using the ComBat R-package (Ritchie et al, 2015; Wang et al, 2017). Then limma was
used to perform differential expression between MetHigh, MetLow, and metastasis. Boxplots
of log2 FPKM values for genes were generated using the ggplot2 R-package. To generate
volcano plots, differential expression data comparing MetLow and MetHigh clones was
plotted using ggplot2 with log base 2-fold change from MetLow compared to MetHigh tumors
of each gene was plotted on the x-axis and the adjusted p-values plotted on the Y axis.
Genes with adjusted p-values less than 0.01 and absolute log2 fold change >1 were
highlighted. Differentially expressed genes were used as input for GSEA MSigDB geneset
enrichment analysis (Mootha et al, 2003; Subramanian et al, 2005). Transcription factor
enrichment on all differentially expressed genes was performed using the Metacore
software package (https://clarivate.com/products/metacore/, Clarivate Analytics, London,
UK). Network analysis was performed on all differentially expressed genes using ingenuity
pathway analysis software (www.ingenuity.com, Ingenuity Systems Inc., Redwood City,
CA). Molecular subtype classification using the Bailey, Moffitt, and Collision (Bailey et al,
2016b; Collisson et al, 2011; Moffitt et al, 2015) signature was performed on each sample
by subtracting the sum of normalized expression for genes corresponding to specific
classes within a particular molecular signature. We then took the maximum score
observed across each class and assigned to the samples. Heatmaps were generated
using differentially expressed genes with adjusted p-value <0.05 and absolute LogFC >1.

Survival analysis of TCGA data
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TCGA PAAD expression and patient and sample level clinical data was downloaded from
cBioportal (http://www.cbioportal.org/) (Cerami et al, 2012; Gao et al, 2013). Samples
were filtered to those classified as pancreatic adenocarcinoma and having available
expression data (162 of 186 samples). To develop a signature gene list associated with
the MetHigh phenotype, we filtered differentially expressed genes between MetHigh and
MetLow tumors using an adjusted p-value <0.05 and absolute logFC >0.58 resulting in a
set of genes that are upregulated or downregulated in the MetHigh tumors (736 Up and
1036 down). To calculate a signature score for each TCGA PAAD sample, we first z-score
normalized the TCGA PAAD expression data and then subtracted the sum of all
downregulated gene expression from the sum of all upregulated gene expression values.
We divided the signature score into high and low strata using a cutoff score >0. KaplanMeier analysis was done to compare survival between the two groups.

Human Stage IV pancreatic tumor and metastasis imaging analysis
CT scans were obtained from patients with metastatic PDAC undergoing treatment at the
University of Pennsylvania (IRB protocol #822028). Patients were filtered to include only
those with CT-scan imaging of the abdomen and chest with IV contrast at the time of
diagnosis and prior to any treatment and found to have Stage IV disease. In total, 55
patients were included. CT images for each patient were reviewed and metastatic lesions
in liver and lung were counted. All metastases were examined in multiple planes to ensure
accurate assessment. Tumor area was pulled from the initial radiologist report and
measured at the largest diameter. Cut-off for high and low metastasis groups was
determined using k-means with n=2 clusters.
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Human pancreatic cancer patient sample acquisition with genomic and RNA-seq
analysis
Sample acquisition resulted from patients recruited as part of the International Cancer
Genome Consortium (ICGC) Pancreatic Cancer Ductal Adenocarcinoma Canadian
sequencing initiative or the COMPASS trial as previously described (Connor et al, 2017).
Tissue samples were collected at the University Health Network (Toronto), Sunnybrook
Health Sciences Centre (Toronto), Kingston General Hospital (Kingston), McGill
University (Montreal), Mayo Clinic (Rochester), or Massachusetts General Hospital
(Boston) with patient informed consent and approval from Institutional Review or Research
Ethics Boards. Whole Genome Sequencing and RNA Sequencing was performed on fresh
frozen tumor tissue samples which were enriched for tumor content by laser capture
microdissection (LCM). Whole genome sequencing (WGS) and RNAseq were performed
at the Ontario Institute of Cancer Research as described previously (Connor et al, 2017)
DNA Read Alignment and MYC Copy Number Variations were performed on paired end
whole genome sequencing reads aligned to human reference genome hg19 using BWA
0.6.2 (Li & Durbin, 2009). PCR duplicates were marked with Picard 1.90. Tumor cellularity,
ploidy, and copy number segments were derived using an in-house algorithm CELLULOID
(Notta et al, 2016). RNA reads were aligned to human reference genome hg38 and to
transcriptome Ensemble v84 using STAR v2.5.2a (Dobin et al, 2013). Duplicate reads
were marked with Picard 1.121. Raw counts were obtained using HTSeq 0.6.1(Anders et
al, 2015). Differential gene expression analysis was performed with DESeq2 v.1.14.1
(Love et al, 2014). using default settings. Briefly, RNA HTSeq count data was imported
to generate a dispersion estimate and a generalized linear model. Wald statistical test was
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used to compare gene expression of MYC amplified to non-amplified cases. Gene set
enrichment analysis was performed using genes ranked based on the P value and sign of
the log2 fold change from differential gene expression analysis. Gene set enrichment
analysis was run using GSEA Preranked 4.0.2 with default settings against hallmark gene
sets (Subramanian et al, 2005). Statistical Analyses included pairwise comparisons of
quantitative variables performed using Wilcoxon rank sum test. All tests were two-sided.
Analyses were carried out in R 3.3.0.

Somatic Copy Number Analysis in murine tumors
DNA purified from dissected murine tumors was processed for Illumina library preparation
and sequencing using standard protocols. In brief, isolated DNA (between 100-100ng in
total) was sonicated on a Covaris instrument. Sonicated DNA was then end-repaired and
ligated to TruSeq dual-index library adaptors. Index libraries were subsequently enriched
by 10 cycles of PCR amplification followed by pooling and multiplex sequencing targeting
a coverage of roughly 2 million reads per sample (Baslan et al, 2015). For data processing
and copy number inference, sequencing data was processed as previously described with
mouse genomic bins computed in a manner similar to human bins (Baslan et al, 2012). In
brief, sequencing reads were mapped to the mouse reference genome built mm9.
Sequencing reads were indexed, sorted, with PCR duplicates removed. Uniquely mapped
reads were counted in each bin and normalized for GC content using lowess smoothing.
Normalized read count data were then segmented using Circular Binary Segmentation
(CBS) (Venkatraman & Olshen, 2007) with the profiles centered around a mean of 1.
Chromosomal segments with variance that is above or below the mean where called as
gains or deletions, respectively. A threshold of 0.2 was used. For hierarchal clustering and
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lineage reconstruction, an analysis based on copy number values and alteration
breakpoints, in a genome-wide manner, was employed.

Bulk and single cell analysis of matched primary and metastasis from human tissue
For 20 patients, tissue sections from flash frozen samples were processed for bulk DNA
purification using Qiagen DNeasy Blood and Tissue kit. Purified DNA was processed as
described above for multiplex sequencing. A coverage of 2 million sequencing reads was
similarly targeted. For a single case, matched pancreatic primary and liver metastasis
tissue was retrieved and processed for single-nuclei isolation as previously described
(Baslan et al, 2012). Single-nuclei were sorted based on DNA content form both diploid
and polyploid populations of each tissue. Approximately 100 nuclei per tissue sample was
amplified using WGA4 kit (Sigma-Aldrich) with the resulting Whole Genome Amplified
(WGA) DNA processed for TruSeq Indexed sequencing library preparation as described
above. Sequencing data was processed as described above with the exception that a
least squares fitting algorithm was used to calculate absolute integer copy number (Baslan
et al, 2015).

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis used is indicated in each figure where relevant. All statistical analyses
were performed with Graphpad Prism 8 (GraphPad). K-means clustering and Survival
analysis were carried out in R 3.3.0. Error bars show standard deviation (SD) or standard
error of the mean (SEM) shown as indicated in the legend and p<0.05 was considered
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statistically significant. * indicates p<0.05; **, p<0.005; ***, p<0.0001, unless otherwise
indicated. ns denotes not significant.
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Chapter 4 Figures and Figure Legends

Chapter 4 Figure 1
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Chapter 4 Figure 1: Advanced pancreatic tumors exhibit intertumoral differences in their
propensity for metastasis

(A) CT imaging of human PDAC liver metastasis demonstrating heterogeneity in
metastatic burden in Stage IV disease. Arrowheads indicate solitary metastasis in the
top panel and selected metastases in the bottom panel
(B) Density plot and histogram showing the distribution of total (liver and lung) metastases
enumerated from CT scans of human Stage IV PDAC at the time of diagnosis (N=55).
Values above each histogram bar represent the number of patients in each group. The
vertical dotted line (red) represents the cutoff between MetLow tumors (£ 10 mets) and
MetHigh tumors (>10 mets) determined by k-means clustering.
(C) Quantification of tumor area (based on tumor dimensions from largest cross-sectional
plane on imaging) comparing MetLow and MetHigh cases from the cohort in (b).
(D) Overall survival analysis of the cohort in (b).
(E) Top: Schematic view of the KPCXY model, showing multiple primary tumors
distinguishable by color arising in the pancreas with matched metastases in the liver.
Bottom: Representative fluorescent stereomicroscopic images showing a YFP+ tumor
adjoining a CFP+ tumor in the pancreas (left) and liver metastases derived from the
CFP+ tumor in the same animal (right).
(F) Density plot and histogram showing the distribution of total (liver and lung) metastases
enumerated at autopsy of KPCXY mice. Values above each histogram bar represent
the number of tumors giving rise to the indicated number of metastases, based on
color (N=85 tumors from 30 KPCXY mice). The vertical dotted line (red) represents
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the cutoff between MetLow tumors (£ 10 mets, N=58) and MetHigh tumors (>10 mets,
N=28) determined by k-means clustering.
(G) Quantification of tumor area comparing MetLow and MetHigh tumors from the cohort
in (f).
Statistical analysis by Student’s unpaired t-test with p-values indicated (ns, not significant).
Box- whisker plots in (c) and (f) indicate mean and interquartile range. Scale bar (e) =
1mm.
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Chapter 4 Figure 2: Somatic copy number alteration analysis confirms fluorescence-based
lineage relationships and reveals genetic heterogeneity in in paired primary pancreatic
tumors and liver metastasis

(A) Schematic representation of KPCXY pancreatic tumor and matching liver metastasis
with multi- region sampling for copy number sequence analysis.
(B) Representative genome-wide copy number profiles of MetHigh (CFP+ fluorescence)
and MetLow (YFP+ fluorescence) tumors from mouse 832 (m832) as depicted in Fig
1e. Gray shading denotes alterations that are unique to the MetHigh (CFP+) tumor. Yaxis illustrate normalized read count values (low-ratio) which are directly proportional
to genome copy number at a given chromosomal location. The copy number profiles
are centered around a mean of 1 with gains and deletions called for segments with
values higher and lower than the mean, respectively (Methods).
(C) Representative genome-wide copy number profiles of three sub-sampled tissue
regions of the MetHigh (CFP+) primary tumor from m832. Gray shading denotes
alterations that are found heterogeneously from multi-region sequencing of the primary
tumor.
(D) Genome-wide heatmap with hierarchal clustering based on copy number alterations
of matched primary and metastatic samples profiled from m832.
(E) Representative genome-wide copy number profiles of fluorescently matched primary
and metastatic tissue from two profiled mice (m832-left panel and m836-right panel)
illustrating the shared clonal genetic lineage.
(F) Zoom-in chromosomal views of copy number alterations with distinguishing breakpoint
patterns supporting shared genetic lineage. Panels are ordered as in (e).
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40

50

Chapter 4 Figure 3: The MetHigh phenotype is associated with focal, high amplitude Myc
amplifications and elevated expression

(A) Schematic representation of focal amplifications identified in profiled primary tumors.
Vertical gray line denotes the location of amplicon and likely driver gene
(B) (Left) Zoomed in schematic representation of three identified Myc amplicons in
MetHigh tumors illustrating the focal and high-amplitude nature of the event. Each
event (amplicon) is illustrated by a different colored segment line. The shared amplified
region between the different amplicons is denoted by the chromosomal cytoband top
of panel and illustrated in UCSC genome browser view (Right) with RefSeq Genes,
including Myc, illustrated.
(C) Box-and-whisker plot showing Myc mRNA levels in MetHigh tumors (N=7) and paired
metastases (N=34) compared to MetLow tumors (N=13).
(D) Volcano plot illustrating genes meeting cutoffs for differential expression (logfoldchange >1, Padj <0.05) between MetHigh and MetLow tumors (N=20 tumors used in
the comparison). Genes upregulated in MetHigh tumors are highlighted in green, and
genes upregulated in MetLow tumors are highlighted in red.
(E) Top ten Hallmark Gene Sets identified as enriched in MetHigh tumors compared to
MetLow tumors using all DEGs (adj. p < 0.05).
(F) Top five transcription factor binding sites enriched in DEG in MetHigh tumors
compared to MetLow tumors (adj. p< 0.05) identified by Metacore prediction software.
(G) Heatmap showing unsupervised clustering of differentially expressed genes (logfoldchange >1, Padj <0.05) between MetHigh and MetLow tumors (N=20) and their
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association with PDAC transcriptional subtypes previously reported by Collison(42),
Moffitt(15), and Bailey(16).
(H) Kaplan-Meier analysis showing overall survival of PDAC patients in the TCGA cohort
stratified into those with a MetHigh signature (red line) versus those with a MetLow
signature (blue line). Signature based on DEGs with absolute logfold-change > 0.58
and Padj <0.05 (736 up and 1036 down regulated genes)
Statistical analysis in (c) was performed by Wilcoxon test (*, p=3.9x10-4; **, p=5.3x10-5).
Box and whiskers represent median mRNA expression and interquartile range. Statistical
analysis in (h) was performed by log-rank test.
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Chapter 4 Figure 4: Myc regulates metastasis by enhancing tumor cell intravasation

(A) Bar graph showing Myc mRNA levels in cell lines derived from MetHigh and MetLow
tumors, normalized to Gapdh. N= 6 MetHigh and 5 MetLow cell lines
(B) Western blot showing corresponding MYC protein levels in cell lines derived from
MetHigh and MetLow tumors described in (a).
(C) Representative fluorescent images of primary tumors and associated liver and lung
metastasis following orthotopic transplantation of the cell lines in (a) and (b) into
NOD.SCID mice. The bar graph shows the total number of metastases (liver and lung)
counted following orthotopic transplantation of 5 MetLow cell lines or 5 MetHigh cell
lines (pooled data from N=49 mice in total).
(D) Representative fluorescent image of primary tumors, liver, and lung metastases
following orthotopic transplantation of MetLow cell lines that were stably transduced
with either a Myc overexpression construct (Myc-OE) or empty vector (EV). The bar
graph shows the total number of metastases (liver and lung) counted following
orthotopic transplantations of Myc-OE or EV cells. Data were pooled from 4
independent MetLow lines transduced with either the MYC-OE or EV construct
transplanted into 12 NOD.SCID (for the Myc-OE cells) or 10 NOD.SCID mice (for the
EV cells).
(E) Quantification of circulating tumor cells (CTCs) in arterial blood derived from the
orthotopic tumors depicted in (c) (N=27 mice examined) and d (N= 12 mice examined).
(F) Representative fluorescent images of lung metastasis following tail vein injection of
cell lines derived from the MetLow and MetHigh primary tumor clones. The bar graph
shows the total number of lung metastases counted following tail vein injection of 5
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MetLow cell lines or 5 MetHigh cell lines (pooled data from N= 36 mice in total).

Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.0152; **,
p = 0.013; ***, p= 0.0008; **** p < 0.0001; ns, not significant). Error bars indicate SEM (cf). Scale bar = 1 mm (c-d,f).
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Chapter 4 Figure 5: Myc recruits pro-metastatic macrophages to the TME

(A-B) Representative immunofluorescence images (top) and quantification (bottom) of
T-cells (CD3+), Neutrophils (anti-neutrophil antibody+), macrophages (F4/80)+, and
Arg1+ macrophages in primary KPCXY tumors categorized as MetLow or MetHigh
(N=3 mice for each subgroup and 4-5 random fields of view analyzed).
(C) Representative immunofluorescence images (left) and quantification (right) of
macrophages that have migrated across a transwell filter following co-culture with
MetHigh or MetLow tumor cells (N= 2 MetLow and 2 MetHigh cell lines used, 3
replicates per cell line with 3 20X images taken per transwell; each dot represents
quantification of an independent image).
(D) Quantification of tumor infiltrating macrophages (as a percentage of total CD45+ cells)
in MetLow or MetHigh subcutaneous tumors assessed by flow cytometry (N=5
MetHigh cell lines and 3 MetLow cell lines; 2 NOD.SCID mice examined per cell line
with 2 tumors per mouse; each dot represents an independent tumor).
(E) Quantification of tumor infiltrating macrophages (as a percentage of total CD45+ cells)
in Myc- OE or control (EV) subcutaneous tumors assessed by flow cytometry (N=2
Myc-OE cell lines and 2 EV cell lines; 2 NOD.SCID mice examined per cell line with 2
tumors per mouse; each dot represents an independent tumor).
(F) Differentially expressed chemokines/cytokines with elevated expression (logfoldchange >1, Padj <0.01) between MetHigh and MetLow tumors (as described in Fig 3d)
(G) Bar graph showing fold change in chemokines/cytokine mRNA levels listed in (f)
comparing Myc-OE to EV cell lines. Data representative of 2 independent cell lines.
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(H) Schematic outline of the macrophage depletion experiment. Mice were orthotopically
implanted with Myc-OE cell lines (N=2 independent cell lines) and after 10d were
treated with a combination of CSFR inhibitor (GW2580) and liposomal clodronate
(CLD) or vehicle. Metastases were quantified 14d later.
(I) Representative
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with

GW2580+CLD or vehicle.
(J) Quantification of total metastases (liver and lung) following the macrophage depletion
strategy outlined in (h) (N=6 control mice and N=7 GW2580+CLD mice; each dot
represents an independent mouse).

Statistical analysis by Student’s unpaired t-test with significance indicated (*, p<0.05; **,
p<0.005; ***, p<0.0001; ns, not significant). Error bars indicate SEM (a-e, h). Scale bars =
10 µm (a-b) and 50µm (c).
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Chapter 4 Figure 6: MYC amplification and enhanced transcriptional activity are
associated with metastasis in human PDAC

(A) Bar graph showing the relative frequencies of MYC amplifications in primary PDAC
tumors and metastases from the COMPASS cohort.
(B) Representative plot of chromosome 8 from a metastatic tumor with MYC amplification.
Orientation of breakpoint junctions from intra-chromosomal rearrangements indicated
by TH, HT, HH, and TT where T = tail (3’ end of fragment) and H = head (5’ end of
fragment).
(C) Box-and-whisker plot showing MYC mRNA levels (FPKM) in primary PDAC tumors
and metastases.
(D) Representative genome-wide absolute copy number plots of single cells retrieved from
a primary (top panel) and its matched metastasis (lower panel) illustrating acquisition
of focal MYC amplification in the metastatic lesion.
(E) Heatmap depiction of cancer single cells sequenced from a matched primary PDAC
and its liver metastasis. Color codes indicate absolute copy number in single-cells.
Top bar plot depicts tissue site from where single-cells were retrieved.
(F) Gene set enrichment analysis of tumors with a major imbalance of mutant KRAS
(compared to those with no major imbalance) in the COMPASS cohort.

Box-whisker plot in (c) indicates mean and interquartile range.
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Extended Data Figure 1
a

Log2 (total metastasis counts)

Human PDAC

b
MetHigh
MetLow

6

4
*
2

Patient Demographics (n=55)
Race

White (48)
Black (1)
Asian (2)
Hispanic (2)

Age

MetLow (66.52 +/- 8.9)
MetHigh (66.33 +/- 10)

Sex

Male (29; MetLow-13, MetHigh -16)
Female (26; MetLow-12, MetHigh -14)

0

d

Murine PDAC

c
Log2 (total metastasis counts)

Primary Tumor

1
Liver

Lung

MetHigh
MetLow

7.5

5

**
2.5

0

YFP/RFP/CFP

MetHigh Primary Tumor

CFP/Dapi/Ki67

YFP/Dapi/Ki67

MetLow Primary Tumor

50

%Ki67+ tumor cells

e

ns

40
30
20
10
0

MetLow

MetHigh

Extended Data Figure 1: Classifying metastatic burden in human and murine advanced PDA. (a) K-means clustering
of human PDAC metastasis counts demonstrating two distinct clusters with MetLow ≤10 and MetHigh >10 total (liver and lung)
Chaptern=55
4 Supplementary
Figure(age
1 of diagnosis, sex, and race) of the patients analyzed in Fig. 1a-d and
metastasis.
patients. (b) Demographics
Extended Data Fig. 1a. (c) Top: Representative stereomicroscopic fluorescent image showing multiple primary tumors
(RFP+, YFP+, and CFP+) in the pancreas with matched metastases in the liver and lung. Liver and lung metastases are
derived primarily from the YFP+ tumor. (d) K-means clustering of murine PDAC metastasis counts demonstrating two
distinct clusters that are defined as having high or low metastatic burden. MetLow ≤10 and MetHigh >10 total (liver and lung)
metastasis, n=85 tumor clones. (e) Ki67 staining in primary MetLow and MetHigh tumors with representative IF images (left)
and counts (right). Data from n=3 MetLow and n=3 MetHigh primary tumors and 4-5 random fields of view. Statistical analysis
by students unpaired t-test with significance indicated (ns, not significant). Error bars indicating SEM. Scale bar 1mm for
Extended Data Fig. 1c and 50um for Extended Data Fig. 1e.

160

Chapter 4 Supplementary Fig. 1: Classifying metastatic burden in human and murine
advanced PDA.

(A) K-means clustering of human PDAC metastasis counts demonstrating two distinct
clusters with MetLow ≤10 and MetHigh >10 total (liver and lung) metastasis. n=55
patients.
(B) Demographics (age of diagnosis, sex, and race) of the patients analyzed in Fig. 1a-d
and Extended Data Fig. 1a.
(C) Top: Representative stereomicroscopic fluorescent image showing multiple primary
tumors (RFP+, YFP+, and CFP+) in the pancreas with matched metastases in the liver
and lung. Liver and lung metastases are derived primarily from the YFP+ tumor.
(D) K-means clustering of murine PDAC metastasis counts demonstrating two distinct
clusters that are defined as having high or low metastatic burden. MetLow ≤10 and
MetHigh >10 total (liver and lung) metastasis, n=85 tumor clones.
(E) Ki67 staining in primary MetLow and MetHigh tumors with representative IF images
(left) and counts (right). Data from n=3 MetLow and n=3 MetHigh primary tumors and
4-5 random fields of view.
Statistical analysis by students unpaired t-test with significance indicated (ns, not
significant). Error bars indicating SEM. Scale bar 1mm for Extended Data Fig. 1c and
50um for Extended Data Fig. 1e.
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Chapter 4 Supplementary Fig. 2: Copy number alteration analysis reveals lineage
relationships and genetic heterogeneity of fluorescently labeled primary PDACs and their
matching metastasis.

(A) Overlay genome-wide copy number profiles of different fluorescently labeled (CFP and
RFP) primary tumors from mouse 842 (m842 - top panel) and mouse 836 (m836 bottom panel) illustrating differing rearrangement profiles.
(B) Overlay genome-wide copy number profiles of tumors where multi-region sampling
was performed. Top panel illustrates three CFP sub-samples from CFP tumor mass
from m842. Bottom panel illustrates three YFP sub-samples from a YFP tumor mass
from m836.
(C) Genome-wide heatmap with hierarchal clustering based on copy number alterations
of matched primary and metastatic samples profiled from m471 (top panel) and m842
(bottom panel). Color codes for Fluorescence label, primary/metastatic designation,
and nature of copy number alteration are provided below.
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Extended Data Figure 3
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Extended Data Figure 3: Global patterns of large scale copy number alterations do not differ between MetHigh and
Low
Chapter
4 while
Supplementary
Figure
3
Met
clones,
Myc amplifications
are maintained
in metastatic lesions. (a) Genome-wide frequency plot
illustration of large scale copy number events found in all primary tumors (left panel) and in MetHigh (right panel) primary
tumors. Alterations in Cdkn2a, Kras, and Trp53 are noted on the plots. (b) Genome-wide copy number profiles of matching
MetHigh primary tumors (left panels) and paired liver metastases (right panels) from different examined mice. Myc
amplifications are noted on profiles.
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Chapter 4 Supplementary Fig. 3: Global patterns of large scale copy number alterations
do not differ between MetHigh and MetLow clones, while Myc amplifications are
maintained in metastatic lesions.

(A) Genome-wide frequency plot illustration of large scale copy number events found in
all primary tumors (left panel) and in MetHigh (right panel) primary tumors. Alterations
in Cdkn2a, Kras, and Trp53 are noted on the plots.
(B) Genome-wide copy number profiles of matching MetHigh primary tumors (left panels)
and paired liver metastases (right panels) from different examined mice. Myc
amplifications are noted on profiles.
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Extended Data Figure 4

Extended Data Figure 4: Ingenuity pathway analysis of the MetHigh transcriptome.

1

Chapter 4 Supplementary Fig. 4: Ingenuity pathway analysis of the MetHigh transcriptome.
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Chapter 4 Supplementary Figure 5
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Chapter 4 Supplementary Fig. 5: Established MetHigh / MetLow cell lines maintain their
overall genomic profile and do not select for Myc amplification during in vitro culture.

(A) Schematic representation of genome wide copy number profile of matching primary
tumor and cell lines samples illustrating the maintenance of their overall copy number
pattern.
(B) Representative genome-wide copy number profiles of matching primary tumors and
cell line samples for a MetHigh tumor from m836 (YFP+) and MetLow tumor from m842
(CFP+), top and bottom panels respectively.
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Extended Data Figure 6

a

MetLow

1.0

0.5

0.0

anti-Myc

MetHigh

Tumor weight (g)

b

ns

1.5

MetLow MetHigh

c

d
*

1.5

Tumor weight (g)

Myc mRNA
(normalized to Tbp)

4

3

2

1

0

ns

1.0

0.5

0.0
EV

Myc_OE

EV Myc_OE

Extended Data Figure 6: Tumor weight and Myc expression in orthotopic primary tumors primary and Myc
overexpressing
cell lines. (a) Tumor weight
in grams
Chapter 4 Supplementary
Figure
6 of MetLow and MetHigh cell line derived orthotopic tumors in
Figure 4c-d. Weight from n= 4 MetLow and 5 MetHigh cell lines. (b) Representative IHC staining of MetLow and MetHigh
orthotopic tumors from Figure 4c-d. (c) Myc gene expression in MetLow_Myc-OE relative to MetLow_EV cell lines
in Figure 4e-f. (d) Tumor weight in grams of MetLow_EV and MetLow_Myc-OE cell line derived orthotopic tumors in
Figure 4e-f. Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.007; ns, not significant).
Error bar indictes SEM (panels a,c,d). Scale bar 50mm (panel b).
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Chapter 4 Supplementary Fig. 6: Tumor weight and Myc expression in orthotopic primary
tumors primary and Myc overexpressing cell lines.

(A) Tumor weight in grams of MetLow and MetHigh cell line derived orthotopic tumors in
Figure 4c-d. Weight from n= 4 MetLow and 5 MetHigh cell lines.
(B) Representative IHC staining of MetLow and MetHigh orthotopic tumors from Figure
4c-d.
(C) Myc gene expression in MetLow_Myc-OE relative to MetLow_EV cell lines in Figure
4e-f.
(D) Tumor weight in grams of MetLow_EV and MetLow_Myc-OE cell line derived
orthotopic tumors in Figure 4e-f.
Statistical analysis by Student’s unpaired t-test with significance indicated (*, p=0.007; ns,
not significant). Error bar indicates SEM (panels a,c,d). Scale bar 50mm (panel b).
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Extended Data Figure 7
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Extended Data Figure 7: MYC amplifications are enriched in metastatic human PDA. (a) Bar graph showing the
relative frequencies of MYC amplifications in resected and advanced PDAC tumors from the COMPASS cohort.
Chapter
4 Supplementary
Figure
(b) MYC expression
in non-MYC amplified
and7MYC amplified tumors in the COMPASS cohort. (c) Measurement of
total structural variant burden in non-MYC amplified and MYC amplified tumors in the COMPASS cohort. (d) Genomewide relative copy number profiles of two patients with matched primary PDAC (left) and liver metastasis (right).
(e) Heatmap depiction of Myc, CDKN5A, TP53, and SMAD4 copy number alteration in cancer single cells sequenced
from a matched primary PDAC and its liver metastasis depicted in Fig. 6e. Color codes indicate absolute copy number
in single-cells. Top bar plot depicts tissue site from which single-cells were retrieved. (f) Gene set enrichment analysis
of MYC amplified tumors (compared to non-amplified tumors) in the COMPASS cohort.
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Chapter 4 Supplementary Fig. 7: MYC amplifications are enriched in metastatic human
PDA

(A) Bar graph showing the relative frequencies of MYC amplifications in resected and
advanced PDAC tumors from the COMPASS cohort.
(B) MYC expression in non-MYC amplified and MYC amplified tumors in the COMPASS
cohort.
(C) Measurement of total structural variant burden in non-MYC amplified and MYC
amplified tumors in the COMPASS cohort.
(D) Genome- wide relative copy number profiles of two patients with matched primary
PDAC (left) and liver metastasis (right).
(E) Heatmap depiction of Myc, CDKN5A, TP53, and SMAD4 copy number alteration in
cancer single cells sequenced from a matched primary PDAC and its liver metastasis
depicted in Fig. 6e. Color codes indicate absolute copy number in single-cells. Top bar
plot depicts tissue site from which single-cells were retrieved.
(F) Gene set enrichment analysis of MYC amplified tumors (compared to non-amplified
tumors) in the COMPASS cohort.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS

Insights into the regulation of epithelial plasticity in vivo
While EMT has been widely studied in cancer, it is considered one of the pivotal
processes during embryogenesis and organogenesis. Elizabeth Hay, who first described
EMT, noted that that major differences between EMT in embryogenesis versus EMT in
cancer is the transition from subtle, highly controlled movements, to aggressive and
uncontrolled movements that resonate well with cancers in other aspects (proliferation,
death evasion, etc). In either scenario, the transition from the static epithelial state to a
more motile mesenchymal state is met with immense protein reprogramming that occurs
through a concurrent downregulation of epithelial genes and an upregulation of
mesenchymal genes. While disruption of any of the pathways involved in EMT/MET
process during development results in disorders of varying severity, understanding how
cancers hijack EMT may have therapeutic implications to hinder cancer progression.
EMT in cancer was first described and studied in vitro (Hay, 1995). There were
initial concerns that EMT was only observed in experimental, mainly cell culture conditions,
and not in human tumors (Tarin, 2005; Ledford, 2011). It was highly likely that studying
EMT in a dish fails to recapitulate the complex in vivo environment that tumor cells
experience creating an artificial induction of EMT. Furthermore, the debate of whether
EMT even exists in vivo has been a long-standing argument. The identification of EMT
tumor cells in vivo remains a challenge due to the high resemblance of an EMT tumor cell
to that of a stromal/fibroblast cell. But histopathological analysis of the invasive fronts of
tumors revealed tumor cells that exist in an EMT phenotype, amidst desmoplastic stroma,
suggesting that tumor cells exist and also that EMT induction may promote the cell
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invasion and dissemination (Brabletz et al, 2001; Huang et al, 2012). But still, the isolation
to characterize tumor cells in vivo has been challenging. With the advent of lineage labeled
genetic engineered mouse models, we are now able to isolate and trace tumor cells in an
EMT state attempting to answer pertinent questions.
The use of these mouse models has been increasing relevant in understanding
the molecular mechanisms that drive EMT in vivo. As noted previously in the introduction,
recent studies have investigated the role of EMT-TFs in cancer which have led to
conflicting results (Stemmler et al, 2019). Deletion of either SNAIL1 or TWIST1 in a
spontaneous mouse model of PDAC had minimal effect on metastasis, whereas ZEB1
ablation in a similar model drastically reduced colonization, invasion, and metastasis
(Zheng et al, 2015; Krebs et al, 2017). But, depletion of SNAIL or TWIST in the PyMT
breast cancer model was capable of reducing metastasis formation(Xu et al, 2017; Ni et
al, 2016). These studies suggest that that tissue- and context-dependent differences
dictate the molecular mechanisms underlying EMT in a given tumor. However, in all of
these studies, while metastasis was affected, it was never entirely hindered, suggesting
that some other mechanism may be responsible for tumor cell metastasis.
Here, we used a lineage labeled mouse model of PDAC to isolate tumor cells that
are in a de novo EMT state revealing that the majority of PDAC tumors use protein relocalization rather than transcriptional repression to subdue the epithelial program(Aiello
et al, 2018). These tumors exhibit low expression of EMT-TFs, suggesting that they may
play a minimal role, and co-express epithelial and mesenchymal genes, consistent with a
P-EMT state. This post-transcriptional program, although not typically discussed as a
potential mechanism for EMT in cancer, is indeed seen in several instances during
development (Song et al, 2013; Wu & McClay, 2007; Zohn et al, 2006), suggesting that

174

both transcriptional and posttranscriptional mechanisms may play distinct roles in tumor
progression under certain circumstances.
One of the most pondered questions of the P-EMT state is regarding its longevity.
Is the P-EMT state just a tumor cell paused in a transitional state (i.e. an intermediate
state along a mesenchymal differentiation continuum) or does it represent a final state in
its own right? Is it just a mixed population composed of epithelial and mesenchymal cells?
Is it a population of mostly transitioning cells? Several recent theoretical and mouse
studies have predicted that a partial EMT state can exist at a single level (Pastushenko et
al, 2018; Puram et al, 2018; Jolly et al, 2016). Indeed, we have no evidence that the PEMT program and the C-EMT program co-exist within the same PDAC tumor, suggesting
that the tendency to use one program over the other is a stable entity of an individual
tumor (see Chapter 2, Figure S4). Yet, to further understand the stability of this state, the
molecular mechanisms dictating this P-EMT state need to be explored.
In Chapter 3, we investigated potential mediators regulating the partial EMT
phenotype seen in vivo. Here, we identified Ca2+ mobilization as an inducer of a stable PEMT state characterized by the re-localization of epithelial proteins along with increased
migration and invasion, mirroring the phenotype seen in vivo (Figure 1). Mechanistically,
upon calcium influx, calmodulin becomes activated and we found that this P-EMT
phenotype is dependent on its activation. Future studies will attempt to identify the precise
mechanism and targets of calmodulin. New studies have implicated Ca2+/calmodulindependent protein kinases (CAMK) as a regulator of P-EMT (Pastushenko et al, 2020).
This is directly downstream of calmodulin and a likely candidate in our system which future
studies will interrogate. Collectively, this data suggests that at one mechanism by which
tumor cells can achieve a partial EMT phenotype is by extracellular signals that result in
increased Ca2+ influx. These findings raise several questions.
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First, what ligands and cognate receptors are responsible for the P-EMT
phenotype. In our study, we have evidence that GPCR signaling activation results in PEMT. However, there are over 800 GPCRs in humans of which anyone of them can be
responsible. Using our sequencing results, we have narrowed that list down to about 90
GPCRs that are differentially expressed between P-EMT and C-EMT in vivo, a number
that is still impractical to study sequentially. We can reason based on our results, that this
GPCR must couple with a Gaq subunit to activate signaling. However, while some
receptors are well known to couple with the Gaq subunit, the structural determinants of
receptor specificity for most GPCRs are not completely understood. Although we have
identified GPCR signaling as one potential avenue for calcium influx and the P-EMT
phenotype, it is highly probable that other signaling pathways in cancer such as
neurotransmitter receptors (Schuller & Al-Wadei, 2010) that are known to induce calcium
signaling may also be capable of inducing a P-EMT. Yet, this issue highlights a broader
problem in the EMT field which is what physiological inducers invoke EMT in vivo. A
plethora

of

developmental

growth

factors

(Wnt,

TGFb,

EGF,

HGF)

and

microenvironmental stimulus (hypoxia, matrix stiffness) have been shown to induce EMT
in vitro (Lamouille et al, 2014). Which of these ligands is responsible within the tumor
microenvironment remains ill-defined. As with the receptors, it is again possible or more
likely, that multiple factors act in combination to achieve critical thresholds of the
necessary signal.

Partial EMT: The best of both worlds?
The idea of a tumor cell invoking a partial EMT state is rather intriguing. In theory,
it would allow tumor cells to utilize traits that are advantageous to both epithelial and
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mesenchymal cells giving it advantages in metastasis, chemoresistance, and immune
evasion.
To metastasize tumor cells must detach from the primary tumor and invade
surrounding or distant tissues. Broadly speaking, there are two major modes of invasion:
single cell migration and collective migration. And depending on the environmental stimuli,
cancer cells are thought to be capable to switch between these two invasion strategies
(Clark & Vignjevic, 2015). In collective migration, cancer cells retain cell-cell adhesions
and display as a group of cells or cluster. These tumor cells that metastasize in a collective
fashion display enhanced metastatic potential compared to single cells. In a 3D
assessment of many types of cancers, it was found that single cell migration was almost
nonexistent (<0.0003%) suggesting that collective migration as the predominant
mechanism used in these cancers (Bronsert et al, 2014). In this thesis, we find that both
modes of cell migration occur and this correlates well with EMT subtype (P-EMT =
collective migration, C-EMT = single cell migration). In accordance with the 3D
assessment (Bronsert et al, 2014), we find that the majority of tumors exist in a P-EMT
state and exhibit collective migration. These tumor cells that exist in a P-EMT retain their
epithelial proteins allowing them the ability re-express these proteins when necessary
endowing them with the ability to form clusters. In contrast, C-EMT tumor cells are
completely devoid of surface E-cadherin and other epithelial proteins, inhibiting the ability
to form tumor clusters. It is tempting to speculate based on this that disruption or breaking
of these clusters in circulation or prior to formation may lead to therapeutic benefit in
patients.
Over many decades of work, a central theme of EMT has been in its role in
chemoresistance (Nieto et al, 2016a). In response to therapeutic pressures, tumor cells
may activate EMT and thus inhibit proliferation or upregulate drug efflux machinery for
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example, to acquire resistance. Recent work in mouse models has suggested that EMTTFs may play a large role in this acquired resistance(Zheng et al, 2015; Fischer et al, 2015;
Wang et al, 2016). However, in some circumstances this dogma may not hold true. Several
studies have suggested that selective sensitivities may exist when tumor cells exist in an
epithelial subtype/state versus tumor cells in a mesenchymal subtype/state (Genovese et
al, 2017; Collisson et al, 2011). This scenario, aligns with the notion that being in a P-EMT
may be superior to combat therapeutic agents. Similarly, to therapeutic resistance, recent
findings have led to increased interest in how EMT might contribute to immune escape
(Terry et al, 2017). We can again speculate that being in a P-EMT may be the perfect
cover for tumor cells to escape from immune detection while maintaining abilities
necessary for progression, another avenue worth exploring.
In summary, all of these observations indicate a primary requisite for the
development of targeted treatment modalities suppressing EMT and the partial EMT
phenotype. While this is merited, there are several drawbacks that should be emphasized:
1) Tumor cells have different resistances in epithelial or mesenchymal states and targeting
one state may leave the other state behind, 2) reversal of EMT may counteract the benefits
of inhibiting EMT since cells in the epithelial state have been found to proliferate and
colonize distant sites more and 3) inhibition of EMT would have minimal impact on
baseline disease burden, leaving already metastatic foci present. Thus, more than one
agent would have to be used to combat the effects of cells in a variety of stages. To this
end, future work should investigate pharmacological agents that are capable of targeting
specific EMT states: epithelial, mesenchymal, and P-EMT states. In this thesis, we have
found a method to stably induce both the P-EMT (calcium influx) and C-EMT (TGFb
treatment). Using these principles, we propose a high throughput pharmacological screen
to extend our own findings and determine compounds that could effectively lead to
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eradication of specific EMT states. Through these studies, we aim to find and then design
combinations that would eradicate all cell populations reducing tumor burden and
subsequent metastatic events.

The existence of metastatic drivers
The presence of plasticity, intratumoral heterogeneity, and intertumoral
heterogeneity has made it increasing challenging to understand mechanisms behind
tumor spread. As tumors develop they successively accumulate genetic alterations that
drive tumor progression. Based on this, one would postulate that the occurrence of
metastasis would depend on the acquisition of yet some other mutation empowering tumor
cells with the ability of metastasis. However, after many years and many studies, no single
mutation has been identified that are characteristically associated with progression to
metastatic disease. In fact, even large-scale genome sequencing studies have yet to
uncover recurrent genetic mutations that can explain metastasis (Lambert et al, 2017).
This has shaped the field to believe that the development of metastasis is not entirely
driven by a single somatic mutation and that other factors play a pioneering role.
In our study, we utilized the KPCXY mouse model of PDAC, which exhibited
varying degrees of metastatic spread to interrogate the molecular mechanisms driving
metastasis in naturally arising tumors. This system revealed a strong association between
the level of MYC at both the genome and transcriptome level and tumor metastasis. MYC
exerts its pro-metastatic effect, in part, by recruiting tumor associated macrophages that
influenced tumor cell metastasis (Figure 2). Depletion of macrophages from the circulation
and the primary tumor nearly completely inhibited metastasis in our system.
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These results raise several questions that challenge the notion that genetic drivers
of metastasis do not exist. The first obvious question is whether genetic drivers do exist?
As indicated, several studies have attempted to uncover genetic drivers to no avail. A
recent study in pancreatic cancer compared matched primary and metastasis from four
patients yet failed to reveal mutations in driver oncogenes (Makohon-Moore et al, 2017).
But the existence of primary tumor heterogeneity may be an explanation for this. To clarify,
in our mouse model, we observed that primary tumors are composed of several (up to 5)
different subclones. If a biopsy was taken from a non-metastatic clone and compared to a
metastatic lesion, no similarities would be concluded, illustrating the power of our model
and the potential relevance of our findings. It is noteworthy that MYC amplifications were
far more common in metastases than primary tumors, including the one instance where
we were able to trace a metastatic lesion directly to a MYC amplified subclone. The more
likely scenario is that genetic drivers do indeed exist but non-genetic drivers (i.e.
epigenetic and transcriptional changes) are present and potentially even more common.
An increase in MYC transcripts, regardless of whether this was the result of an
amplification or an increase in transcription, resulted in increased metastasis.
Our studies implicate non-cell autonomous mechanisms involving the recruitment
of tumor associated macrophages (TAMs) as contributors to metastatic heterogeneity.
The ability of TAMs to promote tumor cell invasion is well described (Cassetta et al, 2019;
Cassetta & Pollard, 2020; Chen et al, 2011; Ginter et al, 2019; Kitamura et al, 2015; Lee
et al, 2018; Linde et al, 2018; Qian et al, 2011; Roh-Johnson et al, 2014; Steele et al, 2016;
Zhu et al, 2014), in concordance with our finding that metastatic high tumors and MYC
overexpression have increased macrophages present. It is also well known that MYC
plays a specific role in both tumor cell intrinsic (i.e. proliferation and cell cycle) and nonintrinsic properties, as many studies have shown that it can shape the makeup of the tumor
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microenvironment. While the specific recruitment factor for TAMs is unknown (and likely
diverse), we can speculate that MYC either directly or indirectly regulates the upregulation
of this factor or potential combination of factors. Follow up experiments will attempt to
identify the genes that MYC directly controls and what factors are necessary for
macrophage recruitment.
Surprisingly, metastatic high tumor clones failed to show any indication of EMT.
Although not entirely unexpected this further adds to the literature that suggests EMT is
not the only method of metastatic spread in tumors. Therefore, understanding many
aspects of tumor biology – plasticity and heterogeneity – are crucial to designing initial
therapies and follow up therapies as tumors adapt to treatment.
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Concluding Remarks

My thesis work sought to investigate the molecular underpinnings of epithelial
plasticity and tumor cell heterogeneity leading to metastasis. These projects were built
upon by observations in genetic engineered mouse models of PDAC. Following the
dogma-shifting finding that EMT occurred frequently and early in PDAC, we utilized our
mouse model of pancreatic cancer to investigate the divergent mechanisms of EMT in
vivo. Notably, the lineage tracing marker, YFP, allowed us distinguish and isolate tumor
cells that have undergone EMT from normal stromal cells that infiltrated into primary
tumors, a technique that had not been previously employed to study EMT. We then
followed up on our initial characterization and identification of a P-EMT phenotype present
in the majority of PDAC tumors, and used GSEA and HOMER motif analysis to initially
hypothesize that calcium signaling is an underlying molecular mechanism that regulates
P-EMT. The identified signaling axis thorough calmodulin may serve as a therapeutically
tractable avenue to inhibit P-EMT. This research strategy could be utilized in many other
scenarios: other tumors (breast, colon, ovarian, etc) to identify if redundant or nonredundant pathways exist for EMT or other types of tumor cell plasticity (refer to Yuan et
al, 2019).
In chapter 4, we utilized a related genetic mouse model of PDAC that utilized a
multi-color confetti allele instead of a YFP lineage label to investigate tumor cell
heterogeneity in PDAC. This allowed for the identification of tumor cell subpopulations
with high or low metastatic capability. The lineage label again allowed for the isolation and
characterization of these two populations and further molecular studies to identify
metastatic drivers in PDAC. While chapters 2 and 3 focused on tumor cell intrinsic
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mechanisms of tumor cell invasion, in chapter 4 we found that MYC amplification or
transcriptional upregulation resulted in a rewiring of the tumor microenvironment and noncell autonomous recruitment of tumor associated macrophages led to greater bloodstream
intravasation and metastasis. Given that MYC family members are amplified in many
different cancers, these results have broad implications for metastasis in tumor types other
than PDAC.
Collectively, these studies highlight the power and utilization of lineage labels in
cancer models to understand several aspects of tumor biology. Understanding both
epithelial plasticity and heterogeneity are dire being the downfall of many cancer patients
before and during treatments. While PDAC mouse models were exclusively used in this
thesis, we have confirmed many results in human cells, patients, and other tumor types,
expanding this thesis to be applicable to other tumor types.
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Chapter 5 Figures and Figure Legends

Figure 1 (Chapter 5): Graphical abstract of classical or complete C-EMT versus partial
EMT (P-EMT)
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Figure 2 (Chapter 5): Using the KPCXY mouse model of PDAC, we found a strong
association between the level of MYC at both the genome and transcriptome level and
tumor metastasis. MYC exerts its pro-metastatic effect, in part, by recruiting tumor
associated macrophages that influenced tumor cell metastasis.
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